<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2185726-B1" country="EP" doc-number="2185726" kind="B1" date="20140108" family-id="39925054" file-reference-id="318261" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588234" ucid="EP-2185726-B1"><document-id><country>EP</country><doc-number>2185726</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08797299-A" is-representative="NO"><document-id mxw-id="PAPP154850426" load-source="docdb" format="epo"><country>EP</country><doc-number>08797299</doc-number><kind>A</kind><date>20080806</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551081" ucid="US-2008072356-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2008072356</doc-number><kind>W</kind><date>20080806</date></document-id></priority-claim><priority-claim mxw-id="PPC140549106" ucid="US-95429007-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>95429007</doc-number><kind>P</kind><date>20070806</date></document-id></priority-claim><priority-claim mxw-id="PPC140547627" ucid="US-98871507-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>98871507</doc-number><kind>P</kind><date>20071116</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130802</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989325032" load-source="docdb">C12Q   1/68        20060101AFI20090226BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989622535" load-source="docdb" scheme="CPC">C12Q2600/172       20130101 LA20130713BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989636951" load-source="docdb" scheme="CPC">C12Q2600/154       20130101 LA20130713BHEP        </classification-cpc><classification-cpc mxw-id="PCL2090154931" load-source="docdb" scheme="CPC">C12Q   1/6876      20130101 FI20140614BHEP        </classification-cpc><classification-cpc mxw-id="PCL2090158582" load-source="docdb" scheme="CPC">C12Q   1/6886      20130101 LI20140614BHEP        </classification-cpc><classification-cpc mxw-id="PCL2090160502" load-source="docdb" scheme="CPC">C12Q   1/6883      20130101 LI20140614BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369335" lang="DE" load-source="patent-office">NEUE EINZELNUKLEOTID-POLYMORPHISMEN UND KOMBINATIONEN NEUER UND BEKANNTER POLYMORPHISMEN ZUR BESTIMMUNG DER ALLELSPEZIFISCHEN EXPRESSION DES IGF2-GENS</invention-title><invention-title mxw-id="PT132369336" lang="EN" load-source="patent-office">NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE</invention-title><invention-title mxw-id="PT132369337" lang="FR" load-source="patent-office">NOUVEAUX POLYMORPHISMES NUCLÉOTIDIQUES UNIQUES ET COMBINAISONS DE NOUVEAUX POLYMORPHISMES CONNUS PERMETTANT DE DÉTERMINER L'EXPRESSION SPÉCIFIQUE D'ALLÈLE DU GÈNE IGF2</invention-title></technical-data><related-documents><relation type="division-into"><child-doc ucid="EP-13193708.8"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13193708.8</doc-number><date>20131120</date></document-id></child-doc><parent-doc ucid="EP-08797299-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>08797299</doc-number><kind>A</kind><date>20080806</date></document-id><parent-grant-document ucid="EP-2185726-B1"><document-id><country>EP</country><doc-number>2185726</doc-number><kind>B1</kind><date>20140108</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919505315" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ORION GENOMICS LLC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919512821" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ORION GENOMICS, LLC</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919545265" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ORDWAY JARED</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919515266" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ORDWAY, JARED</last-name></addressbook></inventor><inventor mxw-id="PPAR919022166" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>ORDWAY, JARED</last-name><address><street>4266 Castleman Avenue</street><city>St. Louis, Missouri 63110</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919535119" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LAKEY NATHAN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919515051" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LAKEY, NATHAN</last-name></addressbook></inventor><inventor mxw-id="PPAR919022168" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>LAKEY, NATHAN</last-name><address><street>2040 Wilson Ridge Lane</street><city>Chesterfield, Missouri 63005</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919535654" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>MALONEY REBECCA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919542929" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>MALONEY, REBECCA</last-name></addressbook></inventor><inventor mxw-id="PPAR919022167" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>MALONEY, REBECCA</last-name><address><street>13581 Lavender Mist Lane</street><city>Centreville, Virginia 20120</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919518769" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>ROHLFING THERESA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919505453" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>ROHLFING, THERESA</last-name></addressbook></inventor><inventor mxw-id="PPAR919022169" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>ROHLFING, THERESA</last-name><address><street>112 E. Glendale Road</street><city>Webster Groves, Missouri 63119</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022171" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Orion Genomics, LLC</last-name><iid>100193253</iid><address><street>4041 Forest Park Avenue</street><city>St. Louis, MO 63108</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022170" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Campbell, Patrick John Henry</last-name><iid>101181598</iid><address><street>J A Kemp 14 South Square Gray's Inn</street><city>LONDON WC1R 5JJ</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2008072356-W"><document-id><country>US</country><doc-number>2008072356</doc-number><kind>W</kind><date>20080806</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009021054-A2"><document-id><country>WO</country><doc-number>2009021054</doc-number><kind>A2</kind><date>20090212</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549876103" load-source="docdb">AT</country><country mxw-id="DS549800310" load-source="docdb">BE</country><country mxw-id="DS549783008" load-source="docdb">BG</country><country mxw-id="DS549868401" load-source="docdb">CH</country><country mxw-id="DS549923237" load-source="docdb">CY</country><country mxw-id="DS549876104" load-source="docdb">CZ</country><country mxw-id="DS549800311" load-source="docdb">DE</country><country mxw-id="DS549923238" load-source="docdb">DK</country><country mxw-id="DS549923239" load-source="docdb">EE</country><country mxw-id="DS549871372" load-source="docdb">ES</country><country mxw-id="DS549783017" load-source="docdb">FI</country><country mxw-id="DS549783018" load-source="docdb">FR</country><country mxw-id="DS549800312" load-source="docdb">GB</country><country mxw-id="DS549923240" load-source="docdb">GR</country><country mxw-id="DS549800317" load-source="docdb">HR</country><country mxw-id="DS549876105" load-source="docdb">HU</country><country mxw-id="DS549868414" load-source="docdb">IE</country><country mxw-id="DS549923241" load-source="docdb">IS</country><country mxw-id="DS549783019" load-source="docdb">IT</country><country mxw-id="DS549923242" load-source="docdb">LI</country><country mxw-id="DS549783930" load-source="docdb">LT</country><country mxw-id="DS549890938" load-source="docdb">LU</country><country mxw-id="DS549783931" load-source="docdb">LV</country><country mxw-id="DS549783932" load-source="docdb">MC</country><country mxw-id="DS549890939" load-source="docdb">MT</country><country mxw-id="DS549800318" load-source="docdb">NL</country><country mxw-id="DS549783020" load-source="docdb">NO</country><country mxw-id="DS549783937" load-source="docdb">PL</country><country mxw-id="DS549868415" load-source="docdb">PT</country><country mxw-id="DS549800319" load-source="docdb">RO</country><country mxw-id="DS549783938" load-source="docdb">SE</country><country mxw-id="DS549871373" load-source="docdb">SI</country><country mxw-id="DS549783025" load-source="docdb">SK</country><country mxw-id="DS549923243" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960660" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">BACKGROUND OF THE INVENTION</heading><p id="p0001" num="0001">The gene for insulin-like growth factor 2, or <i>IGF2,</i> is located in a cluster of imprinted genes on human chromosome 11p15.5. Genomic imprinting is an important mechanism of gene regulation where one copy of the gene is normally expressed and the other copy is silenced through an epigenetic mark of parental origin. <i>IGF2</i> is normally maternally imprinted in human tissues and therefore, expressed only from the paternally inherited copy of the gene (<nplcit id="ncit0001" npl-type="s"><text>DeChiara TM, et al. Cell 64, 849-859 (1991</text></nplcit>); <nplcit id="ncit0002" npl-type="s"><text>Rainier S, et al., Nature 362, 747-749 (1993</text></nplcit>); <nplcit id="ncit0003" npl-type="s"><text>Ogawa, et al, Nature 362, 749-751 (1993</text></nplcit>)). Loss of imprinting of <i>IGF2</i> (referred to as loss of imprinting, or LOI) has been strongly linked to several cancer types (over 20 tumor types reviewed in <nplcit id="ncit0004" npl-type="s"><text>Falls, et al. 1999, AJP 154, 635-647</text></nplcit>). Furthermore, mounting evidence indicates that individuals displaying LOI of <i>IGF2</i> may be at elevated risk for developing colorectal cancer (<nplcit id="ncit0005" npl-type="s"><text>Kinochi et al., 1996, Cancer Letters 107, 105-108 (1996</text></nplcit>); <nplcit id="ncit0006" npl-type="s"><text>Nishihara S. 2000, Int. Jour. Oncol. 17, 317-322</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Cui H 1998, Nature Medicine 4-11, 1276-1280</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Nakagawa H 2001, PNAS 98-2, 591-596</text></nplcit>). LOI of <i>IGF2</i> can be detected in normal tissues of cancer patients including peripheral blood and normal colonic mucosa (<nplcit id="ncit0009" npl-type="s"><text>Kinochi et al., 1996, Cancer Letters 107, 105-108 (1996</text></nplcit>); <nplcit id="ncit0010" npl-type="s"><text>Ogawa, et al, Nature Genetics 5, 408-412 (1993</text></nplcit>); <nplcit id="ncit0011" npl-type="s"><text>Cui H, Science 299, 1753 (2003</text></nplcit>)) and in the normal tissues of people believed to be cancer free (<nplcit id="ncit0012" npl-type="s"><text>Cui H, et al. Nature Medicine 4-11, 1276-1280 (1998</text></nplcit>); <nplcit id="ncit0013" npl-type="s"><text>Cui H, Science 299, 1753 (2003</text></nplcit>); <nplcit id="ncit0014" npl-type="s"><text>Woodson K et al., JNCI 96, 407-410 (2004</text></nplcit>); <nplcit id="ncit0015" npl-type="s"><text>Cruz-Correa Met al., Gastroenterology 126,964-970 (2004</text></nplcit>)).</p><p id="p0002" num="0002">Several studies of peripheral blood of general populations report that between 7-10% of people display loss of imprinting of <i>IGF2</i> in colonic mucosa tissue. Three<!-- EPO <DP n="2"> --> retrospective studies report that the odds of colorectal cancer patients displaying LOI of <i>IGF2</i> in either peripheral blood or colonic mucosa are significantly higher (between 2-21 fold) than the odds of an age matched cancer free control group displaying LOI. These studies suggest that LOI of <i>IGF2</i> may predispose otherwise healthy individuals to colorectal cancer. Therefore, a risk test based on the detection of LOI of IGF2 may have a future clinical benefit, (<nplcit id="ncit0016" npl-type="s"><text>Cui H, et al. Nature Medicine 4-11, 1276-1280 (1998</text></nplcit>); <nplcit id="ncit0017" npl-type="s"><text>Cui H, Science 14, 1753-1755 (2003</text></nplcit>); <nplcit id="ncit0018" npl-type="s"><text>Woodson K 2004, JNCI 96, 407-410</text></nplcit>; <nplcit id="ncit0019" npl-type="s"><text>Cruz-Correa M, Gastroenterology 126, 964-970 (2004</text></nplcit>)). These studies show that people with LOI of <i>IGF2</i> (also referred to as the <i>IGF2</i> biomarker) may be up to 20 times more likely to develop colorectal cancer than individuals without the <i>IGF2</i> biomarker.</p><p id="p0003" num="0003">Detection of LOI of <i>IGF2</i> is based on a quantitative allele specific gene expression assay, where transcripts from both copies of the <i>IGF2</i> gene are each quantified. The quantities are then compared to one another to determine an allelic gene expression ratio, which is subsequently compared to a threshold value. If the concentration of the lesser abundant allele is "relatively similar" to the concentration of the more abundant allele, then the <i>IGF2</i> imprint is determined to be lost. If the concentration of the lesser abundant allele is "relatively dissimilar" to the concentration of the more abundant allele, then the <i>IGF2</i> imprint is determined to be present. One method of measuring the imprinting status of <i>IGF2</i> in a sample is to first determine the genotype(s) of one or more polymorphic sites in the transcribed region of the <i>IGF2</i> gene. Heterozygous markers in the transcribed region of the gene provide for convenient molecular handles by which the individual alleles of the <i>IGF2</i> gene can be distinguished from one another in a sample. RNA transcription from each of the two copies of the <i>IGF2</i> gene may be independently measured with quantitative allele specific assays. Comparison of the amount of expression of one allele to the amount of expression of the other allele can therefore be made and the imprinting status of the <i>IGF2</i> gene can be determined (see <figref idrefs="f0002">Figure 2</figref>).</p><p id="p0004" num="0004"><i>IGF2</i> has four promoters, each driving expression of alternatively spliced transcripts, in a tissue specific manner (<figref idrefs="f0001">Figure 1A</figref>). Exons 7, 8, and 9 are present in all transcripts, while exons 1-6 have been reported to be expressed in a promoter specific fashion. Exon 9 includes a short stretch of protein-coding sequence followed by a considerably longer 3' UTR. Polymorphic markers in exons 7, 8, and 9 are therefore useful in the determination of <i>IGF2</i> imprinting status by enabling the detection of allele specific expression of IGF2 transcription driven from any of the four <i>IGF2</i> promoters.<!-- EPO <DP n="3"> --></p><p id="p0005" num="0005">Four allele-specific expression assays measuring <i>IGF2</i> imprinting status are known to those skilled in the art. Woodson, <i>et al.</i> measured imprinting status of <i>IGF2</i> with a combination of two SNP based assays (rs680 - analogous to SEQ ID NO: 64 in Table 1A; and rs2230949 - analogous to SEQ ID NO: 56 in Table 1A) (<nplcit id="ncit0020" npl-type="s"><text>Woodson K 2004, JNCI 96, 407-410</text></nplcit>). Both SNPs are in exon 9 of IGF2 but are reported by Woodson <i>et al.</i> to be in minimal linkage disequilibrium. Therefore attempts to measure LOI of an individual with such a combination of markers increases the probability that the individual will be heterozygous for at least one of the two SNPs, and thereby increase the likelihood that the LOI status of the individual can be determined. The authors demonstrated that the first SNP, the second SNP, or both SNPs were informative (<i>i.e.,</i> were heterozygous and, therefore, permitted measurement of LOI of <i>IGF2</i>) in 48 of 106 patients evaluated (or 45%). Cui <i>et al.</i> measured <i>IGF2</i> imprinting with a combination of two assays, one targeting a SNP (rs680 - analogous to SEQ ID NO: 64 in Table 1A) and a second measuring restriction fragment length polymorphisms of a simple sequence repeat within exon 9 of IGF2. The authors demonstrated that the SNP, the repeat, or both markers were informative in 191 of 421 (or 45%) patients evaluated (<nplcit id="ncit0021" npl-type="s"><text>Cui H, et al. Nature Medicine 4-11, 1276-1280 (1998</text></nplcit>)).</p><p id="p0006" num="0006">Previous studies have demonstrated that use of these polymorphisms result in a low combined frequency of heterozygosity in patient populations and, therefore, a large number of individuals in these populations were "uninformative" such that their <i>IGF2</i> imprinting status could not be determined. The present application describes newly discovered SNPs in <i>IGF2</i> exon 9, and the discovery of useful combinations of SNPs, which enable successful LOI measurements in an increased proportion of the human population. The ability to measure LOI using these polymorphisms in the general population will have a profound medical benefit, serving as the basis for various molecular diagnostic and therapeutic tests.</p><p id="p0007" num="0007">The informativity of a given SNP for detection of LOI is based on the frequency of heterozygosity of the SNP within a population. Furthermore, the optimal informativity of a combination of different SNPs is dependent upon the linkage among the different markers. For example, if two SNPs fall within a common haplotype block, the combined use of the two SNPs provides a minimal increase in informativity relative to the use of either of the two SNPs alone. However, if two SNPs are not on the same haplotype block (i.e., are in minimal linkage disequilibrium), the combined use of the two SNPs provides an effective increase in informativity relative to the use of either of the two SNPs alone.<!-- EPO <DP n="4"> --></p><p id="p0008" num="0008">The recent release of the HapMap II human genetic variation dataset provides haplotype analysis of genome-wide DNA sequence data. In the HapMap II study, SNPs were identified in 270 people genotyped from four geographically diverse populations, including 30 mother-father-adult child trios from the Yoruba in Ibadan, Nigeria; 30 such trios of northern and western European ancestry living in Utah; unrelated Han Chinese individuals in Beijing and 45 unrelated Japanese individuals in Tokyo. Haplotype analysis of those SNPs within an approximately 70 Kb region including the <i>IGF2</i> locus provides a view of haplotype blocks predicted by this current and extensive dataset. In <figref idrefs="f0003">Figure 3</figref>, the Haploview visualization of linkage prediction is depicted below a to-scale diagram of the <i>IGF2</i> locus. Three haplotype blocks are identified (represented as black horizontal bars positioned in scale with the <i>IGF2</i> locus). The data predict haplotype blocks spanning from approximately 14 to 19 Kb upstream of <i>IGF2</i> exon 1, from approximately 1 Kb upstream of exon 3 to approximately 5 Kb downstream of exon 4, and from approximately 2 Kb upstream of the start of exon 9 to approximately 14 Kb downstream of the end of exon 9, a haplotype block that encompasses exons 8 and 9. In general, regions between these haplotype blocks display minimal linkage disequilibrium and provide strong evidence for historic recombination (indicated by white diamonds representing multiple pairwise SNP comparisons). These data are summarized in <figref idrefs="f0001">Figure 1B</figref>. Haplotype blocks are represented by black horizontal bars and the region of predicted minimal linkage disequilibrium is represented by a grey horizontal bar.</p><p id="p0009" num="0009">Gaunt <i>et al.</i> performed an association studying for body mass index (BMI) in a Caucasian cohort of 2,734 European men using 12 SNPs ranging from just upstream of <i>IGF2</i> exon 1 to approximately 1Kb prior to the end of the exon 9 3' UTR, (<nplcit id="ncit0022" npl-type="s"><text>Gaunt et al. Human Mol Genet. vol. 10, no. 14: 1491-1501</text></nplcit>). This study included linkage analysis of a single SNP (rs680 - analogous to SEQ ID NO: 64 in Table 1A), which had one allele reported to be positively associated with high BMI in the cohort, to each of the other 11 SNPs in a pair wise fashion. The authors report a haplotype block within the 3' UTR of exon 9, containing 3 SNPs from their study (see Example 3 the black horizontal bar in <figref idrefs="f0001">Figure 1C</figref>, and the grey bar in <figref idrefs="f0004">Figure 4</figref>).<!-- EPO <DP n="5"> --></p><heading id="h0002">BRIEF SUMMARY OF THE INVENTION</heading><p id="p0010" num="0010">The present invention provides methods of determining a SNP genotype in a human individual. These methods comprise determining, in a sample containing genomic DNA from the individual, the nucleotide or nucleotides at the polymorphic nucleotide of a single nucleotide polymorphism (SNP), wherein the SNP is SEQ ID NO: 10 and wherein the nucleotide at the polymorphic position of the SNP (and therefore at the corresponding position of the polynucleotide) is the underlined nucleotide as displayed in Table 2A or 2B.</p><p id="p0011" num="0011">The present invention also provides methods of quantifying allelic-specific expression of RNA in a human individual, wherein the human individual is a heterozygote for a single nucleotide polymorphism (SNP) in the <i>Insulin Growth Factor-2 (IGF2)</i> gene. These methods comprise quantifying the amount of RNA in a sample from the human individual comprising each polymorphic option of the SNP, wherein the SNP is SEQ ID NO: 10; and correlating the relative amount of RNA comprising each polymorphic option of the SNP to loss of imprinting of the IGF2 gene.</p><p id="p0012" num="0012">The sample may be a blood or tissue sample. The sample may be a stool sample. The methods may comprise correlating the relative amount of RNA comprising each polymorphic option of the SNP to loss of imprinting of the IGF2 gene. The correlating step may comprise correlating the relative amount of RNA to a prognosis or diagnosis of cancer or a prediction of efficacy of a drug for treating cancer. The RNA may be reverse transcribed into cDNA and the quantity of allele specific cDNA may be used to determine the amount of RNA.</p><p id="p0013" num="0013">In some embodiments, the methods further comprise determining whether the individual is homozygous or heterozygous for one or more SNPs.</p><p id="p0014" num="0014">The present invention also provides isolated polynucleotides of between 8-100 nucleotides, wherein the polynucleotide distinguishes between one allele of a SNP (or complement thereof) and the other allele of the SNP (or complement thereof) in a hybridization reaction, wherein the SNP is SEQ ID NO: 10.</p><p id="p0015" num="0015">In some embodiments, the penultimate or ultimate 3' nucleotide of the polynucleotide hybridizes to the polymorphic nucleotide of the SNP.</p><p id="p0016" num="0016">The present invention also provides isolated polynucleotides of between 8-100 nucleotides wherein the polynucleotide functions as a primer in <i>Insulin-like Growth Factor 2 (IGF2)</i> cDNA, such that the polynucleotide hybridizes to the cDNA and the 3'<!-- EPO <DP n="6"> --> nucleotide of the polynucleotide is complementary to the nucleotide immediately upstream of the polymorphic nucleotide of a SNP, wherein the SNP is SEQ ID NO: 10.</p><p id="p0017" num="0017">In some embodiments, at least the 10 contiguous 3' nucleotides of the polynucleotide are complementary to the cDNA.</p><p id="p0018" num="0018">The present invention also provides isolated polynucleotides comprising the SNP sequence, or complement thereof, of SEQ ID NO: 10, wherein the nucleotide at the polymorphic position of the SNP is T as displayed in Table 2A or 2B.</p><p id="p0019" num="0019">The present invention also provides kits comprising an isolated polynucleotide of between 8-100 nucleotides wherein the polynucleotide functions as a primer in <i>Insulin-like Growth Factor 2 (IGF2)</i> cDNA, such that the polynucleotide hybridizes to the cDNA and the 3' nucleotide of the polynucleotide is complementary to the nucleotide immediately upstream of the polymorphic nucleotide of a SNP, wherein the SNP is SEQ ID NO: 10<!-- EPO <DP n="7"> --></p><p id="p0020" num="0020">In some embodiments, the kit comprises a first isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between a first allele of a SNP and a second allele of the SNP (or complement thereof) in a hybridization reaction.</p><p id="p0021" num="0021">In some embodiments, the kit further comprises a second isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between the first allele of the SNP (or complement thereof) and the second allele of the SNP (or complement thereof), and wherein the first polynucleotide is complementary to the polymorphic nucleotide in the first allele and the second polynucleotide is complementary to the polymorphic nucleotide of the second allele.</p><p id="p0022" num="0022">In some embodiments, the kit further comprises one or more primer for amplifying a region of the IGF2 locus encompassing the polymorphic site, wherein the one or more primer is different from the isolated polynucleotide.</p><p id="p0023" num="0023">The kit may further comprises a DNA polymerase. The polymerase may be a thermostable DNA polymerase. The kit may further comprise a reverse transcriptase. The first and/or second polynucleotide may be detectably labeled.</p><p id="p0024" num="0024">Disclosed is a reaction mixture comprising an isolated polynucleotide: of between 8-100 nucleotides wherein the polynucleotide functions as a primer in <i>Insulin-like Growth Factor 2 (IGF2)</i> cDNA, such that the polynucleotide hybridizes to the cDNA and the 3' terminal nucleotide of the polynucleotide is complementary to the nucleotide immediately upstream of the polymorphic nucleotide of a SNP so that extension of the polynucleotide by a polymerase incorporates a nucleotide complimentary to the polymorphic nucleotide of the SNP; or<br/>
of between 8-100 nucleotides wherein the polynucleotide functions as a primer in <i>Insulin-like Growth Factor 2 (IGF2)</i> cDNA, such that the polynucleotide hybridizes to the cDNA and the 3' nucleotide of the polynucleotide is complementary to the nucleotide immediately upstream of the polymorphic nucleotide of a SNP so that extension of the polynucleotide by a polymerase incorporates a nucleotide complimentary to the polymorphic nucleotide of the SNP, wherein the SNP is selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7,<!-- EPO <DP n="8"> --> 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47.</p><p id="p0025" num="0025">The reaction mixtures may comprise:
<ul><li>a first isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between a first allele of a SNP (or a complement thereof) and a second allele of the SNP (or a complement thereof) in a hybridization reaction; a thermostable DNA polymerase; and human genomic DNA or cDNA from reverse-transcription of human RNA.</li></ul></p><p id="p0026" num="0026">The first isolated polynucleotide may hybridize to the DNA. The polymerase may be a thermostable DNA polymerase.</p><p id="p0027" num="0027">The reaction mixtures may further comprise a second isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between the first allele of the SNP (or complement thereof) and the second allele of the SNP (or complement thereof), and wherein the first polynucleotide is complementary to the polymorphic nucleotide in the first allele and the second polynucleotide is complementary to the polymorphic nucleotide of the second allele.</p><p id="p0028" num="0028">The reaction mixtures may further comprise one or more primer for amplifying a region of the <i>IGF2</i> locus encompassing the polymorphic site, wherein the one or more primer is different from the isolated polynucleotide.</p><p id="p0029" num="0029">Disclosed are methods of quantifying allelic-specific expression of RNA in a human individual, wherein the human individual is a heterozygote for at least two single nucleotide polymorphisms (SNPs) in the <i>Insulin Growth Factor-2 (IGF2)</i> gene. The methods may comprise:
<ul><li>quantifying the amount of RNA in a sample from the human individual comprising one or more polymorphic option of each of at least two SNPs, wherein the two SNPs are each selected from "Linkage Block" 1 of Tables 1A, 1B, 1C, 2A or 2B; or</li><li>quantifying the amount of RNA in a sample from the human individual comprising one or each polymorphic option of each of at least two SNPs, wherein the at least two SNPs are each selected from "Linkage Block" 2 of Tables 1A, 1B, 1C, 2A or 2B; or<!-- EPO <DP n="9"> --></li><li>quantifying the amount of RNA in a sample from the human individual comprising one or each polymorphic option of each of at least two SNPs, wherein the at least two SNPs are each selected from "Linkage Block" 3 of Tables 1A, 1B, 1C, 2A or 2B.</li></ul></p><p id="p0030" num="0030">The sample may be a blood or tissue sample. The sample may be a stool sample. The method may comprise correlating the relative amount of RNA comprising each polymorphic option of the SNPs to loss of imprinting of the IGF2 gene and/or predisposition for cancer.</p><p id="p0031" num="0031">The RNA may be reverse transcribed into cDNA and the quantity of allele-specific cDNA is used to determine the amount of RNA.</p><heading id="h0003">DEFINITIONS</heading><p id="p0032" num="0032">A "thermostable polymerase" refers to a polymerase useful for PCR applications. A thermostable polymerase can generally be heated to 75°C repeatedly (e.g., at least 20 times for a minute each time) and retain at least 80% of its original activity. Examples of such polymerases include, but are not limited to, <i>Taq</i> polymerase.</p><p id="p0033" num="0033">A "single nucleotide polymorphism" or "SNP" refers to a site of one nucleotide that varies between alleles.</p><p id="p0034" num="0034">An "allele" refers to one member of a pair or set of different forms of a gene. In a diploid organism, an individual has two copies of each autosomal gene. For a single nucleotide polymorphism, an individual has two different alleles of the polymorphic nucleotide if the genotype at the polymorphic nucleotide is different on one copy of the gene than the other copy of the gene (i.e. the individual is heterozygous for the polymorphic nucleotide). If an individual has the same genotype at the polymorphic nucleotide on both copies of the gene (i.e. the individual is homozygous for the polymorphic nucleotide), then the individual has two copies of the same allele of the polymorphic nucleotide. A given individual can be homozygous for one polymorphic nucleotide within a gene (two copies of the same allele of the polymorphic nucleotide) and heterozygous for a different polymorphic nucleotide within the same gene (two different alleles of the polymorphic nucleotide).</p><p id="p0035" num="0035">"Hybridization" refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly<!-- EPO <DP n="10"> --> complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch.</p><p id="p0036" num="0036">"Target sequence" or "target region" refers to a region of a nucleic acid that is to be analyzed and comprises the polymorphic site of interest.</p><p id="p0037" num="0037">As used herein, the terms "nucleic acid," "polynucleotide" and "oligonucleotide" refer to nucleic acid regions, nucleic acid segments, primers, probes, amplicons and oligomer fragments. The terms are not limited by length and are generic to linear polymers of polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), and any other N-glycoside of a purine or pyrimidine base, or modified purine or pyrimidine bases. These terms include double- and single-stranded DNA, as well as double-and single-stranded RNA.</p><p id="p0038" num="0038">A nucleic acid, polynucleotide or oligonucleotide can comprise, for example, phosphodiester linkages or modified linkages including, but not limited to phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages.</p><p id="p0039" num="0039">A nucleic acid, polynucleotide or oligonucleotide can comprise the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) and/or bases other than the five biologically occurring bases. For example, a polynucleotide of the invention can contain one or more modified, non-standard, or derivatized base moieties, including, but not limited to, N<sup>6</sup>-methyl-adenine, N<sup>6</sup>-tert-butyl-benzyl-adenine, imidazole, substituted imidazoles, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, uracil-5- oxyacetic acidmethylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, 2,6- diaminopurine, and<!-- EPO <DP n="11"> --> 5-propynyl pyrimidine. Other examples of modified, non-standard, or derivatized base moieties may be found in <patcit id="pcit0001" dnum="US6001611A"><text>U.S. Patent Nos. 6,001,611</text></patcit>; <patcit id="pcit0002" dnum="US5955589A"><text>5,955,589</text></patcit>; <patcit id="pcit0003" dnum="US5844106A"><text>5,844;106</text></patcit>;<patcit id="pcit0004" dnum="US5789562A"><text> 5,789,562</text></patcit>; <patcit id="pcit0005" dnum="US5750343A"><text>5,750,343</text></patcit>; <patcit id="pcit0006" dnum="US5728525A"><text>5,728,525</text></patcit>; and <patcit id="pcit0007" dnum="US5679785A"><text>5,679,785</text></patcit>.</p><p id="p0040" num="0040">Furthermore, a nucleic acid, polynucleotide or oligonucleotide can comprise one or more modified sugar moieties including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and a hexose.</p><p id="p0041" num="0041">"Haplotype block" refers to a region of a chromosome that contains one or more polymorphic sites (e.g., 1-10) that tend to be inherited together. In other words, combinations of polymorphic forms at the polymorphic sites within a block cosegregate in a population more frequently than combinations of polymorphic sites that occur in different haplotype blocks. Polymorphic sites within a haplotype block tend to be in linkage disequilibrium with each other. Often, the polymorphic sites that define a haplotype block are common polymorphic sites. Some haplotype blocks contain a polymorphic site that does not cosegregate with adjacent polymorphic sites in a population of individuals.</p><p id="p0042" num="0042">"Linkage disequilibrium" refers to the preferential segregation of a particular polymorphic form with another polymorphic form at a different chromosomal location more frequently than expected by chance. Linkage disequilibrium can also refer to a situation in which a phenotypic trait displays preferential segregation with a particular polymorphic form or another phenotypic trait more frequently than expected by chance.</p><heading id="h0004">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0043" num="0043"><ul><li><figref idrefs="f0001">Figure 1A</figref> illustrates the structure of the <i>IGF2</i> gene. The scale bar above the gene diagram is drawn in 1 Kb increments and depicts the location of <i>IGF2</i> on chromosome 11 (NCBI build 36). The scale bar is also present in <figref idrefs="f0004">Figure 4</figref>. Arrows in <figref idrefs="f0001">Figure 1A</figref>, represent the four promoters of <i>IGF2.</i> Exons 1 to 9 are indicated below the gene diagram. Black shaded exons 1 to 6 are not protein-coding in most transcripts of <i>IGF2.</i> The white exons 7 and 8 are protein-coding, as is the small white region of exon 9. The black shaded region of exon 9 is the 3' UTR.</li><li><figref idrefs="f0001">Figure 1B</figref> illustrates the regions of <i>IGF2</i> predicted to fall within haplotype blocks (black horizontal bars) and within regions predicted to be in low linkage disequilibrium (grey horizontal bar) based on haplotype analysis of HapMap II genotyping data, as described in the Background section.<!-- EPO <DP n="12"> --></li><li><figref idrefs="f0001">Figure 1C</figref> illustrates the region of <i>IGF2</i> predicted to fall within a haplotype block (black horizontal bars) and within two uncharacterized regions of IGF2 (grey horizontal bars) based on a previous study (<nplcit id="ncit0023" npl-type="s"><text>Gaunt et al. Human Mol Genet. 10(14):1491-1501 (2001</text></nplcit>)), as described in the Background section and in Example 3.</li><li><figref idrefs="f0002">Figure 2</figref> illustrates a basic strategy for determining LOI of <i>IGF2</i> in a biological sample. Genomic DNA and total or polyadenylated RNA are isolated from a biological sample (for example, peripheral blood, peripheral blood mononuclear cells, stool, ect.) from and individual. The genomic DNA sample is used for genotyping of one or more polymorphic markers (DNA SNP Assay). This step determines whether the individual is heterozygous for a specific SNP or combination of SNPs. Any SNP, or combination of SNPs, determined to be heterozygous may be utilized for analysis of allele-specific expression of the <i>IGF2</i> gene in the matched RNA sample (RNA SNP assay). In the example shown, an individual was determined by an allele-discriminating DNA genotyping assay to be homozygous for hypothetical SNPs 1, 3, 4 and 6 and heterozygous for hypothetical SNPs 2 and 5. cDNA is amplified from the relevant region of the <i>IGF2</i> transcript using standard reverse transcriptase and PCR methods such that PCR products including at least SNPs 2 and 5 are amplified. Expression from each of the two copies of the <i>IGF2</i> gene is independently measured using the generated cDNA with a quantitative allele specific gene expression assay, and that can sufficiently discriminate between the two alleles of the gene. Comparison of the amount of expression of one allele relative to the amount of expression of the other allele thereby determines the imprinting status of the <i>IGF2</i> gene. Assays that discriminate SNPs 2 and 5 may be performed simultaneously, and allele specific expression ratios obtained for each assay can be compared to improve accuracy.</li><li><figref idrefs="f0003">Figure 3</figref> illustrates the haplotype analysis of HapMap II SNP genotype data, as described in the Background section. The gene diagram of <i>IGF2</i> (described in <figref idrefs="f0001">Figure 1A</figref>) is shown, with Haploview-generated linkage data represented below. Vertical lines indicate the positions of predicted haplotype blocks (horizontal black bars) relative to the <i>IGF2</i> gene diagram. Diamonds are shaded based on the linkage data for the indicated pair-wise comparison of SNPs. Black diamonds represent SNP pairs for which there is strong evidence for linkage disequilibrium (D=1 and LOD score ≥ 2). White diamonds represent SNP pairs for which there is strong evidence for historical recombination, indicating minimal linkage disequilibrium (D' &lt;1 and LOD score &lt;2). Grey diamonds represent SNP pairs which provided uninformative data for determination of linkage disequilibrium. dbSNP identifiers<!-- EPO <DP n="13"> --> for the SNPs defining the boundaries of the predicted haplotype blocks are indicated at the bottom left of the figure. Analysis of HapMap II data supports a haplotype block encompassing exon 9.</li><li><figref idrefs="f0004">Figure 4</figref> illustrates the haplotype analysis of SNP genotype data for a combined cohort of Caucasian, African American, Chinese, Japanese and Mexican individuals generated by the study described in the present application. The gene diagram of <i>IGF2</i> is shown. Vertical lines indicate the relative positions of analyzed SNPs, and extend to the Haploview visualization of linkage analysis below. The horizontal grey bar represents the haplotype block, and the horizontal white bars represent the uncharacterized regions of exon 9 as determined by Gaunt <i>et al.</i> (see Background section and Example 3). Shading of diamonds is as described in <figref idrefs="f0003">Figure 3</figref>. The SEQ ID NO: numbers for analyzed SNPs and the previously reported linkage block (Gaunt Block) to which each belongs are indicated at the bottom left.</li><li><figref idrefs="f0005">Figure 5</figref> illustrates the use of a restriction enzyme based assay for genotyping the SNP corresponding to SEQ ID NO: 64. The polymorphic nucleotide is located within the recognition sequence of two restriction enzymes. <i>Apa I</i> recognizes and cleaves the sequence when the "G" allele is present, and <i>Ava II</i> recognizes and cleaves the sequence when the "A" allele is present. A PCR amplicon including SEQ ID NO: 64 was amplified from three independent genomic DNA samples derived from three individuals (Samples A, B and C). Amplicons were digested with <i>Apa I or Ava II</i> or a combination of both enzymes (Double). Digestion by <i>Apa I</i> only indicates that the individual is homozygous for the G allele (Sample B), digestion by <i>Ava II</i> only indicates that the individual is homozygous for the A allele (Sample C), and digestion by both enzymes indicates that the individual is heterozygous for the SNP (Sample A).</li><li><figref idrefs="f0006">Figure 6</figref> illustrates the use of a restriction enzyme based method for detecting LOI of <i>IGF2.</i> Total RNA was extracted from three individuals that are heterozygous for SEQ ID NO:64. The region including SEQ ID NO:64 was RT-PCR amplified from each sample. cDNA amplicons were digested with <i>Apa I or Ava II</i> or a combination of both enzymes, as indicated above each lane. Digested products were resolved on an Agilent Bioanalyzer, and concentrations of cut and uncut fragments were determined. The quantity of fragments cut by <i>Apa I</i> represents the proportion of cDNA including the "G" allele. The quantity of fragments cut by <i>Ava II</i> represents the proportion of cDNA including the "A" allele.<!-- EPO <DP n="14"> --> Therefore, the ratio of <i>Apa I</i> cut fragments to <i>Ava II</i> cut fragments indicates the relative ratio of expression of the two alleles in the original RNA sample. The calculated G:A ratio is shown below each triplet of lanes representing each sample. Sample 2 expresses exclusively the "A" allele. Samples 1 and 3 express both alleles (<i>i.e</i>. display LOI <i>IGF2</i>)<i>,</i> with G:A ratios of 0.5 and 0.3, respectively.</li><li><figref idrefs="f0007">Figure 7</figref> diagrams a method for allele-specific detection of a SNP using a single nucleotide primer extension strategy. The SNP represented by SEQ ID NO:64 and its surrounding DNA sequence are shown as an example ("PCR amplicon sequence" - SEQ ID NO: 114). The nucleotide position of SEQ ID NO:64 is indicated by the arrow labeled "SeqID 64". The sequence of the polynucleotide used for single nucleotide primer extension is indicated by the bracket labeled "Primer" (SEQ ID NO:113). The PCR DNA amplicon (or, alternatively a RT-PCR cDNA amplicon) including the sequence of interest is amplified from the sample to be assayed. A primer is added to the purified PCR (or, alternatively RT-PCR) product that anneals with its 3' terminal nucleotide complimentary to the template nucleotide 1 base to the 3' side of the polymorphic nucleotide to be genotyped. Single nucleotide primer extension is carried out using a thermostable DNA polymerase and differentially fluorescently labeled ddNTPs. In this example, either dR110-labeled ddGTP or dR6G-labeled ddATP is added to the 3' end of the primer (generating SEQ ID NOs: 115 and 116, respectively). These labeled polynucleotides are then resolved and the peak areas representative of each possible incorporated nucleotide are calculated. Peak areas are compared to determine the genotype of the individual at that SNP position (or, alternatively the allele-specific gene expression ratio).</li><li><figref idrefs="f0008">Figure 8</figref> illustrates the use of the single nucleotide primer extension assay described in <figref idrefs="f0007">Figure 7</figref> to genotype three individuals for SEQ ID NO:64. The three individuals that were assayed for LOI of <i>IGF2</i> by the restriction enzyme based assay shown in <figref idrefs="f0006">Figure 6</figref> were genotyped. The figure shows the resulting chromatograms for each sample following resolution and peak detection using an ABI Genetic Analyzer and Gene Mapper software. As expected, peaks representing both alleles of SEQ ID NO:64 are obtained in relatively equal proportions, confirming that the three individuals are heterozygous for SEQ ID NO:64 and demonstrating the concordance between results obtained by the restriction enzyme based method and the single nucleotide primer extension based method.<!-- EPO <DP n="15"> --></li><li><figref idrefs="f0009">Figure 9</figref> illustrates the application of the single nucleotide primer extension based method for detecting LOI of <i>IGF2.</i> The region including SEQ ID NO:64 was RT-PCR amplified from a total RNA sample derived from each of the three individuals genotyped in <figref idrefs="f0008">Figure 8</figref>. The cDNA products obtained were purified and analyzed as diagrammed in <figref idrefs="f0007">Figure 7</figref>. The figure shows the resulting chromatograms for each sample following resolution and peak detection using an ABI Genetic Analyzer and Gene Mapper software. For each sample, peak areas representing each of the two possible alleles were calculated and compared to each other. The calculated G:A ratios are indicated to the right of each chromatogram. Consistent with the results shown in <figref idrefs="f0006">Figure 6</figref>, Samples 1 and 3 were determined to show LOI of <i>IGF2,</i> and Sample 2 was determined to show normal imprinting of <i>IGF2.</i></li><li><figref idrefs="f0010">Figure 10</figref> illustrates the quantitative analytical linearity of single nucleotide primer extension assays developed for nine independent SNPs. The SEQ ID number for each assayed SNP is indicated to the right of the graph. For each assay, PCR products were separately amplified from genomic DNA samples derived from two individuals; one homozygous for one allele of the SNP and the other homozygous for the other allele of the SNP. The PCR products were purified and quantified. For each of the nine SNPs, two PCR products (one amplified from the DNA sample homozygous for one allele and the other amplified from the DNA sample homozygous for the other allele) were combined in the following ratios of allele 1 to allele 2; 1:10, 1:8, 1:6, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 6:1, 8:1 and 10:1. For each of the nine SNPs, the single nucleotide primer extension assay was performed in triplicate on each dilution point. Peak areas representing each of the two possible alleles were calculated (y-axis) and compared to the known input ratio of each allele pair (x-axis). Values are plotted on a log10 scale. The average R<sup>2</sup> of the assays is 0.996 ± 0.002 and the average slope is 0.830 ± 0.024, demonstrating that each assay is capable of sensitively and accurately measuring relative quantitative ratios of each allele pair represented in a sample.</li></ul></p><heading id="h0005">DETAILED DESCRIPTION</heading><heading id="h0006"><b><i>I. Introduction</i></b></heading><p id="p0044" num="0044">The present invention provides methods of detecting LOI of <i>IGF2</i> and includes novel single nucleotide polymorphism (SNPs) in the <i>IGF2</i> gene. Detection of these SNPs, alone or in combination with each other, or in combination with previously known SNPs, provide a valuable new way to detect, for example, loss of imprinting of <i>IGF2.</i> The new<!-- EPO <DP n="16"> --> SNPs can, alone or in combination, be used to independently monitor expression of each of a human individual's two copies of the <i>IGF2</i> gene, and can be used to determine the imprinting status of <i>IGF2</i> in a biological sample. For example, if an individual is heterozygous for a particular <i>IGF2</i> SNP, then probes or other reagents can be employed to separately detect and quantify RNA from each <i>IGF2</i> allele. If one allele is predominantly expressed, then imprinting of <i>IGF2</i> is likely occurring. However, if both alleles are expressed at similar levels, it is likely that loss of imprinting of <i>IGF2</i> has occurred.</p><p id="p0045" num="0045">Further, it is now possible to monitor loss of imprinting in many more human genetic and racial backgrounds. As an example, the present invention provides a number of SNPs that commonly occur in African American, Caucasian, Chinese, Japanese and Mexican populations, thereby allowing for more useful methods for determining cancer risk in those populations than ever before.</p><p id="p0046" num="0046">In addition to the discovery of novel IGF2 SNPs, disclosed is for combinations of IGF2 SNPs that provide a surprising improvement in the ability to detect LOI in individuals compared to what was predicted previously. For example, prior research into genetic recombination frequency at the IGF2 locus described the existence of blocks of low recombination, indicating that there would be no advantage for using two or more SNPs within the same block. <i>See, e.g.,</i> HapMap II (NCBI build 36); Gaunt <i>et al., supra.</i> These blocks are depicted in <figref idrefs="f0001">Figures 1B and 1C</figref>. However, as shown in the data presented herein (see, e.g., <figref idrefs="f0004">Figure 4</figref>), there is in fact substantial recombination within these "blocks" and therefore detection of two or more SNPs within these "blocks" provides a substantial improvement in the ability to detect LOI in individuals than was predicted in the prior art.</p><p id="p0047" num="0047">Accordingly, disclosed is the combination of SNPs (either as first described herein or as previously known) that are surprisingly effective in improving the accuracy of LOI determination as well as expanding the possible populations of people for which the assay will be effective (where a person is heterozygous for at least one SNP).</p><heading id="h0007"><b><i>II. IGF2 SNPs</i></b></heading><p id="p0048" num="0048">The following sequence identifiers represent SNP sequences within the IGF2 locus selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,<!-- EPO <DP n="17"> --> 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, and 112.</p><p id="p0049" num="0049">Disclosed are isolated nucleic acids that comprise at least one SNP having one or the other polymorphic sequence, wherein the SNP sequences are selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47.</p><p id="p0050" num="0050">Further disclosed are polynucleotides that distinguish between two alleles of a SNP, wherein the SNP is selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47.</p><p id="p0051" num="0051">For example, the present invention provides polynucleotides that hybridize to a first allele of a particular SNP, but does not significantly hybridize to the second allele of the SNP. "Does not significantly hybridize" means that in the presence of equal amounts of both alleles in a sample, the polynucleotide is able to detect the presence of the first allele but does not detect the presence of the second allele to such an extent so as to interfere with the interpretation of the assay. In some embodiments, in the presence of equal amounts of both alleles in a sample, the polynucleotide provides a signal for a sample having the first allele that is at least, e.g., about 100; 1,000; 10,000; 100,000 times or more than the signal generated by the polynucleotide for a sample having an equal amount of the second allele. "Signal" refers to any output indicative of hybridization of the polynucleotide to a complementary sequence. At least 70%, 80%, 90%, 95% of the sequence of the polynucleotide may be complementary to the SNP of SEQ ID NO: 10, for example, they have at least 8, 10, 15, 20, 30, 40, 50 complementary nucleotides.</p><p id="p0052" num="0052">Alternatively, the polynucleotides can distinguish between two alleles of a SNP by acting as a primer in a template-specific primer extension reaction. In these embodiments, the polynucleotides do not generally encompass the polymorphic nucleotide but instead hybridize to the genomic DNA such that 3' extension of the polynucleotide occurs at the polymorphic nucleotide. Thus, in some embodiments, the 3' end of the polynucleotide is complementary to a nucleotide 1 nucleotide upstream from the polymorphic nucleotide. In some embodiments, the polynucleotides are complementary over at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the polynucleotides length to an IGF2 cDNA. In some embodiments, the polynucleotide comprises at its 3'<!-- EPO <DP n="18"> --> end, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more contiguous nucleotides that are at least at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to an IGF2 cDNA. Optionally, the 5' end of the polynucleotide will comprise a sequence tag or other sequence not complementary to an IGF2 cDNA. As is well known in the art, a variety of primer extension methods can be employed to detect SNPs.</p><p id="p0053" num="0053">The polynucleotides that distinguish between the two alleles may be between 8-100 nucleotides in length. These polynucleotides may be at least 8, 10, 12, 15, 20, 30, 50, or more nucleotides in length. The polynucleotides may be no more than 100, 80, 50, 40, 30, or 25 nucleotides in length. For example, the polynucleotides can be, e.g., 8-25, 8-30, 8-50, 8-100, 10-25, 10-50, 10-100, nucleotides, etc. The polynucleotides that distinguish between the two alleles will typically include a nucleotide that corresponds (i.e., aligns with) and is complementary to one of the polymorphic nucleotides of the SNP. In some embodiments, the ultimate or penultimate 3' nucleotide of the polynucleotide is complementary to a nucleotide at the polymorphic position of the SNP. Such embodiments can be particularly useful in SNP detection methods employing the polynucleotides as primers or probes, for example in amplification-based assays such as those involving the polymerase chain reaction.</p><p id="p0054" num="0054">The polynucleotides of the invention can be detectably labeled. Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., Dynabeads™), fluorescent dyes (e.g., fluorescein, Texas red, rhodamine, green fluorescent protein, and the like, see, e.g., Molecular Probes, Eugene, Oregon, USA), radiolabels (e.g., <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold (e.g., gold particles in the 40-80 nm diameter size range scatter green light with high efficiency) or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels include <patcit id="pcit0008" dnum="US3817837A"><text>U.S. Patent Nos. 3,817,837</text></patcit>; <patcit id="pcit0009" dnum="US3850752A"><text>3,850,752</text></patcit>;<patcit id="pcit0010" dnum="US3939350A"><text> 3,939,350</text></patcit>; <patcit id="pcit0011" dnum="US3996345A"><text>3,996,345</text></patcit>;<patcit id="pcit0012" dnum="US4277437A"><text> 4,277,437</text></patcit>; <patcit id="pcit0013" dnum="US4275149A"><text>4,275,149</text></patcit>; and <patcit id="pcit0014" dnum="US4366241A"><text>4,366,241</text></patcit>.</p><p id="p0055" num="0055">Hybridization reaction conditions can vary depending on the assay that is used to detect the SNPs. Stringent, sequence-specific hybridization conditions, under which an<!-- EPO <DP n="19"> --> oligonucleotide will hybridize only to the exactly complementary target sequence, are well known in the art. Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the base pairs have dissociated. Relaxing the stringency of the hybridizing conditions will allow sequence mismatches to be tolerated; the degree of mismatch tolerated can be controlled by suitable adjustment of the hybridization conditions.</p><p id="p0056" num="0056">For Southern-type hybridization, exemplary conditions are: 50% formamide, 5X SSC, and 1% SDS, incubating at 42°C, or 5X SSC, 1% SDS, incubating at 65°C, with wash in 0.2X SSC, and 0.1% SDS at 55°C, 60°C, or 65°C. Such washes can be performed for 5, 15, 30, 60, 120, or more minutes. For PCR applications (involving hybridization and/or extension of primers and/or probes), hybridization conditions comprising annealing and extension condition are well known, e.g., as described in <nplcit id="ncit0024" npl-type="b"><text>PCR Protocols: A Guide to Methods and Applications (Innis et al., eds., 1990</text></nplcit>).</p><p id="p0057" num="0057">The present invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include <nplcit id="ncit0025" npl-type="b"><text>Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd ed. 2001</text></nplcit>);<nplcit id="ncit0026" npl-type="b"><text> Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990</text></nplcit>); and <nplcit id="ncit0027" npl-type="b"><text>Current Protocols in Molecular Biology (Ausubel et al., eds., 1994</text></nplcit>)).</p><heading id="h0008"><b><i>III. Methods for Measuring Loss of Imprinting and Cancer Predisposition</i></b></heading><p id="p0058" num="0058">Detection of LOI is based on a comparison of the amount of expression derived from each of the two copies of the <i>IGF2</i> gene within a biological sample from an individual. Thus, if an individual has two different alleles of the <i>IGF2</i> gene, then allele-specific detection can be used to quantify expression of each copy of the gene. If imprinting is functioning, then one copy of the gene (typically the maternal copy) will not be expressed in spite of the presence of a genomic copy of the gene. However, if LOI has occurred, then expression will occur from both the maternal and paternal copies of the <i>IGF2</i> gene. Because expression levels are not always exactly equal when LOI has occurred, in some embodiments, a sample is determined to display LOI of <i>IGF2</i> if the quantified proportion of the lesser abundant allele is greater than or equal to 33.3% the quantified proportion of the more abundant allele.<!-- EPO <DP n="20"> --></p><p id="p0059" num="0059">It is generally desirable to know whether an individual is heterozygous for a particular SNP. Thus in some embodiments, both DNA (i.e., genomic DNA) and RNA from a sample are obtained. The genomic DNA is assayed to determine whether the individual is heterozygous for a particular SNP. If the individual is heterozygous, then it is possible to measure loss of imprinting by detecting RNA having either of the two SNP alleles and then comparing their expression. This is illustrated in <figref idrefs="f0002">Figure 2</figref>. In some circumstances, however, it may be beneficial to detect only RNA without knowing whether the individual is a heterozygote for a particular SNP. In this circumstance, observing expression of two alleles indicates LOI, while detecting expression of one allele is not informative because it will not be known if the negative result is due to imprinting or homozygosity of the particular SNP. However, by increasing the number of different SNPs detected, it is possible to design an assay such that the chance of an individual being homozygous for every SNP would be extremely low.</p><p id="p0060" num="0060">More than one SNP may be assayed for an individual. "Assayed" or "assayed for" refers to separately quantifying each possible allele of the SNP. Generally, any combination of SNPs can be assayed for in a sample. 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 75, 100, or more different SNPs may be assayed to determine whether LOI of <i>IGF2</i> has occurred. Optimally, amplicons are designed that encompass more than one SNP, thereby allowing for efficient detection of multiple SNPs.</p><p id="p0061" num="0061">As explained in detail in Example 3, the detection of two SNPs in general proximity to each other improves both accuracy of the assay as well as the number of possible heterozygous candidates. This latter finding is particularly surprising in view of earlier reports implying that certain genomic regions segregate as linkage blocks. In view of the discoveries described in Example 3, disclosed is the detection of the relative amounts of the polymorphic options of two or more SNPs, wherein each SNP is selected from the same "Block" as listed in Tables 1A, 1B, 1C, 2A and 2B. Thus, for example, two or more SNPs are assayed for in Block 1. Or, two or more SNPs are assayed for in Block 2. Or, two or more SNPs are assayed for in Block 3. These options do not preclude further addition of SNPs from other Blocks. Simply as an example, this means that two SNPs from Block 1 and one SNP from Block 2 could be assayed for.<!-- EPO <DP n="21"> --></p><p id="p0062" num="0062">As shown in Tables 4-8, various racial groups display different occurrence rates of heterozygosity for the SNPs. Thus, SNPs may be selected for use within a particular racial group to allow for improved chance of assaying for SNPs that are heterozygous in a particular racial group. Thus, one or more SNPs in Table 4 are assayed for in people of Chinese descent, one or more SNPs in Table 5 are assayed for in people of Japanese descent, one or more SNPs in Tables 6 are assayed for in people of African descent, one or more SNPs in Table 7 are assayed for in Caucasian people, and one or more SNPs in Table 8 are assayed for in people of Mexican descent.</p><p id="p0063" num="0063">Alternatively, one set of SNPs can be selected to allow for the greatest chance of assaying for a heterozygous SNP regardless of race. Thus, a panel of SNPs selected from Tables 4-8 may be used.</p><p id="p0064" num="0064">A person of a certain racial group as listed in Tables 4-8 may be tested with one or more SNPs having the same Linkage Block as listed in Tables 1A-C and 2 A-B for that same racial group.</p><heading id="h0009"><b><i>IV. Methods of SNP Detection</i></b></heading><p id="p0065" num="0065">Detection techniques for evaluating nucleic acids for the presence of a SNP involve procedures well known in the field of molecular genetics. Further, many of the methods involve amplification of nucleic acids. Ample guidance for performing is provided in the art. Exemplary references include manuals such as <nplcit id="ncit0028" npl-type="b"><text>PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992</text></nplcit>); <nplcit id="ncit0029" npl-type="b"><text>PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990</text></nplcit>); <nplcit id="ncit0030" npl-type="s"><text>Current Protocols in Molecular Biology, Ausubel, 1994-1999, including supplemental updates through April 2004</text></nplcit>; <nplcit id="ncit0031" npl-type="b"><text>Sambrook &amp; Russell, Molecular Cloning, A Laboratory Manual (3rd Ed, 2001</text></nplcit>).</p><p id="p0066" num="0066">Although the methods typically employ PCR steps, other amplification or non-amplification-based protocols may also be used. Suitable amplification methods include ligase chain reaction <i>(see, e.g.,</i> <nplcit id="ncit0032" npl-type="s"><text>Wu &amp; Wallace, Genomics 4:560-569, 1988</text></nplcit>); strand displacement assay (<i>see, e.g.,</i> <nplcit id="ncit0033" npl-type="s"><text>Walker et al., Proc. Natl. Acad. Sci. USA 89:392-396, 1992</text></nplcit>; <patcit id="pcit0015" dnum="US5455166A"><text>U.S. Pat. No. 5,455,166</text></patcit>); and several transcription-based amplification systems, including the methods described in <patcit id="pcit0016" dnum="US5437990A"><text>U.S. Pat. Nos. 5,437,990</text></patcit>; <patcit id="pcit0017" dnum="US5409818A"><text>5,409,818</text></patcit>; and <patcit id="pcit0018" dnum="US5399491A"><text>5,399,491</text></patcit>; the transcription amplification system (TAS) (<nplcit id="ncit0034" npl-type="s"><text>Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173-1177, 1989</text></nplcit>);<!-- EPO <DP n="22"> --> and self-sustained sequence replication (3SR) <i>(</i><nplcit id="ncit0035" npl-type="s"><text>Guatelli et al., Proc. Natl. Acad. Sci. USA 87:1874-1878, 1990</text></nplcit>; <patcit id="pcit0019" dnum="WO9208800A"><text>WO 92/08800</text></patcit>). Alternatively, methods that amplify the probe to detectable levels can be used, such as Qβ-replicase amplification (<nplcit id="ncit0036" npl-type="s"><text>Kramer &amp; Lizardi, Nature 339:401-402, 1989</text></nplcit>; <nplcit id="ncit0037" npl-type="s"><text>Lomeli et al., Clin. Chem. 35:1826-1831, 1989</text></nplcit>). A review of known amplification methods is provided, for example, by <nplcit id="ncit0038" npl-type="s"><text>Abramson and Myers in Current Opinion in Biotechnology 4:41-47, 1993</text></nplcit>.</p><p id="p0067" num="0067">Typically, detecting SNPs in an individual is performed using oligonucleotide primers and/or probes. Oligonucleotides can be prepared by any suitable method, usually chemical synthesis. Oligonucleotides can be synthesized using commercially available reagents and instruments. Alternatively, they can be purchased through commercial sources. Methods of synthesizing oligonucleotides are well known in the art <i>(see, e.g,</i> <nplcit id="ncit0039" npl-type="s"><text>Narang et al., Meth. Enzymol. 68:90-99, 1979</text></nplcit>; <nplcit id="ncit0040" npl-type="s"><text>Brown et al., Meth. Enzymol. 68:109-151, 1979</text></nplcit>; <nplcit id="ncit0041" npl-type="s"><text>Beaucage et al., Tetrahedron Lett. 22:1859-1862, 1981</text></nplcit>; and the solid support method of <patcit id="pcit0020" dnum="US4458066A"><text>U.S. Pat. No. 4,458,066</text></patcit>). In addition, modifications to the above-described methods of synthesis may be used to desirably impact enzyme behavior with respect to the synthesized oligonucleotides. For example, incorporation of modified phosphodiester linkages (e.g., phosphorothioate, methylphosphonates, phosphoamidate, or boranophosphate) or linkages other than a phosphorous acid derivative into an oligonucleotide may be used to prevent cleavage at a selected site. In addition, the use of 2'-amino modified sugars tends to favor displacement over digestion of the oligonucleotide when hybridized to a nucleic acid that is also the template for synthesis of a new nucleic acid strand.</p><p id="p0068" num="0068">The amount and/or presence of an allele of a SNP in a sample from an individual can be determined using many detection methods that are well known in the art. A number of SNP assay formats entail one of several general protocols: hybridization using allele-specific oligonucleotides, primer extension, allele-specific ligation, sequencing, or electrophoretic separation techniques, <i>e.g.,</i> singled-stranded conformational polymorphism (SSCP) and heteroduplex analysis. Exemplary assays include 5' nuclease assays, template-directed dye-terminator incorporation, molecular beacon allele-specific oligonucleotide assays, single-base extension assays, and SNP scoring by real-time pyrophosphate sequences. Analysis of amplified sequences can be performed using various technologies such as microchips, fluorescence polarization assays, and matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Two methods that can also be used are assays based on invasive cleavage with Flap nucleases and methodologies employing padlock probes.<!-- EPO <DP n="23"> --></p><p id="p0069" num="0069">Determining the presence or absence of a particular SNP allele is generally performed by analyzing a nucleic acid sample that is obtained from a biological sample from the individual to be analyzed. While the amount and/or presence of a SNP allele can be directly measured using RNA from the sample, often times the RNA in a sample will be reverse transcribed, optionally amplified, and then the SNP allele will be detected in the resulting cDNA.</p><p id="p0070" num="0070">Frequently used methodologies for analysis of nucleic acid samples to measure the amount and/or presence of an allele of a SNP are briefly described. However, any method known in the art can be used in the invention to measure the amount and/or presence of single nucleotide polymorphisms.</p><heading id="h0010"><u>Allele Specific Hybridization</u></heading><p id="p0071" num="0071">This technique, also commonly referred to as allele specific oligonucleotide hybridization (ASO) (<i>e.g.,</i> <nplcit id="ncit0042" npl-type="s"><text>Stoneking et al., Am. J. Hum. Genet. 48:70-382, 1991</text></nplcit>; <nplcit id="ncit0043" npl-type="s"><text>Saiki et al., Nature 324, 163-166, 1986</text></nplcit>; <patcit id="pcit0021" dnum="EP235726A"><text>EP 235,726</text></patcit>; and <patcit id="pcit0022" dnum="WO8911548A"><text>WO 89/11548</text></patcit>), relies on distinguishing between two DNA molecules differing by one base by hybridizing an oligonucleotide probe that is specific for one of the variants to an amplified product obtained from amplifying the nucleic acid sample. This method may employ short oligonucleotides, <i>e.g.,</i> 15-20 bases in length. The probes are designed to differentially hybridize to one variant versus another. Principles and guidance for designing such probe is available in the art, <i>e.g.,</i> in the references cited herein. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA or cDNA such that the polymorphic site aligns with a central position (<i>e.g.,</i> within 4 bases of the center of the oligonucleotide, for example, in a 15-base oligonucleotide at the 7 position; in a 16-based oligonucleotide at either the 8 or 9 position) of the probe (e.g., a polynucleotide of the invention distinguishes between two SNP alleles as set forth herein), but this design is not required.</p><p id="p0072" num="0072">The amount and/or presence of an allele is determined by measuring the amount of allele-specific oligonucleotide that is hybridized to the sample. Typically, the oligonucleotide is labeled with a label such as a fluorescent label. For example, an allele-specific oligonucleotide is applied to immobilized oligonucleotides representing potential<!-- EPO <DP n="24"> --> SNP sequences. After stringent hybridization and washing conditions, fluorescence intensity is measured for each SNP oligonucleotide.</p><p id="p0073" num="0073">The nucleotide present at the polymorphic site is identified by hybridization under sequence-specific hybridization conditions with an oligonucleotide probe exactly complementary to one of the polymorphic alleles in a region encompassing the polymorphic site. The probe hybridizing sequence and sequence-specific hybridization conditions are selected such that a single mismatch at the polymorphic site destabilizes the hybridization duplex sufficiently so that it is effectively not formed. Thus, under sequence- specific hybridization conditions, stable duplexes will form only between the probe and the exactly complementary allelic sequence. Thus, oligonucleotides from about 10 to about 35 nucleotides in length, e.g., from about 15 to about 35 nucleotides in length, which are exactly complementary to an allele sequence in a region which encompasses the polymorphic site are within the scope of the invention (e.g., SEQ ID NO: 10).</p><p id="p0074" num="0074">The amount and/or presence of the nucleotide at the polymorphic site may be identified by hybridization under sufficiently stringent hybridization conditions with an oligonucleotide substantially complementary to one of the SNP alleles in a region encompassing the polymorphic site, and exactly complementary to the allele at the polymorphic site. Because mismatches that occur at non-polymorphic sites are mismatches with both allele sequences, the difference in the number of mismatches in a duplex formed with the target allele sequence and in a duplex formed with the corresponding non-target allele sequence is the same as when an oligonucleotide exactly complementary to the target allele sequence is used. In this embodiment, the hybridization conditions are relaxed sufficiently to allow the formation of stable duplexes with the target sequence, while maintaining sufficient stringency to preclude the formation of stable duplexes with non-target sequences. Under such sufficiently stringent hybridization conditions, stable duplexes will form only between the probe and the target allele. Thus, oligonucleotides from about 10 to about 35 nucleotides in length, preferably from about 15 to about 35 nucleotides in length, which are substantially complementary to an allele sequence in a region which encompasses the polymorphic site, and are exactly complementary to the allele sequence at the polymorphic site, are within the scope of the invention.</p><p id="p0075" num="0075">The use of substantially, rather than exactly, complementary oligonucleotides may be desirable in assay formats in which optimization of hybridization conditions is limited. For<!-- EPO <DP n="25"> --> example, in a typical multi-target immobilized-probe assay format, probes for each target are immobilized on a single solid support. Hybridizations are carried out simultaneously by contacting the solid support with a solution containing target DNA or cDNA. As all hybridizations are carried out under identical conditions, the hybridization conditions cannot be separately optimized for each probe. The incorporation of mismatches into a probe can be used to adjust duplex stability when the assay format precludes adjusting the hybridization conditions. The effect of a particular introduced mismatch on duplex stability is well known, and the duplex stability can be routinely both estimated and empirically determined, as described above. Suitable hybridization conditions, which depend on the exact size and sequence of the probe, can be selected empirically using the guidance provided herein and well known in the art. The use of oligonucleotide probes to detect single base pair differences in sequence is described in, for example, <nplcit id="ncit0044" npl-type="s"><text>Conner et al., 1983, Proc. Natl. Acad. Sci. USA 80:278-282</text></nplcit>, and <patcit id="pcit0023" dnum="US5468613A"><text>U.S. Pat. Nos. 5,468,613</text></patcit> and <patcit id="pcit0024" dnum="US5604099A"><text>5,604,099</text></patcit>.</p><p id="p0076" num="0076">The proportional change in stability between a perfectly matched and a single-base mismatched hybridization duplex depends on the length of the hybridized oligonucleotides. Duplexes formed with shorter probe sequences are destabilized proportionally more by the presence of a mismatch. In practice, oligonucleotides between about 15 and about 35 nucleotides in length are preferred for sequence-specific detection. Furthermore, because the ends of a hybridized oligonucleotide undergo continuous random dissociation and re-annealing due to thermal energy, a mismatch at either end destabilizes the hybridization duplex less than a mismatch occurring internally. Preferably, for discrimination of a single base pair change in target sequence, the probe sequence is selected which hybridizes to the target sequence such that the polymorphic site occurs in the interior region of the probe.</p><p id="p0077" num="0077">The above criteria for selecting a probe sequence that hybridizes to a particular SNP apply to the hybridizing region of the probe, i.e., that part of the probe which is involved in hybridization with the target sequence. A probe may be bound to an additional nucleic acid sequence, such as a poly-T tail used to immobilize the probe, without significantly altering the hybridization characteristics of the probe. One of skill in the art will recognize that for use in the present methods, a probe bound to an additional nucleic acid sequence which is not complementary to the target sequence and, thus, is not involved in the hybridization, is essentially equivalent to the unbound probe.<!-- EPO <DP n="26"> --></p><p id="p0078" num="0078">Suitable assay formats for detecting hybrids formed between probes and target nucleic acid sequences in a sample are known in the art and include the immobilized target (dot-blot) format and immobilized probe (reverse dot-blot or line-blot) assay formats. Dot blot and reverse dot blot assay formats are described in <patcit id="pcit0025" dnum="US5310893A"><text>U.S. Pat. Nos. 5,310,893</text></patcit>; <patcit id="pcit0026" dnum="US5451512A"><text>5,451,512</text></patcit>; <patcit id="pcit0027" dnum="US5468613A"><text>5,468,613</text></patcit>; and <patcit id="pcit0028" dnum="US5604099A"><text>5,604,099</text></patcit>.</p><p id="p0079" num="0079">In a dot-blot format, amplified target DNA or cDNA is immobilized on a solid support, such as a nylon membrane. The membrane-target complex is incubated with labeled probe under suitable hybridization conditions, unhybridized probe is removed by washing under suitably stringent conditions, and the membrane is monitored for the presence of bound probe.</p><p id="p0080" num="0080">In the reverse dot-blot (or line-blot) format, the probes are immobilized on a solid support, such as a nylon membrane or a microtiter plate. The target DNA or cDNA is labeled, typically during amplification by the incorporation of labeled primers. One or both of the primers can be labeled. The membrane-probe complex is incubated with the labeled amplified target DNA or cDNA under suitable hybridization conditions, unhybridized target DNA or cDNA is removed by washing under suitably stringent conditions, and the membrane is monitored for the presence of bound target DNA or cDNA.</p><p id="p0081" num="0081">An allele-specific probe that is specific for one of the polymorphism variants is often used in conjunction with the allele-specific probe for the other polymorphism variant. In some embodiments, the probes are immobilized on a solid support and the target sequence in an individual is analyzed using both probes simultaneously. Examples of nucleic acid arrays are described by <patcit id="pcit0029" dnum="WO9511995A"><text>WO 95/11995</text></patcit>. The same array or a different array can be used for analysis of characterized polymorphisms. <patcit id="pcit0030" dnum="WO9511995A"><text>WO 95/11995</text></patcit> also describes subarrays that are optimized for detection of variant forms of a pre-characterized polymorphism.</p><heading id="h0011"><u>Allele-Specific Primers</u></heading><p id="p0082" num="0082">The amount and/or presence of an allele is also commonly detected using allele-specific amplification or primer extension methods. These reactions typically involve use of primers that are designed to specifically target a polymorphism via a mismatch at the 3' end of a primer. The presence of a mismatch affects the ability of a polymerase to extend a primer when the polymerase lacks error-correcting activity. For example, to detect an allele sequence using an allele-specific amplification- or extension-based method, a primer<!-- EPO <DP n="27"> --> complementary to the polymorphic nucleotide of a SNP is designed such that the 3' terminal nucleotide hybridizes at the polymorphic position. The presence of the particular allele can be determined by the ability of the primer to initiate extension. If the 3' terminus is mismatched, the extension is impeded. If a primer matches the polymorphic nucleotide at the 3' end, the primer will be efficiently extended.</p><p id="p0083" num="0083">Typically, the primer is used in conjunction with a second primer in an amplification reaction. The second primer hybridizes at a site unrelated to the polymorphic position. Amplification proceeds from the two primers leading to a detectable product signifying the particular allelic form is present. Allele-specific amplification- or extension-based methods are described in, for example, <patcit id="pcit0031" dnum="WO9322456A"><text>WO 93/22456</text></patcit>; <patcit id="pcit0032" dnum="US5137806A"><text>U.S. Pat. Nos. 5,137,806</text></patcit>; <patcit id="pcit0033" dnum="US5595890A"><text>5,595,890</text></patcit>; <patcit id="pcit0034" dnum="US5639611A"><text>5,639,611</text></patcit>; and <patcit id="pcit0035" dnum="US4851331A"><text>U.S. Pat. No. 4,851,331</text></patcit>.</p><p id="p0084" num="0084">Using allele-specific amplification-based methods, identification and/or quantification of the alleles require detection of the presence or absence of amplified target sequences. Methods for the detection of amplified target sequences are well known in the art. For example, gel electrophoresis and probe hybridization assays described are often used to detect the presence of nucleic acids.</p><p id="p0085" num="0085">In an alternative probe-less method, the amplified nucleic acid is detected by monitoring the increase in the total amount of double-stranded DNA in the reaction mixture, is described, e.g., in <patcit id="pcit0036" dnum="US5994056A"><text>U.S. Pat. No. 5,994,056</text></patcit>; and European Patent Publication Nos. <patcit id="pcit0037" dnum="EP487218A"><text>487,218</text></patcit> and<patcit id="pcit0038" dnum="EP512334A"><text> 512,334</text></patcit>. The detection of double-stranded target DNA or cDNA relies on the increased fluorescence various DNA-binding dyes, <i>e.g.,</i> SYBR Green, exhibit when bound to double-stranded DNA.</p><p id="p0086" num="0086">As appreciated by one in the art, allele-specific amplification methods can be performed in reactions that employ multiple allele-specific primers to target particular alleles. Primers for such multiplex applications are generally labeled with distinguishable labels or are selected such that the amplification products produced from the alleles are distinguishable by size. Thus, for example, both alleles in a single sample can be identified and/or quantified using a single amplification by various methods.</p><p id="p0087" num="0087">As in the case of allele-specific probes, an allele-specific oligonucleotide primer may be exactly complementary to one of the polymorphic alleles in the hybridizing region or may have some mismatches at positions other than the 3' terminus of the oligonucleotide, which mismatches occur at non-polymorphic sites in both allele sequences.<!-- EPO <DP n="28"> --></p><heading id="h0012"><u>5'-nuclease assay</u></heading><p id="p0088" num="0088">The amount and/or presence of an allele can also be determined using a "TaqMan®" or "5'-nuclease assay", as described in <patcit id="pcit0039" dnum="US5210015A"><text>U.S. Pat. Nos. 5,210,015</text></patcit>; <patcit id="pcit0040" dnum="US5487972A"><text>5,487,972</text></patcit>; and <patcit id="pcit0041" dnum="US5804375A"><text>5,804,375</text></patcit>; and <nplcit id="ncit0045" npl-type="s"><text>Holland et al., 1988, Proc. Natl. Acad. Sci. USA 88:7276-7280</text></nplcit>. In the TaqMan® assay, labeled detection probes that hybridize within the amplified region are added during the amplification reaction. The probes are modified so as to prevent the probes from acting as primers for DNA synthesis. The amplification is performed using a DNA polymerase having 5' to 3' exonuclease activity. During each synthesis step of the amplification, any probe which hybridizes to the target nucleic acid downstream from the primer being extended is degraded by the 5' to 3' exonuclease activity of the DNA polymerase. Thus, the synthesis of a new target strand also results in the degradation of a probe, and the accumulation of degradation product provides a measure of the synthesis of target sequences.</p><p id="p0089" num="0089">The hybridization probe can be an allele-specific probe that discriminates between the SNP alleles. Alternatively, the method can be performed using an allele-specific primer and a labeled probe that binds to amplified product.</p><p id="p0090" num="0090">Any method suitable for detecting degradation product can be used in a 5' nuclease assay. Often, the detection probe is labeled with two fluorescent dyes, one of which is capable of quenching the fluorescence of the other dye. The dyes are attached to the probe, preferably one attached to the 5' terminus and the other is attached to an internal site, such that quenching occurs when the probe is in an unhybridized state and such that cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase occurs in between the two dyes. Amplification results in cleavage of the probe between the dyes with a concomitant elimination of quenching and an increase in the fluorescence observable from the initially quenched dye. The accumulation of degradation product is monitored by measuring the increase in reaction fluorescence. <patcit id="pcit0042" dnum="US5491063A"><text>U.S. Pat. Nos. 5,491,063</text></patcit> and <patcit id="pcit0043" dnum="US5571673A"><text>5,571,673</text></patcit>, both incorporated herein by reference, describe alternative methods for detecting the degradation of probe which occurs concomitant with amplification.</p><heading id="h0013"><u>DNA Sequencing and single base or other primer extensions</u></heading><p id="p0091" num="0091">The amount and/or presence of an allele can also be determined by direct sequencing. Methods include <i>e.g.,</i> dideoxy sequencing-based methods and other methods such as Maxam and Gilbert sequence (<i>see, e.g.,</i> Sambrook and Russell, <i>supra).</i><!-- EPO <DP n="29"> --></p><p id="p0092" num="0092">Other detection methods include Pyrosequencing™ of oligonucleotide-length products. Such methods often employ amplification techniques such as PCR. For example, in pyrosequencing, a sequencing primer is hybridized to a single stranded, PCR-amplified, DNA or cDNA template; and incubated with the enzymes, DNA polymerase, ATP sulfurylase, luciferase and apyrase, and the substrates, adenosine 5' phosphosulfate (APS) and luciferin. The first of four deoxynucleotide triphosphates (dNTP) is added to the reaction. DNA polymerase catalyzes the incorporation of the deoxynucleotide triphosphate into the DNA strand, if it is complementary to the base in the template strand. Each incorporation event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. ATP sulfurylase quantitatively converts PPi to ATP in the presence of adenosine 5' phosphosulfate. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount of ATP. The light produced in the luciferase-catalyzed reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a pyrogram™. Each light signal is proportional to the number of nucleotides incorporated. Apyrase, a nucleotide degrading enzyme, continuously degrades unincorporated dNTPs and excess ATP. When degradation is complete, another dNTP is added.</p><p id="p0093" num="0093">Another similar method for characterizing SNPs does not require use of a complete PCR, but typically uses only the extension of a primer by a single, detectably (e.g., fluorescently)-labeled dideoxyribonucleic acid molecule (ddNTP) that is complementary to the nucleotide to be investigated. The nucleotide at the polymorphic site can be identified via detection of a primer that has been extended by one base and is fluorescently labeled (e.g., <nplcit id="ncit0046" npl-type="s"><text>Kobayashi et al, Mol. Cell. Probes, 9:175-182, 1995</text></nplcit>). Of course extension products can also be detected based on other types of labels, or by mass-spectrometry, as desired.</p><p id="p0094" num="0094">In a similar method, PCR amplified target DNA or RT-PCR amplified target cDNA may be used as template for a single nucleotide primer extension reaction whereby a single fluorescently labeled ddNTP complementary to the polymorphic nucleotide is incorporated on the 3' end of a single primer. Each specific ddNTP can be labeled with a different fluorescent dye <i>(eg.</i> ddATP labeled with dR6G, ddCTP labeled with dTAMRA™, ddGTP labeled with dR110 and ddTTP or ddUTP labeled with dROX™). Therefore, single nucleotide extension of the initially unlabeled primer tags the primer with a specific fluorescent dye that identifies the base that was added to the 3' end of the unlabeled primer. Extended primers can be resolved and analyzed to determine the presence and relative<!-- EPO <DP n="30"> --> quantity of each specific dye-tagged primer, representing the relative quantities of each allele in the target DNA or target cDNA template.</p><heading id="h0014"><u>Restriction Fragment Length Polymorphism Analysis</u></heading><p id="p0095" num="0095">In other embodiments, the amount and/or presence of an allele of a SNP can be determined by differential digestion of amplified target DNA or cDNA when the polymorphic nucleotide of interest lies within the recognition sequence of a restriction enzyme. In one case, one allele of the SNP (the first allele) maintains the recognition sequence of the restriction enzyme and the other allele (the second allele) does not. In this case, the restriction enzyme will cleave the target DNA or cDNA including the first allele, but not the target DNA or cDNA including the second allele. In another case, one allele (the first allele) of the SNP maintains the recognition sequence of a restriction enzyme (the first restriction enzyme) and the other allele (the second allele) maintains the recognition sequence of a different restriction enzyme (the second restriction enzyme). In this case, the first restriction enzyme will cleave the target DNA or cDNA including the first allele, but not the target DNA or cDNA including the second allele. The second restriction enzyme will cleave the target DNA or cDNA including the second allele, but not the target DNA of cDNA including the first allele. The amount and/or presence of alleles can be determined by various methods including, but not limited to, Southern blot hybridization to immobilized restricted fragments and quantification of band intensities, resolution and visualization of restriction fragments by gel electrophoresis, resolution and quantification of restriction fragments by capillary electrophoresis (such as performed using an Agilent BioAnalyzer), or differential quantitative PCR amplification of cleaved versus uncleaved template DNA or cDNA.</p><heading id="h0015"><u>Denaturing Gradient Gel Electrophoresis</u></heading><p id="p0096" num="0096">Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution <i>(see, e.g.,</i> <nplcit id="ncit0047" npl-type="b"><text>Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, W. H. Freeman and Co, New York, 1992, Chapter 7</text></nplcit>).</p><heading id="h0016"><u>Single-Strand Conformation Polymorphism Analysis</u></heading><p id="p0097" num="0097">Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic<!-- EPO <DP n="31"> --> migration of single stranded PCR products, as described, <i>e.g,</i> in<nplcit id="ncit0048" npl-type="s"><text> Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989</text></nplcit>). Amplified PCR or RT-PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence difference between alleles of target</p><p id="p0098" num="0098">SNP detection methods often employ labeled oligonucleotides. Oligonucleotides can be labeled by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Useful labels include fluorescent dyes, radioactive labels, <i>e.g.,</i> <sup>32</sup>P, electron-dense reagents, enzyme, such as peroxidase or alkaline phosphatase, biotin, or haptens and proteins for which antisera or monoclonal antibodies are available. Labeling techniques are well known in the art <i>(see, e.g.,</i> Current Protocols in Molecular Biology, <i>supra;</i> Sambrook &amp; Russell, <i>supra).</i></p><heading id="h0017"><b><i>V</i></b>. <b><i>Methods for Quantifying RNA</i></b></heading><p id="p0099" num="0099">The presence and quantity of RNA corresponding to a particular SNP can be readily determined according to any method for quantifying RNA. Various methods involving linkage of RNA to a solid support and probing the RNA (e.g., northern blots, dot blots, etc.) can be used.</p><p id="p0100" num="0100">In some embodiments, the target RNA is first reverse transcribed (e.g., with reverse transcriptase) and then the resulting cDNA is quantified by any methods known in the art (blot hybridization, RT-PCR, etc.) as a surrogate for RNA quantity. Various methods of reverse transcription are known and described, e.g., in <nplcit id="ncit0049" npl-type="b"><text>Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd ed. 2001</text></nplcit>); <nplcit id="ncit0050" npl-type="b"><text>Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990</text></nplcit>); and <nplcit id="ncit0051" npl-type="b"><text>Current Protocols in Molecular Biology (Ausubel et al., eds., 1994</text></nplcit>)), and can involve reverse transcription using either specific or non -specific primers.</p><p id="p0101" num="0101">In some embodiments, RT-PCR or other quantitative amplification techniques are used to quantify the target RNA. Amplification of cDNA using reactions is well known (see <patcit id="pcit0044" dnum="US4683195A"><text>U.S. Patents 4,683,195</text></patcit> and <patcit id="pcit0045" dnum="US4683202A"><text>4,683,202</text></patcit>; <nplcit id="ncit0052" npl-type="b"><text>PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (Innis et al., eds, 1990</text></nplcit>)).</p><p id="p0102" num="0102">Sequences amplified by the methods disclosed can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR,<!-- EPO <DP n="32"> --> oligomer restriction (<nplcit id="ncit0053" npl-type="s"><text>Saiki, et al., Bio/Technology 3:1008-1012 (1985</text></nplcit>)), allele-specific oligonucleotide (ASO) probe analysis (<nplcit id="ncit0054" npl-type="s"><text>Conner, et al., PNAS USA 80:278 (1983</text></nplcit>)), oligonucleotide ligation assays (OLAs) (<nplcit id="ncit0055" npl-type="s"><text>Landegren, et al., Science 241:1077, (1988</text></nplcit>)), and the like. Molecular techniques for DNA analysis have been reviewed (<nplcit id="ncit0056" npl-type="s"><text>Landegren, et al., Science 242:229-237 (1988</text></nplcit>)).</p><p id="p0103" num="0103">Methods of quantitative amplification are disclosed in, <i>e.g.,</i> <patcit id="pcit0046" dnum="US6180349B"><text>U.S. Patent Nos. 6,180,349</text></patcit>; <patcit id="pcit0047" dnum="US6033854B"><text>6,033,854</text></patcit>; and <patcit id="pcit0048" dnum="US5972602B"><text>5,972,602</text></patcit>, as well as in, <i>e.g.,</i> <nplcit id="ncit0057" npl-type="s"><text>Gibson et al., Genome Research 6:995-1001 (1996</text></nplcit>); <nplcit id="ncit0058" npl-type="s"><text>DeGraves, et al., Biotechniques 34(1):106-10, 112-5 (2003</text></nplcit>); <nplcit id="ncit0059" npl-type="s"><text>Deiman B, et al., Mol Biotechnol. 20(2): 163-79 (2002</text></nplcit>). Amplifications may be monitored in "real time."</p><p id="p0104" num="0104">In general, quantitative amplification is based on the monitoring of the signal (<i>e.g.,</i> fluorescence of a probe) representing copies of the template in cycles of an amplification (<i>e.g.,</i> PCR) reaction. In the initial cycles of the PCR, a very low signal is observed because the quantity of the amplicon formed does not support a measurable signal output from the assay. After the initial cycles, as the amount of formed amplicon increases, the signal intensity increases to a measurable level and reaches a plateau in later cycles when the PCR enters into a non-logarithmic phase. Through a plot of the signal intensity versus the cycle number, the specific cycle at which a measurable signal is obtained from the PCR reaction can be deduced and used to back-calculate the quantity of the target before the start of the PCR. The number of the specific cycles that is determined by this method is typically referred to as the cycle threshold (Ct). Exemplary methods are described in, <i>e.g.,</i><nplcit id="ncit0060" npl-type="s"><text> Heid et al. Genome Methods 6:986-94 (1996</text></nplcit>) with reference to hydrolysis probes.</p><p id="p0105" num="0105">One method for detection of amplification products is the 5'-3' exonuclease "hydrolysis" PCR assay (also referred to as the TaqMan™ assay) (<patcit id="pcit0049" dnum="US5210015A"><text>U.S. Pat. Nos. 5,210,015</text></patcit> and <patcit id="pcit0050" dnum="US5487972A"><text>5,487,972</text></patcit>; <nplcit id="ncit0061" npl-type="s"><text>Holland et al., PNAS USA 88: 7276-7280 (1991</text></nplcit>);<nplcit id="ncit0062" npl-type="s"><text> Lee et al., Nucleic Acids Res. 21: 3761-3766 (1993</text></nplcit>)). This assay detects the accumulation of a specific PCR product by hybridization and cleavage of a doubly labeled fluorogenic probe (the "TaqMan™" probe) during the amplification reaction. The fluorogenic probe consists of an oligonucleotide labeled with both a fluorescent reporter dye and a quencher dye. During PCR, this probe is cleaved by the 5'-exonuclease activity of DNA polymerase if, and only if, it hybridizes to the segment being amplified. Cleavage of the probe generates an increase in the fluorescence intensity of the reporter dye.</p><p id="p0106" num="0106">Another method of detecting amplification products that relies on the use of energy transfer is the "beacon probe" method described by <nplcit id="ncit0063" npl-type="s"><text>Tyagi and Kramer, Nature Biotech. 14:303-309 (1996</text></nplcit>), which is also the subject of <patcit id="pcit0051" dnum="US5119801A"><text>U.S. Patent Nos. 5,119,801</text></patcit> and <patcit id="pcit0052" dnum="US5312728A"><text>5,312,728</text></patcit>.<!-- EPO <DP n="33"> --> This method employs oligonucleotide hybridization probes that can form hairpin structures. On one end of the hybridization probe (either the 5' or 3' end), there is a donor fluorophore, and on the other end, an acceptor moiety. In the case of the Tyagi and Kramer method, this acceptor moiety is a quencher, that is, the acceptor absorbs energy released by the donor, but then does not itself fluoresce. Thus, when the beacon is in the open conformation, the fluorescence of the donor fluorophore is detectable, whereas when the beacon is in hairpin (closed) conformation, the fluorescence of the donor fluorophore is quenched. When employed in PCR, the molecular beacon probe, which hybridizes to one of the strands of the PCR product, is in "open conformation," and fluorescence is detected, while those that remain unhybridized will not fluoresce (<nplcit id="ncit0064" npl-type="s"><text>Tyagi and Kramer, Nature Biotechnol. 14: 303-306 (1996</text></nplcit>)). As a result, the amount of fluorescence will increase as the amount of PCR product increases, and thus may be used as a measure of the progress of the PCR. Those of skill in the art will recognize that other methods of quantitative amplification are also available.</p><p id="p0107" num="0107">Various other techniques for performing quantitative amplification of a nucleic acids are also known. For example, some methodologies employ one or more probe oligonucleotides that are structured such that a change in fluorescence is generated when the oligonucleotide(s) is hybridized to a target nucleic acid. For example, one such method involves is a dual fluorophore approach that exploits fluorescence resonance energy transfer (FRET), <i>e.g.,</i> LightCycler™ hybridization probes, where two oligo probes anneal to the amplicon. The oligonucleotides are designed to hybridize in a head-to-tail orientation with the fluorophores separated at a distance that is compatible with efficient energy transfer. Other examples of labeled oligonucleotides that are structured to emit a signal when bound to a nucleic acid or incorporated into an extension product include: Scorpions™ probes <i>(e.g.,</i> <nplcit id="ncit0065" npl-type="s"><text>Whitcombe et al., Nature Biotechnology 17:804-807, 1999</text></nplcit>, and <patcit id="pcit0053" dnum="US6326145B"><text>U.S. Pat. No. 6,326,145</text></patcit>), Sunrise™ (or Amplifluor™) probes (<i>e.g</i>., <nplcit id="ncit0066" npl-type="s"><text>Nazarenko et al., Nuc. Acids Res. 25:2516-2521, 1997</text></nplcit>, and <patcit id="pcit0054" dnum="US6117635A"><text>U.S. Pat. No. 6,117,635</text></patcit>), and probes that form a secondary structure that results in reduced signal without a quencher and that emits increased signal when hybridized to a target <i>(e.g.,</i> Lux probes™).</p><p id="p0108" num="0108">In other embodiments, intercalating agents that produce a signal when intercalated in double stranded DNA may be used. Exemplary agents include SYBR GREEN™ and SYBR GOLD™. Since these agents are not template-specific, it is assumed that the signal is generated based on template-specific amplification. This can be confirmed by monitoring<!-- EPO <DP n="34"> --> signal as a function of temperature because melting point of template sequences will generally be much higher than, for example, primer-dimers, <i>etc.</i></p><heading id="h0018"><b><i>VI. Kits</i></b></heading><p id="p0109" num="0109">The invention also provides kits as defined in claims 10-13, comprising useful components for practicing the methods. In some embodiments, the kit may comprise one or both allele-specific detection polynucleotides (e.g., primers or probes) for a SNP of the invention, which optionally can be fixed to an appropriate support membrane. In some embodiments, the kits comprise a first isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between a first allele of a SNP (or a complement thereof) and a second allele of the SNP (or a complement thereof) in a hybridization reaction, and optionally a second isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between the first allele of the SNP (or a complement thereof) and the second allele of the SNP (or a complement thereof), and wherein the first polynucleotide is complementary to the polymorphic nucleotide in the first allele and the second polynucleotide is complementary to the polymorphic nucleotide of the second allele. Optionally, the kits comprise one or both allele specific polynucleotides for 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, or more SNPs selected from SEQ ID NOs: 1-112 Such a kit can also contain amplification primers for amplifying a region of the <i>IGF2</i> locus encompassing the polymorphic site. Alternatively, useful kits can contain a set of primers comprising an allele-specific primer for the specific amplification of the polymorphic alleles. Such a kit may also comprises probes for the detection of amplification products. Alternatively, useful kits can contain a set of primers complementary to sequences 5' to but not including the SNP positions of interest (or complements thereof) for use in primer extension methods as described above.</p><p id="p0110" num="0110">Other optional components of the kits include additional reagents used for genotyping patients and/or quantifying the relative amount of specific alleles present. For example, a kit can contain a polymerase, labeled or unlabeled substrate nucleoside triphosphates, means for labeling and/or detecting nucleic acid, appropriate buffers for amplification or hybridization reactions, and instructions for carrying out the present method.</p><heading id="h0019"><b><i>VII. Reaction Mixtures</i></b></heading><p id="p0111" num="0111">Disclosed are reaction mixtures comprising components for practicing the methods. In some embodiments, the kit may comprise one or both allele-specific detection polynucleotides (e.g., primers or probes) for a SNP (or a complement thereof) of<!-- EPO <DP n="35"> --> the invention, which optionally can be fixed to an appropriate support membrane. The reaction mixtures may comprise a first isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between a first allele of a SNP (or a complement thereof) and a second allele of the SNP (or a complement thereof) in a hybridization reaction, and optionally a second isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between the first allele of the SNP (or a complement thereof) and the second allele of the SNP (or a complement thereof), and wherein the first polynucleotide is complementary to the polymorphic nucleotide in the first allele and the second polynucleotide is complementary to the polymorphic nucleotide of the second allele. Optionally, the reaction mixtures comprise one or both allele specific polynucleotides for 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, or more SNPs selected from SEQ ID NO: 1-112. Such reaction mixtures can also contain amplification primers for amplifying a region of the <i>IGF2</i> locus encompassing the polymorphic site. Alternatively, reaction mixtures can contain a set of primers comprising an allele-specific primer for the specific amplification of the polymorphic alleles. Such a reaction mixture may also comprise probes for the detection of amplification products. Optionally, reaction mixtures comprise a set of primers complementary to sequences 5' to but not including the SNP positions for 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, or more SNPs selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, and 112.</p><p id="p0112" num="0112">Other optional components of the reaction mixtures include additional reagents used for genotyping patients and/or quantifying the relative amount of specific alleles present. For example, a reaction mixture can contain a polymerase, labeled or unlabeled substrate nucleoside triphosphates, means for labeling and/or detecting nucleic acid, appropriate buffers for amplification or hybridization reactions.</p><heading id="h0020"><i><b>VIII.</b> CANCER DETECTION</i></heading><p id="p0113" num="0113">IGF2 LOI is associated with, for example, a predisposition of cancer as well as predicting the efficacy of treatment of cancer using various drugs. <i>See, e.g.,</i> <patcit id="pcit0055" dnum="WO2004003003A"><text>WO2004/003003</text></patcit>;<nplcit id="ncit0067" npl-type="s"><text> Kaneda et al. Proc. Natl. Acad. Sci. USA 104(52):20926-20931 (2007</text></nplcit>).<!-- EPO <DP n="36"> --> Accordingly, detection of LOI in IGF2 as described herein can be used in the diagnosis, prognosis, classification, prediction of cancer risk, detection of recurrence of cancer, and selection of treatment of a number of types of cancers. A cancer at any stage of progression can be detected, such as primary, metastatic, and recurrent cancers. Information regarding numerous types of cancer can be found, <i>e.g.,</i> from the American Cancer Society (available on the worldwide web at cancer.org), or from, <i>e.g.,</i> <nplcit id="ncit0068" npl-type="b"><text>Harrison's Principles of Internal Medicine, Kaspar, et al., eds., 16th Edition, 2005, McGraw-Hill, Inc.</text></nplcit> Exemplary cancers that can be detected include bladder, breast, cervical, choriocarcinoma, colorectal neoplasia (colorectal adenoma or colorectal cancer), esophageal, gastric adenocarcinoma, glioma, hepatocellular, acute myeloid leukemia, chronic myelogenous leukemia, lung, medulloblastoma, prostate, mesothelioma, ovarian, renal cell carcinoma, testicular germ cell, and uterine cancer.</p><p id="p0114" num="0114">Disclosed are methods for determining whether or not a mammal (e.g., a human) has cancer, whether or not a biological sample taken from a mammal contains cancerous cells, estimating the risk or likelihood of a mammal developing cancer, classifying cancer types and stages, monitoring the efficacy of anti-cancer treatment, or selecting the appropriate anti-cancer treatment in a mammal with cancer.</p><p id="p0115" num="0115">The biological sample may comprise a tissue sample from a tissue suspected of containing cancerous cells. For example, in an individual suspected of having cancer, breast tissue, lymph tissue, lung tissue, brain tissue, or blood can be evaluated. Alternatively, lung, renal, liver, ovarian, head and neck, thyroid, bladder, cervical, colon, endometrial, esophageal, prostate, or skin tissue can be evaluated. The tissue or cells can be obtained by any method known in the art including, <i>e.g.,</i> by surgery, biopsy, phlebotomy, swab, nipple discharge, stool, etc. A tissue sample known to contain cancerous cells, <i>e.g.,</i> from a tumor, may be analyzed for the presence or quantity of methylation at one or more of the diagnostic biomarkers to determine information about the cancer, <i>e.g.,</i> the efficacy of certain treatments, the survival expectancy of the individual, <i>etc.</i> The methods may be used in conjunction with additional diagnostic methods, e.g., detection of other cancer biomarkers, etc.</p><p id="p0116" num="0116">The methods can be used to evaluate individuals known or suspected to have cancer or as a routine clinical test, <i>i.e.,</i> in an individual not necessarily suspected to have cancer. Further diagnostic assays can be performed to confirm the status of cancer in the individual.<!-- EPO <DP n="37"> --></p><p id="p0117" num="0117">Further, the present methods may be used to assess the efficacy of a course of treatment. For example, the efficacy of an anti-cancer treatment can be assessed by monitoring LOI over time in a mammal having cancer. For example, a reduction or absence of LOI in IGF2 in a biological sample taken from a mammal following a treatment, compared to a level in a sample taken from the mammal before, or earlier in, the treatment, indicates efficacious treatment. Further, a patient can be screened for LOI of IGF2 prior to selection of an appropriate drug for cancer treatment. For example, once LOI is detected, the patient is likely a good candidate for an IGF1R inhibitor. <i>See, e.g.,</i> Kaneda <i>et al., supra.</i></p><p id="p0118" num="0118">The methods may comprise recording a diagnosis, prognosis, risk assessment or classification, based on the methylation status determined from an individual. Any type of recordation is contemplated, including electronic recordation, e.g., by a computer.</p><heading id="h0021">EXAMPLES</heading><p id="p0119" num="0119">The following examples are offered to illustrate, but not to limit the claimed invention.</p><heading id="h0022"><b>Example 1. Discovery of novel SNPs within exon 9 of the <i>IGF2</i> gene.</b></heading><p id="p0120" num="0120">A collection of SNPs within exon 9 of the <b><i>IGF2</i></b> gene have previously been reported. Tables 1A, 1B and 1C list the genomic coordinates (NCBI build 36), single nucleotide sequence variants, NCBI dbSNP reference identifier and surrounding nucleotide sequences of previously identified SNPs (dbSNP build 129). To identify previously uncharacterized SNPs, we designed 15 PCR amplicons that tile the majority of <i>IGF2</i> exon 9. Each was used to amplify by PCR the genomic DNA derived from a panel of 589 individuals, including 462 samples that are part of the International HapMap Project collection. The panel included 225 Caucasian individuals (98 from Coriell Human Variation Panel including unrelated healthy Caucasian individuals and 127 individuals from which blood samples were commercially obtained), 96 African American individuals (Coriell Human Variation Panel), 96 individuals of Mexican descent (Coriell Human Variation panel of Mexican-American Community of Los Angeles including unrelated individuals, each having either three or four grandparents born in Mexico), 88 Japanese individuals (International Hapmap Project collection including individuals from Tokyo, Japan), and 84 Chinese individuals (International Hapmap Project collection including Han Chinese individuals from Beijing,<!-- EPO <DP n="38"> --> China). Multiple direct sequencing attempts were made in both directions for all amplicons. Sequences were assembled and aligned, genotypes were scored, and SNPs were identified for each person in the panel by an automated polyphred and polyscan sequencing analysis pipeline. Genotype designations for high heterozygosity frequency SNPs were manually confirmed by manual inspection of sequence chromatograms within CONSED. As an additional measure of the confidence of genotype designations based on sequencing data, an independent restriction enzyme based genotyping assay was designed for the SNP corresponding to SEQ ID NO: 64 in Table 1A, as described in Example 4. Genotype designations were compared to those based on the sequencing data. Seventy individuals from the Caucasian panel were genotyped by both methods. The concordance between genotype designations based on the two independent methods (sequencing and restriction enzyme digestion based assays) was 100%.</p><p id="p0121" num="0121">Tables 2A and 2B list the genomic coordinates (NCBI build 36) of single nucleotide sequence variants and surrounding nucleotide sequences of novel SNPs discovered in the study described in the present application. The observed frequencies of heterozygosity for selected SNPs (including both novel and previously identified SNPs) in the sequenced panels of all individuals, as well as in the African American, Caucasian, Chinese, Japanese and Mexican individuals are listed in Table 3. The identification of novel SNPs implies that the novel SNPs described in the present application can be useful for improved detection of LOI of <i>IGF2.</i> For example, the observed heterozygosity frequency of SEQ ID 10 among individuals in the African American panel is 17.33%.</p><p id="p0122" num="0122">This study demonstrates the differential heterozygosity frequencies of both novel and previously identified SNPs between different racial groups. SNPs that were genotyped as heterozygous in at least 2% of individuals within the Chinese, Japanese, African American, Caucasian, and Mexican cohorts are listed in Tables 4-8, respectively. Therefore, the optimal SNP or combinations of SNPs for monitoring LOI of <i>IGF2</i> can vary between racial groups.</p><heading id="h0023"><b>Example 2. Use of any one of the novel SNPs for improved detection of LOI of the <i>IGF2</i> gene.</b></heading><p id="p0123" num="0123">As described above, the detection of LOI of the <b><i>IGF2</i></b> gene is based on the independent comparison of the amount of expression derived from each of the two copies of the <b><i>IGF2</i></b> gene isolated from a biological sample from a given individual. The <i>IGF2</i> gene is<!-- EPO <DP n="39"> --> normally maternally imprinted, (<i>i.e.</i> the copy inherited from an individual's mother is normally transcriptionally repressed), while the paternally inherited copy of the gene is normally expressed. LOI occurs when the <i>IGF2</i> maternal imprint is relaxed, resulting in similar expression levels of both the paternally and maternally inherited copies of the gene. One method of measuring the imprinting status of <i>IGF2</i> in a sample is to first isolate genomic DNA from a biological sample and then determine the genotype(s) of one or more polymorphic sites in the transcribed region of the <i>IGF2</i> gene. Second, allele-specific expression of <i>IGF2</i> is then measured by utilizing one or more heterozygous nucleotides in RNA that is extracted from the same biological sample. Expression from each of the two copies of the <i>IGF2</i> gene may be independently measured with an assay(s) that is quantitative, and that can sufficiently discriminate between the two alleles of one or more heterozygous SNPs within the sample. Third, a ratio of the amount of expression from one allele to the amount of expression of the other allele is computed and compared to a threshold value, thereby determining the imprinting status of the <i>IGF2</i> gene in the sample.</p><p id="p0124" num="0124">As an example of the utility of any one or more of the novel SNPs reported in the present application for monitoring LOI of <i>IGF2,</i> one specific intended approach is described here. It is apparent to those skilled in the art that multiple approaches for detection and quantification of SNPs exist, and any of these may be utilized for both the genotyping of genomic DNA from a biological sample for a particular SNP and the quantification of relative levels of each sequence variant present in expressed mRNA of a biological sample. A basic strategy is outlined in <figref idrefs="f0002">Figure 2</figref>. This involves isolating both genomic DNA and total or polyadenylated RNA from a biological sample (for example, peripheral blood, peripheral blood mononuclear cells, colonic mucosa sample, stool sample, ect.) derived from an individual. The genomic DNA sample is then genotyped with assays detecting the alleles of one or more SNP. This step determines what SNPs, if any, may be utilized for analysis of allele-specific expression of the <i>IGF2</i> gene in the matched RNA sample. If the individual is homozygous for all SNPs evaluated by an assay, the individual is not informative for those SNPs and can not be measured for LOI of <i>IGF2.</i> If the individual is heterozygous (informative) for one or more SNPs, cDNA is amplified from the relevant region of the <i>IGF2</i> transcript using standard reverse transcriptase/PCR (RT-PCR) methods. Expression from each of the two copies of the <i>IGF2</i> gene is independently measured using the generated cDNA with an assay that is quantitative, and that can sufficiently discriminate between the two alleles. Computation of the ratio of the amount of expression of one allele relative to the<!-- EPO <DP n="40"> --> amount of expression of the other allele, and comparison of this ratio to a threshold value determines the imprinting status of the IGF2 gene. If multiple heterozygous SNPs exist for a given sample, assays that discriminate each of the SNPs may be used simultaneously. This allows redundant measurements of allele-specific expression within a sample, and comparison of these measurements may be used to determine the accuracy of the determination of LOI. While a range of threshold values can be used, typically, a sample is classically determined to display LOI of <i>IGF2</i> if the quantified proportion of the lesser abundant allele is greater than or equal to 33.3% the quantified proportion of the more abundant allele.</p><p id="p0125" num="0125">One method for genotyping an individual for a given SNP is accomplished by designing an oligonucleotide primer that is complementary to the sequence of the <i>IGF2</i> gene and that has a 3' terminal nucleotide that is complementary to the <i>IGF2</i> template nucleotide one base 3' to the template polymorphic nucleotide (see <figref idrefs="f0007">Figure 7</figref> for example). Assays may be designed to genotype any one or more of the SNPs listed in Tables 1A, 1B, 1C, 2A and 2B. The oligonucleotide primer is combined with and hybridized to the PCR amplified DNA product from the genomic DNA sample in a mixture including all ddNTPs (ddATP, ddCTP, ddGTP, ddTTP (or ddUTP)), each tagged with a different fluorescent moiety. For example, if a G/A polymorphism is to be genotyped (and the G/A nucleotide is on the template strand of the genomic DNA sample), the oligonucleotide primer is designed to hybridize to the complementary template with its 3' terminal nucleotide hybridized to the complementary template nucleotide one base 3' to the template G/A position. Single nucleotide primer extension is catalyzed by a DNA polymerase in the presence of the differentially fluorescently labeled ddNTPs such that oligonucleotides that extend by incorporation of ddCTP (representing the G allele) or by incorporation of ddTTP (representing the A allele) are differentially fluorescently labeled at their 3' termini. Extended oligonucleotides are then resolved by capillary electrophoresis and analyzed in the presence of a fifth-fluorescent dye-labeled size standard. Peaks representing specific single nucleotide primer extension products are detected and quantified to determine the genotype for the given DNA sample. Multiple SNPs may be genotyped in one reaction by multiplexing with oligonucleotides of different lengths designed to terminate just 3' to different polymorphic sites. Different genotypes are obtained based on i) resolution of different length extended oligonucleotides and ii) the specific fluorescent tagged ddNTP incorporated during single nucleotide extension.<!-- EPO <DP n="41"> --></p><p id="p0126" num="0126">One method for determining the imprinting status of <i>IGF2</i> involves an analogous single nucleotide primer extension approach that is designed to discriminate different alleles of a particular SNP. Assays may be designed to utilize any one or more of the SNPs listed in Tables 1 and 2. If a given SNP is determined to be heterozygous in a genomic DNA sample, first strand cDNA is amplified from the matched RNA sample by a reverse transcriptase (RT) using random hexamer or decamer primers, oligodT primers complementary to polyA tails of mRNA or a primer complementary to a specific region of the <i>IGF2</i> transcript. Oligonucleotide primers complementary to sequences flanking the SNP site are subsequently used to PCR amplify a cDNA product including the polymorphic site. Alternatively, nested PCR approaches may be used to generate cDNA products. Alternatively, approaches including generation of aRNA from cDNA by linear <i>in vitro</i> transcription, followed by a second reverse transcription reaction using random hexomer or decamer primers or <i>IGF2</i> transcript-specific primer and subsequent PCR amplification may be used to generate cDNA products. These RT-PCR products are then assayed for the specific sequence variants of the polymorphic site using the same single nucleotide primer extension assay(s) described above. Peaks representing specific single nucleotide primer extension products are detected and quantified. The ratio of the quantified amount of one allele to the other allele is determined. LOI is detected if the quantified proportion of the PCR product representing the lesser abundant allele is greater than or equal to 33.3% the quantified proportion of the PCR product representing the more abundant allele. As described above, multiple heterozygous SNPs may be used to measure LOI in a common reaction by multiplexing with oligonucleotides of different lengths designed to terminate just 3' to different polymorphic sites or with oligonucleotides that incorporate different labeled ddNTPs into the extended primer.</p><heading id="h0024"><b>Example 3. Linkage analysis indicates minimal linkage disequilibrium among numerous SNPs.</b></heading><p id="p0127" num="0127">The present application describes the discovery of numerous novel SNPs in exon 9 of IGF2. These data allowed high resolution haplotype analyses of 589 individuals (see example 1 for a description of the discovery panel). Genotype data was analyzed by Haploview (Broad Institute of MIT and Harvard University) to determine the presence, or absence, of haplotype blocks across the analyzed regions.<!-- EPO <DP n="42"> --></p><p id="p0128" num="0128"><figref idrefs="f0004">Figure 4</figref> shows haplotype analyses of SNPs distributed throughout the IGF2 exon 9 region in the entire individual panel. SNPs included in the analysis displayed at least 1% heterozygosity frequency within the genotyped individuals.</p><p id="p0129" num="0129">Across all individuals (<figref idrefs="f0004">Figure 4</figref>), eight SNPs distributed throughout exon 9 were analyzed (SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 64, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 32, SEQ ID NO: 102). Included in the eight SNP subset is SEQ ID 10, which, of all novel SNPs included in this study, had the highest heterozygosity frequency within a given cohort (17.33% heterozygosity frequency in the African American cohort). This study demonstrated minimal linkage disequilibrium between SNPs within the previously reported haplotype block (<i>i.e.</i> within "Gaunt Block 2" as indicated in <figref idrefs="f0004">Figure 4</figref>). For example, strong evidence for historical recombination was detected between the high frequency SNP SEQ ID NO: 10 and SEQ ID NO: 16 (indicated by the white diamond in the Haploview output). Minimal linkage disequilibrium was also observed between SNPs within the previously reported haplotype block and SNPs within the up and downstream regions of exon 9 (uncharacterized regions block 1 and block 3). One example of this is the high frequency SNP in block 2, SEQ ID 10, which reported minimal linkage disequilibrium with SEQ ID 102 in block 3. Additional examples of these SNP pairs include SEQ ID NO: 4 and SEQ ID NO: 64; SEQ ID NO: 4 and SEQ ID NO: 16; SEQ ID NO: 64 and SEQ ID NO: 32; and SEQ ID NO: 10 and SEQ ID NO: 102. Surprisingly, and contrary to the finding of Gaunt and of the HAPMAP linkage analysis of this region, we found no evidence for strong linkage disequilibrium. These findings indicate an unexpected frequency of recombination within this relatively small region of genomic sequence. These findings support the conclusion that for this locus, the use of assays detecting more than one polymorphic marker which are collocated on what were believed to be the same prior art "linkage block" will increase the informativity of a test to determine imprinting status of a sample. Panels of markers to be quantified may be based on combinations of SNPs among the previously described SNPs and the novel SNPs described in this application, and these findings demonstrate, counter to what was known prior to our study, that such combinations of markers can improve the ability to monitor LOI of <b><i>IGF2</i></b> by dramatically increasing the percentage of populations that can be tested.<!-- EPO <DP n="43"> --></p><heading id="h0025"><b>Example 4. Demonstration of use of SNPs to determine LOI status of <i>IGF2.</i></b></heading><p id="p0130" num="0130">The SNP corresponding to SEQ ID NO: 64 (rs680) falls within the target recognition sequences of two restriction enzymes, <i>Apa I</i> and <i>Ava II.</i> These two enzymes cleave in an allele-specific manner. <i>Apa I</i> recognizes and cleaves the sequence when the "G" allele is present, <i>and Ava II</i> recognizes and cleaves the sequence when the "A" allele is present. To independently assess genotypes within a selected panel of individuals, a PCR amplicon including the position of SEQ ID NO: 64 was amplified from a genomic DNA sample derived from each individual. Amplicons were digested with <i>Apa I</i> or <i>Ava II</i> or a combination of both enzymes. Digestion by <i>Apa I</i> only indicates that the individual is homozygous for the G allele, digestion by A va <i>II</i> only indicates that the individual is homozygous for the A allele, and digestion by both enzymes indicates that the individual is heterozygous for the SNP. An example of the data output for each possible genotype of SEQ ID NO: 64 is shown in <figref idrefs="f0005">Figure 5</figref>. As described above, the genotype call determined by the digestion-based assay exactly matched the genotype call based on DNA sequencing in 70 of 70 individuals (100%).</p><p id="p0131" num="0131">The same basic assay strategy can be utilized to detect LOI of <i>IGF2,</i> provided the individual being tested is heterozygous for SEQ ID NO: 64. An example is shown in <figref idrefs="f0006">Figure 6</figref>. Total RNA was extracted from three individuals heterozygous for SEQ ID NO: 64. Two individuals were previously shown to be LOI for <b><i>IGF2</i></b> and the third was previously shown to display normal imprinting of <i>IGF2.</i> The region including SEQ ID NO: 64 was RT-PCR amplified from each sample. Reactions lacking reverse transcriptase were performed in parallel to confirm that there was no amplification from genomic DNA. RT-PCR amplicons were then digested with <i>Apa I</i> or <i>Ava II</i> or a combination of both enzymes, as described above. Digested products were resolved on an Agilent Bioanalyzer, and concentrations of cut and uncut fragments were determined. The quantity of fragments cut by <i>Apa I</i> represents the proportion of cDNA amplified from the "G" allele. The quantity of fragments cut by <i>Ava II</i> represents the proportion of cDNA amplified from the "A" allele. Therefore, the ratio of <i>Apa I</i> cut fragments to <i>Ava II</i> cut fragments indicates the relative ratio of expression of the two alleles in the original RNA sample. As shown in <figref idrefs="f0006">Figure 6</figref>, Sample 2 expresses exclusively the "A" allele. Samples 1 and 3 express both alleles (<i>i.e.</i> display LOI <i>IGF2</i>)<i>,</i> with G:A ratios of 0.5 and 0.3, respectively. As described above, previous studies have used a threshold of 33.3% expression from the lesser abundant allele relative to the more abundant allele as the definition for LOI of <i>IGF2.</i><!-- EPO <DP n="44"> --></p><p id="p0132" num="0132">Other SNPs that can be useful for detecting LOI of <i>IGF2</i> do not fall within restriction enzyme recognition sequences. Therefore, the ability to monitor LOI in a given individual is improved by developing allele-specific gene expression assays that do not require restriction enzyme digestion. As a demonstration, we developed a primer extension based assay for SEQ ID NO: 64. <figref idrefs="f0007">Figure 7</figref> diagrams the use of a primer extension assay for genotyping SEQ ID NO: 64. The region including the SNP of interest is PCR amplified using genomic DNA obtained from the individual to be genotyped. A primer is added to the purified PCR product that anneals with its 3' terminal nucleotide complimentary to the template nucleotide 1 base to the 3' side of the polymorphic nucleotide to be genotyped. Single nucleotide primer extension is carried out using a thermostable DNA polymerase and differentially fluorescently labeled ddNTPs. In the example diagrammed in <figref idrefs="f0007">Figure 7</figref>, either dR110 labeled ddGTP or dR6G labeled ddATP is added to the 3' end of the primer. These labeled polynucleotides are then resolved and the peak areas representative of each possible incorporated nucleotide are calculated (<i>i.e</i>. using an ABI 3730 Gene Analyzer with Gene Mapper software). Peak areas are compared to determine the genotype of the individual at that SNP position.</p><p id="p0133" num="0133">The three individuals that were assayed for LOI of <i>IGF2</i> by the restriction enzyme based assay (<figref idrefs="f0006">Figure 6</figref>) were genotyped for SEQ ID NO: 64 using the primer extension assay (<figref idrefs="f0008">Figure 8</figref>). As expected, peaks representing both alleles of the SNP were detected, confirming that the three individuals are heterozygous for SEQ ID NO: 64.</p><p id="p0134" num="0134">To measure allele-specific expression of <i>IGF2</i> in the same three individuals, the region including SEQ ID NO: 64 was RT-PCR amplified from a total RNA sample derived from each individual. Reactions lacking reverse transcriptase were performed in parallel to confirm that there was no amplification from genomic DNA. The cDNA products obtained were purified and analyzed as diagrammed in <figref idrefs="f0007">Figure 7</figref>. Peak areas representing each of the two possible alleles were calculated. To correct for differences in dye intensities, these values were normalized based on comparisons of peak areas calculated using predetermined 1:1 ratios of each allele (<i>i.e</i>. 1:1 ratio of DNA amplicons derived from individuals that are homozygous for each of the two alleles). The resulting chromatograms and calculated allele ratios are shown in <figref idrefs="f0009">Figure 9</figref>. In agreement with the results shown in <figref idrefs="f0006">Figure 6</figref>, Samples 1 and 3 were determined to show LOI of <i>IGF2,</i> and Sample 2 was determined to show normal imprinting of <i>IGF2.</i> The same type of single nucleotide primer extension assay that utilizes<!-- EPO <DP n="45"> --> any SNP within the transcribed region of <i>IGF2</i> could be used to monitor allele-specific expression of <i>IGF2.</i></p><p id="p0135" num="0135">To demonstrate the use of additional SNPs for measuring allele-specific expression of <i>IGF2,</i> single nucleotide primer extension assays were designed based on eight additional SNPs (SEQ ID NO: 1, 10, 21, 56, 83, 85, 102 and 111). The SNPs corresponding to SEQ ID NO: 1, 10 and 21 are novel SNPs. For each of the nine SNPs (including SEQ ID NO: 64), PCR products were separately amplified from genomic DNA samples derived from two individuals; one homozygous for one allele of the SNP and the other homozygous for the other allele of the SNP. The PCR products were purified and quantified. For each of the nine SNPs, two PCR products (one amplified from the DNA sample homozygous for one allele and the other amplified from the DNA sample homozygous for the other allele) were combined in the following ratios of allele 1 to allele 2; 1:10, 1:8, 1:6, 1:4, 1:3, 1:2, 1:1, 2: 1, 3:1, 4:1, 6:1, 8:1 and 10:1. For each of the nine SNPs, the single nucleotide primer extension assay was performed in triplicate on each dilution point. Peak areas representing each of the two possible alleles were calculated. To correct for differences in dye intensities, these values were normalized based on comparisons of peak areas calculated using predetermined 1:1 ratios of each allele. The analytical quantitative linearity of each assay is shown in <figref idrefs="f0010">Figure 10</figref>. The average R<sup>2</sup> of the assays is 0.996 ± 0.002 and the average slope is 0.830 ± 0.024.<!-- EPO <DP n="46"> -->
<tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="25mm"/><colspec colnum="4" colname="col4" colwidth="21mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="69mm"/><thead><row><entry namest="col1" nameend="col6" rowsep="0" align="left"><b>Table 1A. Known Polymorphisms in <i>IGF2</i> exons 8 &amp; 9.</b></entry></row><row><entry align="center"><b>Seq. ID</b></entry><entry align="center"><b>Genomic Position*</b></entry><entry align="center"><b>dbSNP</b></entry><entry align="center"><b>Alleles</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>Sequence</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">48</entry><entry align="center" valign="bottom">2111395</entry><entry align="center" valign="bottom">rs1803647</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">TGCTGTTTCCGCAGCTGTGACCTGGC[C/G]CTCCTGGAGACGTACTGTGCTACCC</entry></row><row><entry align="center" valign="bottom">49</entry><entry align="center" valign="bottom">2110976</entry><entry align="center" valign="bottom">rs14367</entry><entry align="center" valign="bottom">[G/A]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AGTTCTTCCAATATGACACCTGGAA[G/A]CAGTCCACCCAGCGCCTGCGCAGGG</entry></row><row><entry align="center" valign="bottom">50</entry><entry align="center" valign="bottom">2110955</entry><entry align="center" valign="bottom">rs1065443</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">GGAAGCAGTCCACCCAGCGCCTGCG[C/T]AGGGGCCTGCCTGCCCTCCTGCGTG</entry></row><row><entry align="center" valign="bottom">51</entry><entry align="center" valign="bottom">2110819</entry><entry align="center" valign="bottom">rs11545014</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AAGACCCCGCCCACGGGGGCGCCCCC[C/T]CAGAGATGGCCAGCAATCGGAAGTG</entry></row><row><entry align="center" valign="bottom">52</entry><entry align="center" valign="bottom">2110818</entry><entry align="center" valign="bottom">rs1050342</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AGACCCCGCCCACGGGGGCGCCCCCC[A/C]AGAGATGGCCAGCAATCGGAAGTGA</entry></row><row><entry align="center" valign="bottom">53</entry><entry align="center" valign="bottom">2110796</entry><entry align="center" valign="bottom">rs12993</entry><entry align="center" valign="bottom">[G/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CCCCCAGAGATGGCCAGCAATCGGAA[G/T]TGAGCAAAACTGCCGCRAGTCTGCA</entry></row><row><entry align="center" valign="bottom">54</entry><entry align="center" valign="bottom">2110779</entry><entry align="center" valign="bottom">rs9282726</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CAATCGGAAKTGAGCAAAACTGCCGC[A/G]AGTCTGCAGCCYGGYGCCACCATCC</entry></row><row><entry align="center" valign="bottom">55</entry><entry align="center" valign="bottom">2110767</entry><entry align="center" valign="bottom">rs3741214</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AGCAAAACTGCCGCAAGTCTGCAGCC[C/T]GGCGCCACCATCCTGCAGCCTCCTC</entry></row><row><entry align="center" valign="bottom">56</entry><entry align="center" valign="bottom">2110764</entry><entry align="center" valign="bottom">rs2230949</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AAACTGCCGCAAGTCTGCAGCCCGG[C/T]GCCACCATCCTGCAGCCTCCTCCTG</entry></row><row><entry align="center" valign="bottom">57</entry><entry align="center" valign="bottom">2110733</entry><entry align="center" valign="bottom">rs3213234</entry><entry align="center" valign="bottom">[G/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CATCCTGCAGCCTCCTCCTGACCAC[G/T]GACGTTTCCATCAGGTTCCATCCCG</entry></row><row><entry align="center" valign="bottom">58</entry><entry align="center" valign="bottom">2110683</entry><entry align="center" valign="bottom">rs34337549</entry><entry align="center" valign="bottom">[-/G]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CGGGGACTGGGTCAGGAGAAGCCCCA[-/G]GGGGACGTGGAACCGAGAGATTTTC</entry></row><row><entry align="center" valign="bottom">59</entry><entry align="center" valign="bottom">2110613</entry><entry align="center" valign="bottom">rs6223</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CAGGCTACTCTCCTCGGCCCCCTCC[A/C]TCGGGCTGAGGAAGCACAGCAGCAT</entry></row><row><entry align="center" valign="bottom">60</entry><entry align="center" valign="bottom">2110586</entry><entry align="center" valign="bottom">rs11510</entry><entry align="center" valign="bottom">[A/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">TCGGGCTGAGGAAGCACAGCAGCATC[A/T]TCAAACATGTACAAAATCGATTGGC</entry></row><row><entry align="center" valign="bottom">61</entry><entry align="center" valign="bottom">2110554</entry><entry align="center" valign="bottom">rs 1803648</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">ATGTACAAAATCGATTGGCTTTAAA[A/C]ACCCTTCACATACCCTCCCCCCAAA</entry></row><row><entry align="center" valign="bottom">62</entry><entry align="center" valign="bottom">2110470</entry><entry align="center" valign="bottom">rs11564731</entry><entry align="center" valign="bottom">[-/AC]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AAAACATTAAACTAACCCCCTTCCCC[-/AC]CCCCCCCACAACAACCCTCTTAAAA</entry></row><row><entry align="center" valign="bottom">63</entry><entry align="center" valign="bottom">2110279</entry><entry align="center" valign="bottom">rs15737</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">TGGCACTCCCCACCCCCCTCTTTCT[C/T]TTCTCCCTTGGACTTTGAGTCAAAT</entry></row><row><entry align="center" valign="bottom">64</entry><entry align="center" valign="bottom">2110210</entry><entry align="center" valign="bottom">rs680</entry><entry align="center" valign="bottom">[G/A/C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CTGAACCAGCAAAGAGAAAAGAAGG[G/A/C/T]CCCCAGAAATCACAGGTGGGCACGT</entry></row><row><entry align="center" valign="bottom">65</entry><entry align="center" valign="bottom">2110180</entry><entry align="center" valign="bottom">rs1065685</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CAGAAATCACAGGTGGGCACGTCGCT[C/G]CTACCGCCATCTCCCTTCTCACGGG</entry></row><row><entry align="center" valign="bottom">66</entry><entry align="center" valign="bottom">2109887</entry><entry align="center" valign="bottom">rs56731553</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GTGCTCGTGTGTGTGCTGTGTTCATG[C/T]GTGTGCTGTGTGTTGTGTGTGTGTA</entry></row><row><entry align="center" valign="bottom">67</entry><entry align="center" valign="bottom">2109881</entry><entry align="center" valign="bottom">rs56154171</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TGTGCTGTGCTCGTGTGTGTGCTGTG[C/T]TCATGCGTGTGCTGTGTGTTGTGTG</entry></row><row><entry align="center" valign="bottom">68</entry><entry align="center" valign="bottom">2109862</entry><entry align="center" valign="bottom">rs59198946</entry><entry align="center" valign="bottom">[-/AT]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GTGCTGTGCGTTTGTGTGTGTGCTGT[-/AT]GCTCGTGTGTGTGCTGTGTTCA TGC</entry></row><row><entry align="center" valign="bottom">69</entry><entry align="center" valign="bottom">2109849</entry><entry align="center" valign="bottom">rs61872709</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TCTGTGTGCTGTGTGTGCTGTGCGTT[C/T]GTGTGTGTGCTGTGCTCGTGTGTGT</entry></row><row><entry align="center" valign="bottom">70</entry><entry align="center" valign="bottom">2109847</entry><entry align="center" valign="bottom">rs61872708</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CATCTGTGTGCTGTGTGTGCTGTGCG[C/T]TTGTGTGTGTGCTGTGCTCGTGTGT</entry></row><row><entry align="center" valign="bottom">71</entry><entry align="center" valign="bottom">2109730</entry><entry align="center" valign="bottom">rs61872707</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TGCGTTTGTGTGTGTGCTGTGTGTGC[A/G]TGTGTGTGCGTGTGTGTGCCGTGCG</entry></row><row><entry align="center" valign="bottom">72</entry><entry align="center" valign="bottom">2109724</entry><entry align="center" valign="bottom">rs61872706</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GTGCTGTGCGTTTGTGTGTGTGCTGT[A/G]TGTGCATGTGTGTGCGTGTGTGTGC</entry></row><row><entry align="center" valign="bottom">73</entry><entry align="center" valign="bottom">2109712</entry><entry align="center" valign="bottom">rs11042774</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">gtgcgtttgtgtgctgtgcgtttg[C/T]gtgtgtgctgtgtgtgcatgtgtgt</entry></row><row><entry align="center" valign="bottom">74</entry><entry align="center" valign="bottom">2109604</entry><entry align="center" valign="bottom">rs59630895</entry><entry align="center" valign="bottom">[-/TGTG]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TTGTGTGTGTGCTGTGTGCTAGTGTG[-TGTG]CTGTGTGTGCATGTGTGTGCGTGTG</entry></row><row><entry align="center" valign="bottom">75</entry><entry align="center" valign="bottom">2109541</entry><entry align="center" valign="bottom">rs7111331</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">tgctgtgttcgtgtgtgctgtgttcg[C/T]gtgtgtgctgtgtgtgcatgtgt</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="25mm"/><colspec colnum="4" colname="col4" colwidth="21mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="69mm"/><tbody><row><entry namest="col1" nameend="col6" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="47"> -->
<tables id="tabl0002" num="0002"><table frame="all"><title><b>Table 1B. Known Polymorphisms in <i>IGF2</i> exon 9.</b></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="68mm"/><thead><row><entry align="center"><b>Seq. ID</b></entry><entry align="center"><b>Genomic Position*</b></entry><entry align="center"><b>dbSNP</b></entry><entry align="center"><b>Alleles</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>Sequence</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">76</entry><entry align="center" valign="bottom">2108682</entry><entry align="center" valign="bottom">rs11042767</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ACATTTCTTGGGGGGTCCCCAGGAGA[C/T]GGGCAAAGATGATCCCTAGGTGTGC</entry></row><row><entry align="center" valign="bottom">77</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">rs7129583</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT</entry></row><row><entry align="center" valign="bottom">78</entry><entry align="center" valign="bottom">2108395</entry><entry align="center" valign="bottom">rs28462050</entry><entry align="center" valign="bottom">[T/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCATTTTTCCTTTTTTTTTTTTTTT[T/G]GTTTTTTTTTTACCCCTCCTTAGCT</entry></row><row><entry align="center" valign="bottom">79</entry><entry align="center" valign="bottom">2108344</entry><entry align="center" valign="bottom">rs28472590</entry><entry align="center" valign="bottom">[-/GG]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGCCCCCCTGTTACATGGGGGGGGGG[-/GG]TTTAATTTGGTTTCTGAGCGCATAA</entry></row><row><entry align="center" valign="bottom">80</entry><entry align="center" valign="bottom">2108288</entry><entry align="center" valign="bottom">rs58312807</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GAGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT</entry></row><row><entry align="center" valign="bottom">81</entry><entry align="center" valign="bottom">2107971</entry><entry align="center" valign="bottom">rs60649995</entry><entry align="center" valign="bottom">[G/A]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGGCTGGCCGGAGGGGAAGGGGCTA[G/A]CAGGTGTGTAAACAGAGGGTTCCAT</entry></row><row><entry align="center" valign="bottom">82</entry><entry align="center" valign="bottom">2107909</entry><entry align="center" valign="bottom">rs58562468</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAGGGTGGCCGCCTTCCGCACACTTG[A/G] GGAACCCTCCCCTCTCCCTCGGTGA</entry></row><row><entry align="center" valign="bottom">83</entry><entry align="center" valign="bottom">2107900</entry><entry align="center" valign="bottom">rs1065687</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CGCCTTCCGCACACTTGAGGAACCCT[C/G]CCCTCTCCCTCGGTGACATCTTGCC</entry></row><row><entry align="center" valign="bottom">84</entry><entry align="center" valign="bottom">2109167</entry><entry align="center" valign="bottom">rs3208122</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TAAGCAACTACGATATCTGTATGGAT[A/C]AGGCCAAAGTCCCGCTAAGATTCTC</entry></row><row><entry align="center" valign="bottom">85</entry><entry align="center" valign="bottom">2109117</entry><entry align="center" valign="bottom">rs3168310</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CCAATGTTTTCATGGTCTGAGCCCC[C/G]CTCCTGTTCCCATCTCCACTGCCCC</entry></row><row><entry align="center" valign="bottom">86</entry><entry align="center" valign="bottom">2108911</entry><entry align="center" valign="bottom">rs58527086</entry><entry align="center" valign="bottom">[-/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CATCGTGGCTCACGCTGCGGGGGCCG[-/T]GGGGACAGGCGCCAAGGAGGCCAGC</entry></row><row><entry align="center" valign="bottom">87</entry><entry align="center" valign="bottom">2108682</entry><entry align="center" valign="bottom">ras57156844</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ACATTTCTTGGGGGGTCCCCAGGAGA[C/T]GGGCAAAGATGATCCCTAGGTGTGC</entry></row><row><entry align="center" valign="bottom">88</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">rs3802971</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT</entry></row><row><entry align="center" valign="bottom">89</entry><entry align="center" valign="bottom">2108395</entry><entry align="center" valign="bottom">rs3180700</entry><entry align="center" valign="bottom">[T/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCATTTTTCCTTTTTTTTTTTTTTT[T/G]GTTTTTTTTTTACCCCTCCTTAGCT</entry></row><row><entry align="center" valign="bottom">90</entry><entry align="center" valign="bottom">2108344</entry><entry align="center" valign="bottom">rs57423851</entry><entry align="center" valign="bottom">[-/GG]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGCCCCCCTGTTACATGGGGGGGGGG[-/GG]TTTAATTTGGTTTCTGAGCGCATAA</entry></row><row><entry align="center" valign="bottom">91</entry><entry align="center" valign="bottom">2108288</entry><entry align="center" valign="bottom">rs35818489</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GAGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT</entry></row><row><entry align="center" valign="bottom">92</entry><entry align="center" valign="bottom">2107971</entry><entry align="center" valign="bottom">rs11825733</entry><entry align="center" valign="bottom">[G/A]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGGCTGGCCGGAGGGGAAGGGGCTA[G/A]CAGGTGTGTAAACAGAGGGTTCCAT</entry></row><row><entry align="center" valign="bottom">93</entry><entry align="center" valign="bottom">2107909</entry><entry align="center" valign="bottom">rs11541377</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAGGGTGGCCGCCTTCCGCACACTTG[A/G]GGAACCCTCCCCTCTCCCTCGGTGA</entry></row><row><entry align="center" valign="bottom">94</entry><entry align="center" valign="bottom">2107900</entry><entry align="center" valign="bottom">rs11541375</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CGCCTTCCGCACACTTGAGGAACCCT[C/G]CCCCCTCGGTGACATCTTGCC</entry></row><row><entry align="center" valign="bottom">95</entry><entry align="center" valign="bottom">2107862</entry><entry align="center" valign="bottom">rs11541373</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGTGACATCTTGCCCGCCCCTCAGCA[C/T]CCTGCCTTGTCTCCAGGAGGTCCGA</entry></row><row><entry align="center" valign="bottom">96</entry><entry align="center" valign="bottom">2107847</entry><entry align="center" valign="bottom">rs11541372</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCCCTCAGCACCCTGCCTTGTCTCC[A/C]GGAGGTCCGAAGCTCTGTGGGACCT</entry></row><row><entry align="center" valign="bottom">97</entry><entry align="center" valign="bottom">2107755</entry><entry align="center" valign="bottom">rs11541374</entry><entry align="center" valign="bottom">[G/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAGGCGGGTCTGAGCCCACAGAGCAG[G/T]AGAGCTGCCAGGTCTGCCCATCGAC</entry></row><row><entry align="center" valign="bottom">98</entry><entry align="center" valign="bottom">2107602</entry><entry align="center" valign="bottom">rs3189464</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCTCGCCCCCACTTGTGCCCCCAGCT[A/C] AGCCCCCCTGCACGCAGCCCGACTA</entry></row><row><entry align="center" valign="bottom">99</entry><entry align="center" valign="bottom">2107472</entry><entry align="center" valign="bottom">rs61745040</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAGTCGCAGAGGGTCCCTCGGCAAG[C/T]GCCCTGTGAGTGGGCCATTCGGAAC</entry></row><row><entry align="center" valign="bottom">100</entry><entry align="center" valign="bottom">2107471</entry><entry align="center" valign="bottom">rs11564732</entry><entry align="center" valign="bottom">[G/A/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGTCGCAGAGGGTCCCTCGGCAAGC[G/A/T]CCCTGTGAGTGGGCCATTCGGAACA</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="68mm"/><tbody><row><entry namest="col1" nameend="col6" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="48"> -->
<tables id="tabl0003" num="0003"><table frame="all"><title><b>Table 1C. Known Polymorphisms in <i>IGF2</i> exon 9.</b></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="25mm"/><colspec colnum="4" colname="col4" colwidth="22mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="67mm"/><thead><row><entry align="center"><b>Seq. ID</b></entry><entry align="center"><b>Genomic Position*</b></entry><entry align="center"><b>dbSNP</b></entry><entry align="center"><b>Alleles</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>Sequence</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">101</entry><entry align="center" valign="bottom">2107452</entry><entry align="center" valign="bottom">rs11541376</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCAAGCGCCCTGTGAGTGGGCCATT[C/T]GGAACATTGGACAGAAGCCCAAAGA</entry></row><row><entry align="center" valign="bottom">102</entry><entry align="center" valign="bottom">2107273</entry><entry align="center" valign="bottom">rs7873</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GTGTTCCCGGGGGCACTTGCCGACC[A/G]GCCCCTTGCGTCCCCAGGTTTGCAG</entry></row><row><entry align="center" valign="bottom">103</entry><entry align="center" valign="bottom">2107263</entry><entry align="center" valign="bottom">rs61745039</entry><entry align="center" valign="bottom">[G/A/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGGCACTTGCCGACCAGCCCCTTGC[G/A/T]TCCCCAGGTTTGCAGCTCTCCCCTG</entry></row><row><entry align="center" valign="bottom">104</entry><entry align="center" valign="bottom">2107147</entry><entry align="center" valign="bottom">rs3177805</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TTGTCTCCTCCCCGTGTCCCCAATGT[C/T]TTCAGTGGGGGGCCCCCTCTTGGGT</entry></row><row><entry align="center" valign="bottom">105</entry><entry align="center" valign="bottom">2107135</entry><entry align="center" valign="bottom">rs1065715</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CGTGTCCCCAATGTCTTCAGTGGGGG[C/G]CCCCCTCTTGGGTCCCCTCCTCTGC</entry></row><row><entry align="center" valign="bottom">106</entry><entry align="center" valign="bottom">2107134</entry><entry align="center" valign="bottom">rs11541371</entry><entry align="center" valign="bottom">[C/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGTCCCCAATGTCTTCAGTGGGGGG[C/G]CCCCTCTTGGGTCCCCTCCTCTGCC</entry></row><row><entry align="center" valign="bottom">107</entry><entry align="center" valign="bottom">2107128</entry><entry align="center" valign="bottom">rs1049926</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCAATGTCTTCAGTGGGGGGCCCCCT[C/T]TTGGGTCCCCTCCTCTGCCATCACC</entry></row><row><entry align="center" valign="bottom">108</entry><entry align="center" valign="bottom">2107113</entry><entry align="center" valign="bottom">rs3177946</entry><entry align="center" valign="bottom">[C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGGGCCCCCTCTTGGGTCCCCTCCT[C/T]GCCATCACCTGAAGACCCCCACGC</entry></row><row><entry align="center" valign="bottom">109</entry><entry align="center" valign="bottom">2107049</entry><entry align="center" valign="bottom">rs1050035</entry><entry align="center" valign="bottom">[A/C]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GTCACCTGTGCCTGCCGCCTCGGTCC[A/C]CCTTGCGGCCCGTGTTTGACTCAAC</entry></row><row><entry align="center" valign="bottom">110</entry><entry align="center" valign="bottom">2107027</entry><entry align="center" valign="bottom">rs11541370</entry><entry align="center" valign="bottom">[A/G]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AATATTAGCGTTAAAGGAGCTGAGTT[A/G]AGTCAAACACGGGCCGCAAGGTGGA</entry></row><row><entry align="center" valign="bottom">111</entry><entry align="center" valign="bottom">2107020</entry><entry align="center" valign="bottom">rs2585</entry><entry align="center" valign="bottom">[G/A/C/T]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGCGGCCCGTGTTTGACTCAACTCA[G/A/C/T]CTCCTTTAACGCTAATATTTCCGGC</entry></row><row><entry align="center" valign="bottom">112</entry><entry align="center" valign="bottom">2106955</entry><entry align="center" valign="bottom">rs1050141</entry><entry align="center" valign="bottom">[C/A]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGGTTTTGTCTTTAACCTTGTAACG[C/A]TTGCAATCCCAATAAAGCATTAAAA</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="25mm"/><colspec colnum="4" colname="col4" colwidth="22mm"/><colspec colnum="5" colname="col5" colwidth="17mm"/><colspec colnum="6" colname="col6" colwidth="67mm"/><tbody><row><entry namest="col1" nameend="col6" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="49"> -->
<tables id="tabl0004" num="0004"><table frame="all"><title><b><u>Table 2A. Novel Polymorphisms</u> in IGF2 exon 9.</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="17mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="87mm"/><thead><row><entry align="center"><b>Seq. ID</b></entry><entry align="center"><b>Genomic Position*</b></entry><entry align="center"><b>Alleles</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>Sequence</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">2110869</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">GCGTTCAGGGAGGCCAAACGTCACC[G/A]TCCCCTGATTGCTCTACCCACCCAA</entry></row><row><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">2110827</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CCCACCCAAGACCCCGCCCACGGGG[G/A]CGCCCCCCCAGAGATGGCCAGCAAT</entry></row><row><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2110825</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CACCCAAGACCCCGCCCACGGGGGC[G/A]CCCCCCCAGAGATGGCCAGCAATCG</entry></row><row><entry align="center" valign="bottom">4</entry><entry align="center" valign="bottom">2110781</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">GCAATCGGAAGTGAGCAAAACTGCC[G/A]CAAGTCTGCAGCCCGGCGCCACCAT</entry></row><row><entry align="center" valign="bottom">5</entry><entry align="center" valign="bottom">2110657</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">TGGGGCTTCTCCTGACCCAGTCCCC[G/A]TGCCCCGCCTCCCCGAAACAGGCTA</entry></row><row><entry align="center" valign="bottom">6</entry><entry align="center" valign="bottom">2110465</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">TTAAACTAACCCCCTTCCCCCCCCC[C/T]CACAACAACCCTCTTAAAACTAATT</entry></row><row><entry align="center" valign="bottom">7</entry><entry align="center" valign="bottom">2110430</entry><entry align="center" valign="bottom">[G/<u>A</u>/<u>T</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">CCTCTTAAAACTAATTGGCTTTTTA[G/A/T]AAACACCCCACAAAAGCTCAGAAAT</entry></row><row><entry align="center" valign="bottom">8</entry><entry align="center" valign="bottom">2110287</entry><entry align="center" valign="bottom">[C/<u>G</u>]</entry><entry align="center" valign="bottom">1</entry><entry valign="bottom">AAGGAATTTGGCACTCCCCACCCCC[C/G]TCTTTCTCTTCTCCCTTGGACTTTG</entry></row><row><entry align="center" valign="bottom">9</entry><entry align="center" valign="bottom">2110197</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GAGAAAAGAAGGACCCCAGAAATCA[C/T]AGGTGGGCACGTCGCTGCTACCGCC</entry></row><row><entry align="center" valign="bottom">10</entry><entry align="center" valign="bottom">2110187</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GGACCCCAGAAATCACAGGTGGGCA[C/T]GTCGCTGCTACCGCCATCTCCCTTC</entry></row><row><entry align="center" valign="bottom">11</entry><entry align="center" valign="bottom">2110129</entry><entry align="center" valign="bottom"><u>[</u>G/<u>A</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">AATTTTCAGGGTAAACTGGCCATCC[G/A]AAAATAGCAACAACCCAGACTGGCT</entry></row><row><entry align="center" valign="bottom">12</entry><entry align="center" valign="bottom">2110109</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CATCCGAAAATAGCAACAACCCAGA[C/T]TGGCTCCTCACTCCCTTTTCCATCA</entry></row><row><entry align="center" valign="bottom">13</entry><entry align="center" valign="bottom">2110063</entry><entry align="center" valign="bottom">[A/<u>C</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CATCACTAAAAATCACAGAGCAGTC[A/C]GAGGGACCCAGTAAGACCAAAGGAG</entry></row><row><entry align="center" valign="bottom">14</entry><entry align="center" valign="bottom">2110060</entry><entry align="center" valign="bottom">[G/<u>C</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CACTAAAAATCACAGAGCAGTCAGA[G/C]GGACCCAGTAAGACCAAAGGAGGGG</entry></row><row><entry align="center" valign="bottom">15</entry><entry align="center" valign="bottom">2110058</entry><entry align="center" valign="bottom">[G/<u>T</u>/<u>A</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">CTAAAAATCACAGAGCAGTCAGAGG[G/T/A]ACCCAGTAAGACCAAAGGAGGGGAG</entry></row><row><entry align="center" valign="bottom">16</entry><entry align="center" valign="bottom">2109220</entry><entry align="center" valign="bottom">[A/<u>C</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">GCGCACACACACGCACACCCCCACA[A/C]AATTGGATGAAAACAATAAGCATAT</entry></row><row><entry align="center" valign="bottom">17</entry><entry align="center" valign="bottom">2109153</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">2</entry><entry valign="bottom">TCTGTATGGATCAGGCCAAAGTCCC[G/A]CTAAGATTCTCCAATGTTTTCATGG</entry></row><row><entry align="center" valign="bottom">18</entry><entry align="center" valign="bottom">2109095</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCCGCTCCTGTTCCCATCTCCACTG[C/T]CCCTCGGCCCTGTCTGTGCCCTGCC</entry></row><row><entry align="center" valign="bottom">19</entry><entry align="center" valign="bottom">2109074</entry><entry align="center" valign="bottom">[C/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ACTGCCCCTCGGCCCTGTCTGTGCC[C/G]TGCCTCTCAGAGGAGGGGGCTCAGA</entry></row><row><entry align="center" valign="bottom">20</entry><entry align="center" valign="bottom">2108843</entry><entry align="center" valign="bottom">[T/<u>C</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CATTCCCGATACACCTTACTTACTG[T/C]GTGTTGGCCCAGCCAGAGTGAGGAA</entry></row><row><entry align="center" valign="bottom">21</entry><entry align="center" valign="bottom">2108835</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ATACACCTTACTTACTGTGTGTTGG[C/T]CCAGCCAGAGTGAGGAAGGAGTTTG</entry></row><row><entry align="center" valign="bottom">22</entry><entry align="center" valign="bottom">2108806</entry><entry align="center" valign="bottom">[A/<u>C</u>/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCCAGAGTGAGGAAGGAGTTTGGCC[A/C/T]CATTGGAGATGGCGGTAGCTGAGCA</entry></row><row><entry align="center" valign="bottom">23</entry><entry align="center" valign="bottom">2108738</entry><entry align="center" valign="bottom">[G/<u>A</u>/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGCCTGACTCCCTGGTGTGCTCCTG[G/A/T]AAGGAAGATCTTGGGGACCCCCCCA</entry></row><row><entry align="center" valign="bottom">24</entry><entry align="center" valign="bottom">2108440</entry><entry align="center" valign="bottom">[C/<u>T</u>/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAAATTTCATGTCAATTGATCTATT[C/T/G]CCCCTCTTTGTTTCTTGGGGCATTT</entry></row><row><entry align="center" valign="bottom">25</entry><entry align="center" valign="bottom">2108424</entry><entry align="center" valign="bottom">[T/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGATCTATTCCCCCTCTTTGTTTCT[T/G]GGGGCATTTTTCCTTTTTTTTTTTT</entry></row><row><entry align="center" valign="bottom">26</entry><entry align="center" valign="bottom">2108417</entry><entry align="center" valign="bottom">[T/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TTCCCCCTCTTTGTTTCTTGGGGCA[T/G]TTTTCCTTTTTTTTTTTTTTTTGTT</entry></row><row><entry align="center" valign="bottom">27</entry><entry align="center" valign="bottom">2108326</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AATTAAACCCCCCCCCCATGTAACA[G/A]GGGGGCAGTGACAAAAGCAAGAACG</entry></row><row><entry align="center" valign="bottom">28</entry><entry align="center" valign="bottom">2107988</entry><entry align="center" valign="bottom">[C/<u>T</u>/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGCTCCTGGCTGGCCTGAGGCTGGC[C/T/A]GGAGGGGAAGGGGCTAGCAGGTGTG</entry></row><row><entry align="center" valign="bottom">29</entry><entry align="center" valign="bottom">2107918</entry><entry align="center" valign="bottom">[G/<u>C</u>/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGCTGGGGCAGGGTGGCCGCCTTCC[G/C/A]CACACTTGAGGAACCCTCCCCTCTC</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="17mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="87mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="50"> -->
<tables id="tabl0005" num="0005"><table frame="all"><title><b>Table 2B. Novel Polymorphisms in <i>IGF2</i> exon 9.</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="17mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="87mm"/><thead><row><entry align="center"><b>Seq. ID</b></entry><entry align="center"><b>Genomic Position*</b></entry><entry align="center"><b>Alleles</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>Sequence</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">30</entry><entry align="center" valign="bottom">2107819</entry><entry align="center" valign="bottom">[T/<u>G]</u></entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGGTCCGAAGCTCTGTGGGACCTCT[T/G]GGGGGCAAGGTGGGGTGAGGCCGGG</entry></row><row><entry align="center" valign="bottom">31</entry><entry align="center" valign="bottom">2107776</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGGCCGGGGAGTAGGGAGGTCAGGC[G/A]GGTCTGAGCCCACAGAGCAGGAGAG</entry></row><row><entry align="center" valign="bottom">32</entry><entry align="center" valign="bottom">2107668</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ATGCCATAGCAGCCACCACCGCGGC[G/A]CCTAGGGCTGCGGCAGGGACTCGGC</entry></row><row><entry align="center" valign="bottom">33</entry><entry align="center" valign="bottom">2107664</entry><entry align="center" valign="bottom">[A/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CATAGCAGCCACCACCGCGGCGCCT[A/T]GGGCTGCGGCAGGGACTCGGCCTCT</entry></row><row><entry align="center" valign="bottom">34</entry><entry align="center" valign="bottom">2107625</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GACTCGGCCTCTGGGAGGTTTACCT[C/T]GCCCCCACTTGTGCCCCCAGCTCAG</entry></row><row><entry align="center" valign="bottom">35</entry><entry align="center" valign="bottom">2107595</entry><entry align="center" valign="bottom">[C/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCACTTGTGCCCCCAGCTCAGCCCC[C/G]CTGCACGCAGCCCGACTAGCAGTCT</entry></row><row><entry align="center" valign="bottom">36</entry><entry align="center" valign="bottom">2107523</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCTGGTGACGGGGCTGGCATGACCC[C/T]GGGGGTCGTCCATGCCAGTCCGCCT</entry></row><row><entry align="center" valign="bottom">37</entry><entry align="center" valign="bottom">2107478</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CCGCCTCAGTCGCAGAGGGTCCCTC[G/A]GCAAGCGCCCTGTGAGTGGGCCATT</entry></row><row><entry align="center" valign="bottom">38</entry><entry align="center" valign="bottom">2107472</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">CAGTCGCAGAGGGTCCCTCGGCAAG[C/T]GCCCTGTGAGTGGGCCATTCGGAAC</entry></row><row><entry align="center" valign="bottom">39</entry><entry align="center" valign="bottom">2107469</entry><entry align="center" valign="bottom">[C/<u>T</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TCGCAGAGGGTCCCTCGGCAAGCGC[C/T]CTGTGAGTGGGCCATTCGGAACATT</entry></row><row><entry align="center" valign="bottom">40</entry><entry align="center" valign="bottom">2107379</entry><entry align="center" valign="bottom">[C/<u>T]</u></entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ACCCACATTGGCCTGAGATCCAAAA[C/T]GCTTCGAGGCACCCCAAATTACCTG</entry></row><row><entry align="center" valign="bottom">41</entry><entry align="center" valign="bottom">2107353</entry><entry align="center" valign="bottom">[C/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCTTCGAGGCACCCCAAATTACCTG[C/G]CCATTCGTCAGGACACCCACCCACC</entry></row><row><entry align="center" valign="bottom">42</entry><entry align="center" valign="bottom">2107278</entry><entry align="center" valign="bottom">[C/<u>T]</u></entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">AGTGGGTGTTCCCGGGGGCACTTGC[C/T]GACCAGCCCCTTGCGTCCCCAGGTT</entry></row><row><entry align="center" valign="bottom">43</entry><entry align="center" valign="bottom">2107263</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GGGCACTTGCCGACCAGCCCCTTGC[G/A]TCCCCAGGTTTGCAGCTCTCCCCTG</entry></row><row><entry align="center" valign="bottom">44</entry><entry align="center" valign="bottom">2107151</entry><entry align="center" valign="bottom">[A/<u>G</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">ATCTTGTCTCCTCCCCGTGTCCCCA[A/G]TGTCTTCAGTGGGGGGCCCCCTCTT</entry></row><row><entry align="center" valign="bottom">45</entry><entry align="center" valign="bottom">2107054</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GAATGTCACCTGTGCCTGCCGCCTC[G/A]GTCCACCTTGCGGCCCGTGTTTGAC</entry></row><row><entry align="center" valign="bottom">46</entry><entry align="center" valign="bottom">2107037</entry><entry align="center" valign="bottom">[G/<u>A</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">GCCGCCTCGGTCCACCTTGCGGCCC[G/A]TGTTTGACTCAACTCAACTCCTTTA</entry></row><row><entry align="center" valign="bottom">47</entry><entry align="center" valign="bottom">2106956</entry><entry align="center" valign="bottom">[G/<u>A</u>/<u>C</u>]</entry><entry align="center" valign="bottom">3</entry><entry valign="bottom">TGGGTTTTGTCTTTAACCTTGTAAC[G/A/C]CTTGCAATCCCAATAAAGCATTAAA</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="17mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="87mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="51"> -->
<tables id="tabl0006" num="0006"><table frame="all"><title><b>Table 3. Observed Heterozygosity of Transcribed IGF2 SNPs in Human Populations</b></title><tgroup cols="9"><colspec colnum="1" colname="col1" colwidth="14mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="16mm"/><colspec colnum="4" colname="col4" colwidth="20mm"/><colspec colnum="5" colname="col5" colwidth="20mm"/><colspec colnum="6" colname="col6" colwidth="20mm"/><colspec colnum="7" colname="col7" colwidth="20mm"/><colspec colnum="8" colname="col8" colwidth="20mm"/><colspec colnum="9" colname="col9" colwidth="20mm"/><thead><row><entry align="center"><b>SEQ ID NO:</b></entry><entry align="center"><b>Genomic Position</b></entry><entry align="center"><b>Block</b></entry><entry align="center"><b>All ObsHET</b></entry><entry align="center"><b>AA ObsHET</b></entry><entry align="center"><b>CAU ObsHET</b></entry><entry align="center"><b>CHI ObsHET</b></entry><entry align="center"><b>JAP ObsHET</b></entry><entry align="center"><b>MEX ObsHET</b></entry></row></thead><tbody><row><entry align="right" valign="bottom">1</entry><entry align="center" valign="bottom">2110869</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">1.08% (6 of 553)</entry><entry align="center" valign="bottom">3.3% (3 of 91)</entry><entry align="center" valign="bottom">1% (2 of 201)</entry><entry align="center" valign="bottom">0% (0 of 84)</entry><entry align="center" valign="bottom">0% (0 of 90)</entry><entry align="center" valign="bottom">1.15% (1 of 87)</entry></row><row><entry align="right" valign="bottom">4</entry><entry align="center" valign="bottom">2110781</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">0.95% (4 of 421)</entry><entry align="center" valign="bottom">2.9% (2 of 69)</entry><entry align="center" valign="bottom">0% (0 of 155)</entry><entry align="center" valign="bottom">0% (0 of 61)</entry><entry align="center" valign="bottom">2.86% (2 of 70)</entry><entry align="center" valign="bottom">0% (0 of 66)</entry></row><row><entry align="right" valign="bottom">56</entry><entry align="center" valign="bottom">2110764</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">1.45% (1 of 69)</entry><entry align="center" valign="bottom">6.25% (1 of 16)</entry><entry align="center" valign="bottom">0% (0 of 35)</entry><entry align="center" valign="bottom">0% (0 of 8)</entry><entry align="center" valign="bottom">0% (0 of 2)</entry><entry align="center" valign="bottom">0% (0 of</entry></row><row><entry align="right" valign="bottom">6</entry><entry align="center" valign="bottom">2110465</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">3.38% (7 of 207)</entry><entry align="center" valign="bottom">11.48% (7 of 61)</entry><entry align="center" valign="bottom">0% (0 of 51)</entry><entry align="center" valign="bottom">0% (0 of 21)</entry><entry align="center" valign="bottom">0% (0 of 29)</entry><entry align="center" valign="bottom">0% (0 of 45)</entry></row><row><entry align="right" valign="bottom">7</entry><entry align="center" valign="bottom">2110430</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">1.23% (1 of 81)</entry><entry align="center" valign="bottom">16.67% (1 of 6)</entry><entry align="center" valign="bottom">0% (0 of 54)</entry><entry align="center" valign="bottom">0% (0 of 8)</entry><entry align="center" valign="bottom">0% (0 of 7)</entry><entry align="center" valign="bottom">0% (0 of 6)</entry></row><row><entry align="right" valign="bottom">64</entry><entry align="center" valign="bottom">2110210</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">54.46% (110 of 202)</entry><entry align="center" valign="bottom">13.89% (5 of 36)</entry><entry align="center" valign="bottom">63.08% (41 of 65)</entry><entry align="center" valign="bottom">70.83% (17 of 24)</entry><entry align="center" valign="bottom">64.1% (25 of 39)</entry><entry align="center" valign="bottom">57.89% (22 of 38)</entry></row><row><entry align="right" valign="bottom">10</entry><entry align="center" valign="bottom">2110187</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">2.82% (15 of 531)</entry><entry align="center" valign="bottom">17.33% (13 of 75)</entry><entry align="center" valign="bottom">1% (2 of 201)</entry><entry align="center" valign="bottom">0% (0 of 80)</entry><entry align="center" valign="bottom">0% (0 of 89)</entry><entry align="center" valign="bottom">0% (0 of 86)</entry></row><row><entry align="right" valign="bottom">16</entry><entry align="center" valign="bottom">2109220</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">1.57% (9 of 572)</entry><entry align="center" valign="bottom">9.88% (8 of 81)</entry><entry align="center" valign="bottom">0% (0 of 214)</entry><entry align="center" valign="bottom">0% (0 of 90)</entry><entry align="center" valign="bottom">0% (0 of 91)</entry><entry align="center" valign="bottom">1.04% (1 of 96)</entry></row><row><entry align="right" valign="bottom">83</entry><entry align="center" valign="bottom">2109215</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">3.28% (19 of 579)</entry><entry align="center" valign="bottom">0% (0 of 94)</entry><entry align="center" valign="bottom">8.13% (17 of 209)</entry><entry align="center" valign="bottom">0% (0 of 90)</entry><entry align="center" valign="bottom">0% (0 of 91)</entry><entry align="center" valign="bottom">2.11% (2 of 95)</entry></row><row><entry align="right" valign="bottom">85</entry><entry align="center" valign="bottom">2109117</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">38.59% (137 of 355)</entry><entry align="center" valign="bottom">27.27% (18 of 66)</entry><entry align="center" valign="bottom">40.16% (49 of 122)</entry><entry align="center" valign="bottom">40.74% (22 of 54)</entry><entry align="center" valign="bottom">53.85% (35 of 65)</entry><entry align="center" valign="bottom">27.08% (13 of 48)</entry></row><row><entry align="right" valign="bottom">20</entry><entry align="center" valign="bottom">2108843</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">0.35% (2 of 566)</entry><entry align="center" valign="bottom">2.3% (2 of 87)</entry><entry align="center" valign="bottom">0% (0 of 202)</entry><entry align="center" valign="bottom">0% (0 of 90)</entry><entry align="center" valign="bottom">0% (0 of 91)</entry><entry align="center" valign="bottom">0% (0 of 96)</entry></row><row><entry align="right" valign="bottom">21</entry><entry align="center" valign="bottom">2108835</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">4.07% (20 of 492)</entry><entry align="center" valign="bottom">1.43% (1 of 70)</entry><entry align="center" valign="bottom">9.94% (18 of 181)</entry><entry align="center" valign="bottom">0% (0 of 79)</entry><entry align="center" valign="bottom">0% (0 of 81)</entry><entry align="center" valign="bottom">1.23% (1 of 81)</entry></row><row><entry align="right" valign="bottom">87</entry><entry align="center" valign="bottom">2108682</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">1.89% (5 of 265)</entry><entry align="center" valign="bottom">14.29% (4 of 28)</entry><entry align="center" valign="bottom">1.01% (1 of 99)</entry><entry align="center" valign="bottom">0% (0 of 41)</entry><entry align="center" valign="bottom">0% (0 of 52)</entry><entry align="center" valign="bottom">0% (0 of 45)</entry></row><row><entry align="right" valign="bottom">88</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">7.57% (14 of 185)</entry><entry align="center" valign="bottom">3.13% (1 of 32)</entry><entry align="center" valign="bottom">4.88% (2 of 41)</entry><entry align="center" valign="bottom">12.2% (5 of 41)</entry><entry align="center" valign="bottom">20% (5 of 25)</entry><entry align="center" valign="bottom">2.17% (1 of 46)</entry></row><row><entry align="right" valign="bottom">25</entry><entry align="center" valign="bottom">2108424</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">0.35% (1 of 288)</entry><entry align="center" valign="bottom">2.17% (1 of 46)</entry><entry align="center" valign="bottom">0% (0 of 89)</entry><entry align="center" valign="bottom">0% (0 of 67)</entry><entry align="center" valign="bottom">0% (0 of 57)</entry><entry align="center" valign="bottom">0% (0 of 29)</entry></row><row><entry align="right" valign="bottom">26</entry><entry align="center" valign="bottom">2108417</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">3.38% (9 of 266)</entry><entry align="center" valign="bottom">7.32% (3 of 41)</entry><entry align="center" valign="bottom">6.74% (6 of 89)</entry><entry align="center" valign="bottom">0% (0 of 44)</entry><entry align="center" valign="bottom">0% (0 of 56)</entry><entry align="center" valign="bottom">0% (0 of 36)</entry></row><row><entry align="right" valign="bottom">92</entry><entry align="center" valign="bottom">2107971</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2.8% (15 of 536)</entry><entry align="center" valign="bottom">16.3% (15 of 92)</entry><entry align="center" valign="bottom">0% (0 of 185)</entry><entry align="center" valign="bottom">0% (0 of 79)</entry><entry align="center" valign="bottom">0% (0 of 87)</entry><entry align="center" valign="bottom">0% (0 of 93)</entry></row><row><entry align="right" valign="bottom">32</entry><entry align="center" valign="bottom">2107668</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2.35% (12 of 511)</entry><entry align="center" valign="bottom">0% (0 of 94)</entry><entry align="center" valign="bottom">0.7% (1 of 142)</entry><entry align="center" valign="bottom">10.23% (9 of 88)</entry><entry align="center" valign="bottom">2.2% (2 of 91)</entry><entry align="center" valign="bottom">0% (0 of 96)</entry></row><row><entry align="right" valign="bottom">100</entry><entry align="center" valign="bottom">2107471</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">4.66% (26 of 558)</entry><entry align="center" valign="bottom">1.05% (1 of 95)</entry><entry align="center" valign="bottom">1.97% (4 of 203)</entry><entry align="center" valign="bottom">1.16% (1 of 86)</entry><entry align="center" valign="bottom">5.75% (5 of 87)</entry><entry align="center" valign="bottom">17.24% (15 of 87)</entry></row><row><entry align="right" valign="bottom">102</entry><entry align="center" valign="bottom">2107273</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">6.41% (32 of 499)</entry><entry align="center" valign="bottom">14.81% (8 of 54)</entry><entry align="center" valign="bottom">9.34% (17 of 182)</entry><entry align="center" valign="bottom">0% (0 of 86)</entry><entry align="center" valign="bottom">0% (0 of 85)</entry><entry align="center" valign="bottom">7.61% (7 of 92)</entry></row><row><entry align="right" valign="bottom">111</entry><entry align="center" valign="bottom">2107020</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">50.19% (135 of 269)</entry><entry align="center" valign="bottom">23.08% (3 of 13)</entry><entry align="center" valign="bottom">49.58% (59 of 119)</entry><entry align="center" valign="bottom">50% (24 of 48)</entry><entry align="center" valign="bottom">53.85% (21 of 39)</entry><entry align="center" valign="bottom">56% (28 of 50)</entry></row><row><entry align="right" valign="bottom">47</entry><entry align="center" valign="bottom">2106956</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">0.33% (1 of 304)</entry><entry align="center" valign="bottom">0% (0 of 70)</entry><entry align="center" valign="bottom">0% (0 of 115)</entry><entry align="center" valign="bottom">0% (0 of 43)</entry><entry align="center" valign="bottom">0% (0 of 42)</entry><entry align="center" valign="bottom">2.94% (1 of 34)</entry></row></tbody></tgroup><!-- EPO <DP n="52"> --><tgroup cols="9" rowsep="0"><colspec colnum="1" colname="col1" colwidth="14mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="16mm"/><colspec colnum="4" colname="col4" colwidth="20mm"/><colspec colnum="5" colname="col5" colwidth="20mm"/><colspec colnum="6" colname="col6" colwidth="20mm"/><colspec colnum="7" colname="col7" colwidth="20mm"/><colspec colnum="8" colname="col8" colwidth="20mm"/><colspec colnum="9" colname="col9" colwidth="20mm"/><tbody><row><entry namest="col1" nameend="col9" align="justify">* Coordinates relative to NCBI Build 36, Chr:11</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry namest="col1" nameend="col4" align="left"><b><i>Table 4: Informative SNPs in Chinese</i></b></entry></row></thead><tbody><row><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/></row></tbody></tgroup><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry align="center"><b><i>SEQ ID NO:</i></b></entry><entry align="center"><b><i>Genomic Position</i></b></entry><entry align="center"><b><i>Block</i></b></entry><entry align="center"><b><i>Obs Het</i></b></entry></row></thead><tbody><row><entry align="center" valign="bottom">64</entry><entry align="center" valign="bottom">2110210</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">70.83% (17 of 24)</entry></row><row><entry align="center" valign="bottom">85</entry><entry align="center" valign="bottom">2109117</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">40.74% (22 of 54)</entry></row><row><entry align="center" valign="bottom">88</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">12.2% (5 of 41)</entry></row><row><entry align="center" valign="bottom">32</entry><entry align="center" valign="bottom">2107668</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">10.23% (9 of 88)</entry></row><row><entry align="center" valign="bottom">111</entry><entry align="center" valign="bottom">2107020</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">50% (24 of 48)</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry namest="col1" nameend="col4" align="left"><b><i>Table 5: Informative SNPs in Japanese</i></b></entry></row></thead><tbody><row><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/><entry align="center" valign="bottom"/></row></tbody></tgroup><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry align="center"><b><i>SEQ ID NO:</i></b></entry><entry align="center"><b><i>Genomic Position</i></b></entry><entry align="center"><b><i>Block</i></b></entry><entry align="center"><b><i>Obs Het</i></b></entry></row></thead><tbody><row><entry align="center" valign="bottom">4</entry><entry align="center" valign="bottom">2110781</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">2.86% (2 of 70)</entry></row><row><entry align="center" valign="bottom">64</entry><entry align="center" valign="bottom">2110210</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">64.1% (25 of 39)</entry></row><row><entry align="center" valign="bottom">85</entry><entry align="center" valign="bottom">2109117</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">53.85% (35 of 65)</entry></row><row><entry align="center" valign="bottom">88</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">20% (5 of 25)</entry></row><row><entry align="center" valign="bottom">32</entry><entry align="center" valign="bottom">2107668</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2.2% (2 of 91)</entry></row><row><entry align="center" valign="bottom">100</entry><entry align="center" valign="bottom">2107471</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">5.75% (5 of 87)</entry></row><row><entry align="center" valign="bottom">111</entry><entry align="center" valign="bottom">2107020</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">53.85% (21 of 39)</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0009" num="0009"><table frame="all"><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry namest="col1" nameend="col4" align="left"><b><i>Table 6: Inf. SNPs in African Amer.</i></b></entry></row></thead><tbody><row><entry valign="bottom"/><entry valign="bottom"/><entry valign="bottom"/><entry valign="bottom"/></row></tbody></tgroup><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry align="center"><b><i>SEQ ID NO:</i></b></entry><entry align="center"><b><i>Genomic Position</i></b></entry><entry align="center"><b><i>Block</i></b></entry><entry align="center"><b><i>Obs Het</i></b></entry></row></thead><tbody><row><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">2110869</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">3.3% (3 of 91)</entry></row><row><entry align="center" valign="bottom">4</entry><entry align="center" valign="bottom">2110781</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">2.9% (2 of 69)</entry></row><row><entry align="center" valign="bottom">56</entry><entry align="center" valign="bottom">2110764</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">6.25% (1 of 16)</entry></row><row><entry align="center" valign="bottom">6</entry><entry align="center" valign="bottom">2110465</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">11.48% (7 of 61)</entry></row><row><entry align="center" valign="bottom">7</entry><entry align="center" valign="bottom">2110430</entry><entry align="center" valign="bottom">1</entry><entry align="center" valign="bottom">16.67% (1 of 6)</entry></row><row><entry align="center" valign="bottom">64</entry><entry align="center" valign="bottom">2110210</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">13.89% (5 of 36)</entry></row><row><entry align="center" valign="bottom">10</entry><entry align="center" valign="bottom">2110187</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">17.33% (13 of 75)</entry></row><row><entry align="center" valign="bottom">16</entry><entry align="center" valign="bottom">2109220</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">9.88% (8 of 81)</entry></row><row><entry align="center" valign="bottom">85</entry><entry align="center" valign="bottom">2109117</entry><entry align="center" valign="bottom">2</entry><entry align="center" valign="bottom">27.27% (18 of 66)</entry></row><row><entry align="center" valign="bottom">20</entry><entry align="center" valign="bottom">2108843</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2.3% (2 of 87)</entry></row><row><entry align="center" valign="bottom">87</entry><entry align="center" valign="bottom">2108682</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">14.29% (4 of 28)</entry></row><row><entry align="center" valign="bottom">88</entry><entry align="center" valign="bottom">2108628</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">3.13% (1 of 32)</entry></row><row><entry align="center" valign="bottom">25</entry><entry align="center" valign="bottom">2108424</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">2.17% (1 of 46)</entry></row><row><entry align="center" valign="bottom">26</entry><entry align="center" valign="bottom">2108417</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">7.32% (3 of 41)</entry></row><row><entry align="center" valign="bottom">92</entry><entry align="center" valign="bottom">2107971</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">16.3% (15 of 92)</entry></row><row><entry align="center" valign="bottom">102</entry><entry align="center" valign="bottom">2107273</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">14.81% (8 of 54)</entry></row><row><entry align="center" valign="bottom">111</entry><entry align="center" valign="bottom">2107020</entry><entry align="center" valign="bottom">3</entry><entry align="center" valign="bottom">23.08% (3 of 13)</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0010" num="0010"><table frame="all"><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="15mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="15mm"/><colspec colnum="4" colname="col4" colwidth="32mm" colsep="1"/><thead><row><entry namest="col1" nameend="col4" align="left" valign="top"><b><i>Table 7: Informative SNPs in Caucasian</i></b></entry></row><row><entry align="center" valign="top"><b><i>SEQ</i></b></entry><entry align="center" valign="top"><b><i>Genomic</i></b></entry><entry align="center" valign="top"><b><i>Block</i></b></entry><entry align="center" valign="top"><b><i>Obs Het</i></b></entry></row></thead><tbody><row><entry align="center">64</entry><entry align="center">2110210</entry><entry align="center">2</entry><entry align="center">63.08% (41 of 65)</entry></row><row><entry align="center">83</entry><entry align="center">2109215</entry><entry align="center">2</entry><entry align="center">8.13% (17 of 209)</entry></row><row><entry align="center">85</entry><entry align="center">2109117</entry><entry align="center">2</entry><entry align="center">40.16% (49 of 122)</entry></row><row><entry align="center">21</entry><entry align="center">2108835</entry><entry align="center">3</entry><entry align="center">9.94% (18 of 181)</entry></row><row><entry align="center">88</entry><entry align="center">2108628</entry><entry align="center">3</entry><entry align="center">4.88% (2 of 41)</entry></row><row><entry align="center">26</entry><entry align="center">2108417</entry><entry align="center">3</entry><entry align="center">6.74% (6 of 89)</entry></row><row><entry align="center">100</entry><entry align="center">2107471</entry><entry align="center">3</entry><entry align="center">1.97% (4 of 203)</entry></row><row><entry align="center">102</entry><entry align="center">2107273</entry><entry align="center">3</entry><entry align="center">9.34% (17 of 182)</entry></row><row><entry align="center">111</entry><entry align="center">2107020</entry><entry align="center">3</entry><entry align="center">49.58% (59 of 119)</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0011" num="0011"><table frame="all"><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="18mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="30mm" colsep="1"/><thead><row><entry namest="col1" nameend="col4" align="left" valign="top"><b><i>Table 8: Informative SNPs in Mexicans</i></b></entry></row><row><entry align="center" valign="top"><b><i>SEQ ID</i></b></entry><entry align="center" valign="top"><b><i>Genomic</i></b></entry><entry align="center" valign="top"><b><i>Block</i></b></entry><entry align="center" valign="top"><b><i>Obs Het</i></b></entry></row></thead><tbody><row><entry align="center">64</entry><entry align="center">2110210</entry><entry align="center">2</entry><entry align="center">57.89% (22 of 38)</entry></row><row><entry align="center">83</entry><entry align="center">2109215</entry><entry align="center">2</entry><entry align="center">2.11% (2 of 95)</entry></row><row><entry align="center">85</entry><entry align="center">2109117</entry><entry align="center">2</entry><entry align="center">27.08% (13 of 48)</entry></row><row><entry align="center">88</entry><entry align="center">2108628</entry><entry align="center">3</entry><entry align="center">2.17% (1 of 46)</entry></row><row><entry align="center">100</entry><entry align="center">2107471</entry><entry align="center">3</entry><entry align="center">17.24% (15 of 87)</entry></row><row><entry align="center">102</entry><entry align="center">2107273</entry><entry align="center">3</entry><entry align="center">7.61% (7 of 92)</entry></row><row><entry align="center">111</entry><entry align="center">2107020</entry><entry align="center">3</entry><entry align="center">56% (28 of 50)</entry></row><row><entry align="center">47</entry><entry align="center">2106956</entry><entry align="center">3</entry><entry align="center">2.94% (1 of 34)</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="53"> --></p><heading id="h0026">SEQUENCE LISTING</heading><p id="p0136" num="0136"><ul><li>&lt;110&gt; Ordway, Jared<br/>
Lakey, Nathan<br/>
Maloney, Rebecca<br/>
Rohlfing, Theresa<br/>
Orion Genomics LLC</li><li>&lt;120&gt; Novel Single Nucleotide Polymorphisms<br/>
and Combinations of Novel and Known Polymorphisms for<br/>
Determining the Allele-Specific Expression of the IGF2 Gene</li><li>&lt;130&gt; 021031-002520PC</li><li>&lt;140&gt; WO PCT/US08/Not yet assigned<br/>
&lt;141&gt; Not yet assigned</li><li>&lt;150&gt; <patcit id="pcit0056" dnum="US60954290B"><text>US 60/954,290</text></patcit><br/>
&lt;151&gt; 2007-08-06</li><li>&lt;150&gt; <patcit id="pcit0057" dnum="US60988715B"><text>US 60/988,715</text></patcit><br/>
&lt;151&gt; 2007-11-16</li><li>&lt;160&gt; 116</li><li>&lt;170&gt; FastSEQ for Windows Version 4.0</li><li>&lt;210&gt; 1<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 1<br/>
gcgttcaggg aggccaaacg tcaccrtccc ctgattgctc tacccaccca a   51</li><li>&lt;210&gt; 2<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 2<br/>
cccacccaag accccgccca cggggdcgcc cccccagaga tggccagcaa t   51</li><li>&lt;210&gt; 3<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9<!-- EPO <DP n="54"> --></li><li>&lt;400&gt; 3<br/>
cacccaagac cccgcccacg ggggcrcccc cccagagatg gccagcaatc g   51</li><li>&lt;210&gt; 4<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 4<br/>
gcaatcggaa gtgagcaaaa ctgccrcaag tctgcagccc ggcgccacca t   51</li><li>&lt;210&gt; 5<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 5<br/>
tggggcttct cctgacccag tccccrtgcc ccgcctcccc gaaacaggct a   51</li><li>&lt;210&gt; 6<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 6<br/>
ttaaactaac ccccttcccc ccccchcaca acaaccctct taaaactaat t   51</li><li>&lt;210&gt; 7<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 7<br/>
cctcttaaaa ctaattggct ttttadaaac accccacaaa agctcagaaa t   51</li><li>&lt;210&gt; 8<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 8<br/>
<!-- EPO <DP n="55"> -->aaggaatttg gcactcccca cccccstctt tctcttctcc cttggacttt g   51</li><li>&lt;210&gt; 9<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 9<br/>
gagaaaagaa ggaccccaga aatcayaggt gggcacgtcg ctgctaccgc c   51</li><li>&lt;210&gt; 10<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 10<br/>
ggaccccaga aatcacaggt gggcaygtcg ctgctaccgc catctccctt c   51</li><li>&lt;210&gt; 11<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 11<br/>
aattttcagg gtaaactggc catccraaaa tagcaacaac ccagactggc t   51</li><li>&lt;210&gt; 12<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 12<br/>
catccgaaaa tagcaacaac ccagaytggc tcctcactcc cttttccatc a   51</li><li>&lt;210&gt; 13<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 13<br/>
catcactaaa aatcacagag cagtchgagg gacccagtaa gaccaaagga g   51<!-- EPO <DP n="56"> --></li><li>&lt;210&gt; 14<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 14<br/>
cactaaaaat cacagagcag tcagasggac ccagtaagac caaaggaggg g   51</li><li>&lt;210&gt; 15<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 15<br/>
ctaaaaatca cagagcagtc agaggdaccc agtaagacca aaggagggga g   51</li><li>&lt;210&gt; 16<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 16<br/>
gcgcacacac acgcacaccc ccacamaatt ggatgaaaac aataagcata t   51</li><li>&lt;210&gt; 17<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 17<br/>
tctgtatgga tcaggccaaa gtcccvctaa gattctccaa tgttttcatg g   51</li><li>&lt;210&gt; 18<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 18<br/>
cccgctcctg ttcccatctc cactgyccct cggccctgtc tgtgccctgc c   51<!-- EPO <DP n="57"> --></li><li>&lt;210&gt; 19<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 19<br/>
actgcccctc ggccctgtct gtgccstgcc tctcagagga gggggctcag a   51</li><li>&lt;210&gt; 20<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 20<br/>
cattcccgat acaccttact tactgygtgt tggcccagcc agagtgagga a   51</li><li>&lt;210&gt; 21<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 21<br/>
atacacctta cttactgtgt gttggyccag ccagagtgag gaaggagttt g   51</li><li>&lt;210&gt; 22<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 22<br/>
gccagagtga ggaaggagtt tggcchcatt ggagatggcg gtagctgagc a   51</li><li>&lt;210&gt; 23<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 23<br/>
agcctgactc cctggtgtgc tcctgdaagg aagatcttgg ggaccccccc a   51</li><li>&lt;210&gt; 24<br/>
<!-- EPO <DP n="58"> -->&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 24<br/>
caaatttcat gtcaattgat ctattbcccc tctttgtttc ttggggcatt t   51</li><li>&lt;210&gt; 25<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 25<br/>
tgatctattc cccctctttg tttctkgggg catttttcct tttttttttt t   51</li><li>&lt;210&gt; 26<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 26<br/>
ttccccctct ttgtttcttg gggcadtttt cctttttttt ttttttttgt t   51</li><li>&lt;210&gt; 27<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 27<br/>
aattaaaccc cccccccatg taacargggg gcagtgacaa aagcaagaac g   51</li><li>&lt;210&gt; 28<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 28<br/>
ggctcctggc tggcctgagg ctggchggag gggaaggggc tagcaggtgt g   51</li><li>&lt;210&gt; 29<br/>
&lt;211&gt; 51<br/>
<!-- EPO <DP n="59"> -->&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 29<br/>
ggctggggca gggtggccgc cttccvcaca cttgaggaac cctcccctct c   51</li><li>&lt;210&gt; 30<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 30<br/>
aggtccgaag ctctgtggga cctctkgggg gcaaggtggg gtgaggccgg g   51</li><li>&lt;210&gt; 31<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 31<br/>
aggccgggga gtagggaggt caggcrggtc tgagcccaca gagcaggaga g   51</li><li>&lt;210&gt; 32<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 32<br/>
atgccatagc agccaccacc gcggcrccta gggctgcggc agggactcgg c   51</li><li>&lt;210&gt; 33<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 33<br/>
catagcagcc accaccgcgg cgcctwgggc tgcggcaggg actcggcctc t   51</li><li>&lt;210&gt; 34<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="60"> -->&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 34<br/>
gactcggcct ctgggaggtt tacctygccc ccacttgtgc ccccagctca g   51</li><li>&lt;210&gt; 35<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 35<br/>
ccacttgtgc ccccagctca gccccsctgc acgcagcccg actagcagtc t   51</li><li>&lt;210&gt; 36<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 36<br/>
cctggtgacg gggctggcat gacccygggg gtcgtccatg ccagtccgcc t   51</li><li>&lt;210&gt; 37<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (26)...(26)<br/>
&lt;223&gt; n = g, a, c or t</li><li>&lt;400&gt; 37<br/>
ccgcctcagt cgcagagggt ccctcngcaa gcgccctgtg agtgggccat t   51</li><li>&lt;210&gt; 38<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 38<br/>
cagtcgcaga gggtccctcg gcaagygccc tgtgagtggg ccattcggaa c   51<!-- EPO <DP n="61"> --></li><li>&lt;210&gt; 39<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 39<br/>
tcgcagaggg tccctcggca agcgcbctgt gagtgggcca ttcggaacat t   51</li><li>&lt;210&gt; 40<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 40<br/>
acccacattg gcctgagatc caaaaygctt cgaggcaccc caaattacct g   51</li><li>&lt;210&gt; 41<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 41<br/>
gcttcgaggc accccaaatt acctgsccat tcgtcaggac acccacccac c   51</li><li>&lt;210&gt; 42<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 42<br/>
agtgggtgtt cccgggggca cttgcygacc agccccttgc gtccccaggt t   51</li><li>&lt;210&gt; 43<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 43<br/>
gggcacttgc cgaccagccc cttgcdtccc caggtttgca gctctcccct g   51<!-- EPO <DP n="62"> --></li><li>&lt;210&gt; 44<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 44<br/>
atcttgtctc ctccccgtgt ccccartgtc ttcagtgggg ggccccctct t   51</li><li>&lt;210&gt; 45<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 45<br/>
gaatgtcacc tgtgcctgcc gcctcrgtcc accttgcggc ccgtgtttga c   51</li><li>&lt;210&gt; 46<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nucleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 46<br/>
gccgcctcgg tccaccttgc ggcccrtgtt tgactcaact caactccttt a   51</li><li>&lt;210&gt; 47<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; novel single nueleotide polymorphism (SNP) in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (25) ... (25)<br/>
&lt;223&gt; n = g, a, c or t</li><li>&lt;400&gt; 47<br/>
tgggttttgt ctttaacctt gtaacncttg caatcccaat aaagcattaa a   51</li><li>&lt;210&gt; 48<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1803647 in human insulin growth factor-2 (IGF2)<!-- EPO <DP n="63"> --> gene</li><li>&lt;400&gt; 48<br/>
tgctgtttcc gcagctgtga cctggcsctc ctggagacgt actgtgctac cc   52</li><li>&lt;210&gt; 49<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs14367 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 49<br/>
agttcttcca atatgacacc tggaarcagt ccacccagcg cctgcgcagg g   51</li><li>&lt;210&gt; 50<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1065443 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 50<br/>
ggaagcagtc cacccagcgc ctgcgyaggg gcctgcctgc cctcctgcgt g   51</li><li>&lt;210&gt; 51<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11545014 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 51<br/>
aagaccccgc ccacgggggc gcccccycag agatggccag caatcggaag tg   52</li><li>&lt;210&gt; 52<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1050342 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 52<br/>
agaccccgcc cacgggggcg ccccccmaga gatggccagc aatcggaagt ga   52</li><li>&lt;210&gt; 53<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="64"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs12993 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 53<br/>
cccccagaga tggccagcaa tcggaaktga gcaaaactgc cgcragtctg ca   52</li><li>&lt;210&gt; 54<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs9282726 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 54<br/>
caatcggaak tgagcaaaac tgccgcragt ctgcagccyg gygccaccat cc   52</li><li>&lt;210&gt; 55<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3741214 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 55<br/>
agcaaaactg ccgcaagtct gcagccyggc gccaccatcc tgcagcctcc tc   52</li><li>&lt;210&gt; 56<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs2230949 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 56<br/>
aaactgccgc aagtctgcag cccggygcca ccatcctgca gcctcctcct g   51</li><li>&lt;210&gt; 57<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3213234 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 57<br/>
catcctgcag cctcctcctg accackgacg tttccatcag gttccatccc g   51</li><li>&lt;210&gt; 58<br/>
&lt;211&gt; 52<br/>
<!-- EPO <DP n="65"> -->&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs34337549 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (27)...(27)<br/>
&lt;223&gt; g   at position 27 may be present or absent</li><li>&lt;400&gt; 58<br/>
cggggactgg gtcaggagaa gccccagggg gacgtggaac cgagagattt tc   52</li><li>&lt;210&gt; 59<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs6223 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 59<br/>
caggctactc tcctcggccc cctccmtcgg gctgaggaag cacagcagca t   51</li><li>&lt;210&gt; 60<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11510 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 60<br/>
tcgggctgag gaagcacagc agcatcwtca aacatgtaca aaatcgattg gc   52</li><li>&lt;210&gt; 61<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1803648 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 61<br/>
atgtacaaaa tcgattggct ttaaamaccc ttcacatacc ctccccccaa a   51</li><li>&lt;210&gt; 62<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11564731 in human insulin growth factor-2 (IGF2)<!-- EPO <DP n="66"> --> gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7) ... (8)<br/>
&lt;223&gt; ac at positions 7 and 8 may be present or absent</li><li>&lt;400&gt; 62<br/>
aaaacattaa actaaccccc ttccccaccc cccccacaac aaccctctta aaa   53</li><li>&lt;210&gt; 63<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs15737 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 63<br/>
tggcactccc cacccccctc tttctyttct cccttggact ttgagtcaaa t   51</li><li>&lt;210&gt; 64<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs680 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (26)...(26)<br/>
&lt;223&gt; n = g, a, c or t</li><li>&lt;400&gt; 64<br/>
ctgaaccagc aaagagaaaa gaaggncccc agaaatcaca ggtgggcacg t   51</li><li>&lt;210&gt; 65<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1065685 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 65<br/>
cagaaatcac aggtgggcac gtcgctscta ccgccatctc ccttctcacg gg   52</li><li>&lt;210&gt; 66<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs56731553 in human insulin growth factor-2 (IGF2) gene<!-- EPO <DP n="67"> --></li><li>&lt;400&gt; 66<br/>
gtgctcgtgt gtgtgctgtg ttcatgygtg tgctgtgtgt tgtgtgtgtg ta   52</li><li>&lt;210&gt; 67<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs56154171 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 67<br/>
tgtgctgtgc tcgtgtgtgt gctgtgytca tgcgtgtgct gtgtgttgtg tg   52</li><li>&lt;210&gt; 68<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs59198946 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7)...(8)<br/>
&lt;223&gt; at at positions 7 and 8 may be present or absent</li><li>&lt;400&gt; 68<br/>
gtgctgtgcg tttgtgtgtg tgctgtatgc tcgtgtgtgt gctgtgttca tgc   53</li><li>&lt;210&gt; 69<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61872709 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 69<br/>
tctgtgtgct gtgtgtgctg tgcgttygtg tgtgtgctgt gctcgtgtgt gt   52</li><li>&lt;210&gt; 70<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61872708 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 70<br/>
catctgtgtg ctgtgtgtgc tgtgcgyttg tgtgtgtgct gtgctcgtgt gt   52<!-- EPO <DP n="68"> --></li><li>&lt;210&gt; 71<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61872707 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 71<br/>
tgcgtttgtg tgtgtgctgt gtgtgcrtgt gtgtgcgtgt gtgtgccgtg cg   52</li><li>&lt;210&gt; 72<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61872706 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 72<br/>
gtgctgtgcg tttgtgtgtg tgctgtrtgt gcatgtgtgt gcgtgtgtgt gc   52</li><li>&lt;210&gt; 73<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11042774 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 73<br/>
gtgcgtttgt gtgtgctgtg cgtttgygtg tgtgctgtgt gtgcatgtgt gt   52</li><li>&lt;210&gt; 74<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs59630895 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7)...(10)<br/>
&lt;223&gt; tgtg at positions 7-10 may be present or absent</li><li>&lt;400&gt; 74<br/>
ttgtgtgtgt gctgtgtgct agtgtgtgtg ctgtgtgtgc atgtgtgtgc gtgtg   55</li><li>&lt;210&gt; 75<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="69"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs7111331 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 75<br/>
tgctgtgttc gtgtgtgctg tgttcgygtg tgtgtgctgt gtgtgcatgt gt   52</li><li>&lt;210&gt; 76<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11042767 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 76<br/>
acatttcttg gggggtcccc aggagayggg caaagatgat ccctaggtgt gc   52</li><li>&lt;210&gt; 77<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs7129583 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 77<br/>
agtcctcggg ggccgtgcac tgatgygggg agtgtgggaa gtctggcggt t   51</li><li>&lt;210&gt; 78<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs28462050 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 78<br/>
gcatttttcc tttttttttt tttttygttt tttttttacc cctccttagc t   51</li><li>&lt;210&gt; 79<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs28472590 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7) ... (8)<br/>
<!-- EPO <DP n="70"> -->&lt;223&gt; gg at positions 7 and 8 may be present or absent</li><li>&lt;400&gt; 79<br/>
tgcccccctg ttacatgggg ggggggggtt taatttggtt tctgagcgca taa   53</li><li>&lt;210&gt; 80<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs58312807 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 80<br/>
gagtcctcgg gggccgtgca ctgatgyggg gagtgtggga agtctggcgg tt   52</li><li>&lt;210&gt; 81<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs60649995 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 81<br/>
aggctggccg gaggggaagg ggctarcagg tgtgtaaaca gagggttcca t   51</li><li>&lt;210&gt; 82<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs58562468 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 82<br/>
cagggtggcc gccttccgca cacttgrgga accctcccct ctccctcggt ga   52</li><li>&lt;210&gt; 83<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1065687 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 83<br/>
cgccttccgc acacttgagg aaccctsccc tctccctcgg tgacatcttg cc   52</li><li>&lt;210&gt; 84<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="71"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3208122 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 84<br/>
taagcaacta cgatatctgt atggatmagg ccaaagtccc gctaagattc tc   52</li><li>&lt;210&gt; 85<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3168310 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 85<br/>
ccaatgtttt catggtctga gccccsctcc tgttcccatc tccactgccc c   51</li><li>&lt;210&gt; 86<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs58527086 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7) ... (7)<br/>
&lt;223&gt; t at position 7 may be present or absent</li><li>&lt;400&gt; 86<br/>
catcgtggct cacgctgcgg gggccgtggg gacaggcgcc aaggaggcca gc   52</li><li>&lt;210&gt; 87<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs57156844 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 87<br/>
acatttcttg gggggtcccc aggagayggg caaagatgat ccctaggtgt gc   52</li><li>&lt;210&gt; 88<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3802971 in human insulin growth factor-2 (IGF2)<!-- EPO <DP n="72"> --> gene exon 9</li><li>&lt;400&gt; 88<br/>
agtcctcggg ggccgtgcac tgatgygggg agtgtgggaa gtctggcggt t   51</li><li>&lt;210&gt; 89<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3180700 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 89<br/>
gcatttttcc tttttttttt tttttkgttt tttttttacc cctccttagc t   51</li><li>&lt;210&gt; 90<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs57423851 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (7) ... (8)<br/>
&lt;223&gt; gg at positions 7 and 8 may be present or absent</li><li>&lt;400&gt; 90<br/>
tgcccccctg ttacatgggg ggggggggtt taatttggtt tctgagcgca taa   53</li><li>&lt;210&gt; 91<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs35818489 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 91<br/>
gagtcctcgg gggccgtgca ctgatgyggg gagtgtggga agtctggcgg tt   52</li><li>&lt;210&gt; 92<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11825733 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 92<br/>
aggctggccg gaggggaagg ggctarcagg tgtgtaaaca gagggttcca t   51<!-- EPO <DP n="73"> --></li><li>&lt;210&gt; 93<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541377 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 93<br/>
cagggtggcc gccttccgca cacttgrgga accctcccct ctccctcggt ga   52</li><li>&lt;210&gt; 94<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541375 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 94<br/>
cgccttccgc acacttgagg aaccctsccc tctccctcgg tgacatcttg cc   52</li><li>&lt;210&gt; 95<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541373 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 95<br/>
ggtgacatct tgcccgcccc tcagcaycct gccttgtctc caggaggtcc ga   52</li><li>&lt;210&gt; 96<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541372 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 96<br/>
cccctcagca ccctgccttg tctccmggag gtccgaagct ctgtgggacc t   51</li><li>&lt;210&gt; 97<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541374 in human insulin growth factor-2 (IGF2)<!-- EPO <DP n="74"> --> gene exon 9</li><li>&lt;400&gt; 97<br/>
caggcgggtc tgagcccaca gagcagkaga gctgccaggt ctgcccatcg ac   52</li><li>&lt;210&gt; 98<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3189464 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 98<br/>
cctcgccccc acttgtgccc ccagctmagc ccccctgcac gcagcccgac ta   52</li><li>&lt;210&gt; 99<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61745040 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 99<br/>
cagtcgcaga gggtccctcg gcaagygccc tgtgagtggg ccattcggaa c   51</li><li>&lt;210&gt; 100<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11564732 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 100<br/>
agtcgcagag ggtccctcgg caagcdccct gtgagtgggc cattcggaac a   51</li><li>&lt;210&gt; 101<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541376 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 101<br/>
gcaagcgccc tgtgagtggg ccattyggaa cattggacag aagcccaaag a   51</li><li>&lt;210&gt; 102<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="75"> --></li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs7873 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 102<br/>
gtgttcccgg gggcacttgc cgaccrgccc cttgcgtccc caggtttgca g   51</li><li>&lt;210&gt; 103<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs61745039 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 103<br/>
gggcacttgc cgaccagccc cttgcdtccc caggtttgca gctctcccct g   51</li><li>&lt;210&gt; 104<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3177805 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 104<br/>
ttgtctcctc cccgtgtccc caatgtyttc agtggggggc cccctcttgg gt   52</li><li>&lt;210&gt; 105<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1065715 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 105<br/>
cgtgtcccca atgtcttcag tgggggsccc cctcttgggt cccctcctct gc   52</li><li>&lt;210&gt; 106<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541371 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 106<br/>
tgtccccaat gtcttcagtg gggggscccc tcttgggtcc cctcctctgc c   51</li><li>&lt;210&gt; 107<br/>
<!-- EPO <DP n="76"> -->&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1049926 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 107<br/>
ccaatgtctt cagtgggggg ccccctyttg ggtcccctcc tctgccatca cc   52</li><li>&lt;210&gt; 108<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs3177946 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 108<br/>
ggggccccct cttgggtccc ctcctytgcc atcacctgaa gacccccacg c   51</li><li>&lt;210&gt; 109<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1050035 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 109<br/>
gtcacctgtg cctgccgcct cggtccmcct tgcggcccgt gtttgactca ac   52</li><li>&lt;210&gt; 110<br/>
&lt;211&gt; 52<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs11541370 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 110<br/>
aatattagcg ttaaaggagc tgagttragt caaacacggg ccgcaaggtg ga   52</li><li>&lt;210&gt; 111<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs2585 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;220&gt;<br/>
<!-- EPO <DP n="77"> -->&lt;221&gt; modified_base<br/>
&lt;222&gt; (26)...(26)<br/>
&lt;223&gt; n = g, a, c or t</li><li>&lt;400&gt; 111<br/>
tgcggcccgt gtttgactca actcanctcc tttaacgcta atatttccgg c   51</li><li>&lt;210&gt; 112<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; known single nucleotide polymorphism (SNP) rs1050141 in human insulin growth factor-2 (IGF2) gene exon 9</li><li>&lt;400&gt; 112<br/>
gggttttgtc tttaaccttg taacgmttgc aatcccaata aagcattaaa a   51</li><li>&lt;210&gt; 113<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; primer for single nucleotide extension assay using PCR amplicon of known single nucleotide polymorphism (SNP) rs680 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 113<br/>
gtccctgaac cagcaaagag aaaagaagg   29</li><li>&lt;210&gt; 114<br/>
&lt;211&gt; 84<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; PCR amplicon for known single nucleotide polymorphism (SNP) rs680 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;400&gt; 114
<img id="ib0001" file="imgb0001.tif" wi="151" he="10" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 115<br/>
&lt;211&gt; 30<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; single nucleotide primer extension for known single nucleotide polymorphism (SNP) rs680 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (30)...(30)<br/>
<!-- EPO <DP n="78"> -->&lt;223&gt; g modified by dR110 fluorescent dye label</li><li>&lt;400&gt; 115<br/>
gtccctgaac cagcaaagag aaaagaaggg   30</li><li>&lt;210&gt; 116<br/>
&lt;211&gt; 30<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; single nucleotide primer extension for known single nucleotide polymorphism (SNP) rs680 in human insulin growth factor-2 (IGF2) gene</li><li>&lt;220&gt;<br/>
&lt;221&gt; modified_base<br/>
&lt;222&gt; (30)...(30)<br/>
&lt;223&gt; a modified by dR6G fluorescent dye label</li><li>&lt;400&gt; 116<br/>
gtccctgaac cagcaaagag aaaagaagga   30</li></ul></p></description><claims mxw-id="PCLM56984717" lang="DE" load-source="patent-office"><!-- EPO <DP n="81"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zur Quantifizierung einer Allel-spezifischen RNA-Expression in einem menschlichen Individuum, welches ein Heterozygot für einen Einzelnukleotid-Polymorphismus (SNP) im Insulinwachstumsfaktor-2- (IGF2-) Gen ist, wobei das Verfahren umfasst:
<claim-text>Quantifizieren der Menge an RNA, umfassend jede polymorphe Option des SNP, wobei der SNP die SEQ ID NO:10 ist, in einer Probe von dem Individuum; und</claim-text>
<claim-text>Korrelieren der relativen RNA-Menge, umfassend jede polymorphe Option des SNP, mit Imprinting-Verlust des IGF2-Gens.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren gemäß Anspruch 1, wobei der Korrelierungsschritt das Korrelieren der relativen RNA-Menge mit einer Prognose oder Diagnose von Krebs oder der Vorhersage der Wirksamkeit eines Medikaments zur Behandlung von Krebs umfasst.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren gemäß Anspruch 1, des Weiteren umfassend Bestimmen, ob das Individuum homozygot oder heterozygot für den SNP ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren zur Bestimmung eines SNP-Genotyps in einem menschlichen Individuum, wobei das Verfahren umfasst:
<claim-text>Bestimmen des Nukleotids oder der Nukleotide an der polymorphen Position eines Einzelnukleotid-Polymorphismus<!-- EPO <DP n="82"> --> (SNP), wobei der SNP SEQ ID NO:10 ist, und wobei das Nukleotid das in Tabelle 2A oder 2B gezeigte unterstrichene Nukleotid ist, in einer Probe, die genomische DNA von dem Individuum enthält.</claim-text></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Isoliertes Polynukleotid von zwischen 8-100 Nukleotiden, wobei das Polynukleotid zwischen einem Allel eines SNP (oder Komplements davon) und dem anderen Allel des SNP (oder Komplements davon) in einer Hybridisierungsreaktion unterscheidet, wobei der SNP SEQ ID NO:10 ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Polynukleotid gemäß Anspruch 5, wobei das vorletzte oder letzte 3'-Nukleotid des Polynukleotids an das polymorphe Nukleotid des SNP hybridisiert.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Isoliertes Polynukleotid von zwischen 8-100 Nukleotiden, wobei das Polynukleotid als Primer in Insulin-artigem Wachstumsfaktor-2-(IGF2-)cDNA fungiert, so dass das Polynukleotid an die cDNA hybridisiert, und das 3'-Nukleotid des Polynukleotids komplementär zum Nukleotid unmittelbar stromaufwärts des polymorphen Nukleotids eines SNP ist, wobei der SNP SEQ ID NO:10 ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Polynukleotid gemäß Anspruch 7, wobei zumindest die 10 aufeinanderfolgenden 3'-Nukleotide des Polynukleotids komplementär zu der cDNA sind.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Isoliertes Polynukleotid, umfassend die SNP-Sequenz SEQ ID NO:10 oder ein Komplement davon, wobei das Nukleotid an der polymorphen Position des SNP T ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Kit, umfassend ein isoliertes Polynukleotid gemäß Anspruch 5 oder 7.<!-- EPO <DP n="83"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Kit gemäß Anspruch 10, umfassend das isolierte Polynukleotid gemäß Anspruch 5 als erstes Polynukleotid.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Kit gemäß Anspruch 11, wobei der Kit des Weiteren ein zweites isoliertes Polynukleotid von zwischen 8-100 Nukleotiden umfasst, wobei das zweite Polynukleotid zwischen dem ersten Allel des SNP (oder Komplements davon) und dem zweiten Allel des SNP (oder Komplements davon) unterscheidet, und wobei das erste Polynukleotid komplementär zum polymorphen Nukleotid im ersten Allel ist, und das zweite Polynukleotid komplementär zum polymorphen Nukleotid des zweiten Allels ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Kit gemäß Anspruch 10, wobei der Kit des Weiteren einen oder mehrere Primer zur Amplifizierung einer Region des IGF2-Locus, umfassend die polymorphe Stelle, umfasst, wobei der eine oder mehrere Primer verschieden von dem isolierten Polynukleotid ist/sind.</claim-text></claim></claims><claims mxw-id="PCLM56984718" lang="EN" load-source="patent-office"><!-- EPO <DP n="79"> --><claim id="c-en-01-0001" num="0001"><claim-text>A method of quantifying allelic-specific expression of RNA in a human individual that is a heterozygote for a single nucleotide polymorphism (SNP) in the Insulin Growth Factor-2 (IGF2) gene, the method comprising<br/>
quantifying in a sample from the individual the amount of RNA comprising each polymorphic option of the SNP, wherein the SNP is SEQ ID NO: 10; and<br/>
correlating the relative amount of RNA comprising each polymorphic option of the SNP to loss of imprinting of the IGF2 gene.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The method of claim 1, wherein the correlating step comprises correlating the relative amount of RNA to a prognosis or diagnosis of cancer or a prediction of efficacy of a drug for treating cancer.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The method of claim 1, further comprising determining whether the individual is homozygous or heterozygous for the SNP.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A method of determining a SNP genotype in a human individual, the method comprising;<br/>
determining, in a sample containing genomic DNA from the individual, the nucleotide or nucleotides at the polymorphic position of a single nucleotide polymorphism (SNP), wherein the SNP is SEQ ID NO: 10 and wherein the nucleotide is the underlined nucleotide as displayed in Table 2A or 2B.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An isolated polynucleotide of between 8-100 nucleotides, wherein the polynucleotide distinguishes between one allele of a SNP (or complement thereof) and the other allele of the SNP (or complement thereof) in a hybridization reaction, wherein the SNP is SEQ ID NO: 10.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The polynucleotide of claim 5, wherein the penultimate or ultimate 3' nucleotide of the polynucleotide hybridizes to the polymorphic nucleotide of the SNP.<!-- EPO <DP n="80"> --></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>An isolated polynucleotide of between 8-100 nucleotides wherein the polynucleotide functions as a primer in Insulin-like Growth Factor 2 (IGF2) cDNA, such that the polynucleotide hybridizes to the cDNA and the 3' nucleotide of the polynucleotide is complementary to the nucleotide immediately upstream of the polymorphic nucleotide of a SNP, wherein the SNP is SEQ ID NO: 10.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The polynucleotide of claim 7, wherein at least the 10 contiguous 3' nucleotides of the polynucleotide are complementary to the cDNA.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>An isolated polynucleotide comprising the SNP sequence, or complement thereof, SEQ ID NO: 10, wherein the nucleotide at the polymorphic position of the SNP is T.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A kit comprising an isolated polynucleotide of claim 5 or 7.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The kit of claim 10 comprising the isolated polynucleotide of claim 5 as a first polynucleotide.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The kit of claim 11, wherein the kit further comprises a second isolated polynucleotide of between 8-100 nucleotides, wherein said second polynucleotide distinguishes between the first allele of the SNP (or complement thereof) and the second allele of the SNP (or complement thereof), and wherein the first polynucleotide is complementary to the polymorphic nucleotide in the first allele and the second polynucleotide is complementary to the polymorphic nucleotide of the second allele.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The kit of claim 10, wherein the kit Further comprises one or more primer for amplifying a region of the IGF2 locus encompassing the polymorphic site, wherein the one or more primer is different from the isolated polynucleotide.</claim-text></claim></claims><claims mxw-id="PCLM56984719" lang="FR" load-source="patent-office"><!-- EPO <DP n="84"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Procédé permettant de quantifier l'expression spécifique d'un allèle d'un ARN chez un individu humain qui est hétérozygote pour un site SNP (polymorphisme à nucléotide unique) dans le gène du facteur IGF-2 (facteur de croissance apparenté à l'insuline de type 2), lequel procédé comporte les opérations suivantes :
<claim-text>- déterminer, dans un échantillon provenant de l'individu, la quantité d'ARN comprenant chaque option de polymorphisme dudit site SNP, lequel site SNP est la Séquence N° 10 ;</claim-text>
<claim-text>- et corréler la quantité relative d'ARN comprenant chaque option de polymorphisme dudit site SNP avec la perte d'empreinte du gène de facteur IGF-2.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Procédé conforme à la revendication 1, dans lequel l'étape de corrélation comporte le fait de corréler la quantité relative d'ARN à un pronostic ou un diagnostic de cancer ou à une prévision de l'efficacité d'un médicament conçu pour le traitement d'un cancer.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Procédé conforme à la revendication 1, qui comporte en outre le fait de déterminer si l'individu est homozygote ou hétérozygote pour le site SNP.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Procédé de détermination du génotype d'un site SNP chez un individu humain, lequel procédé comporte l'opération suivante :
<claim-text>- déterminer, dans un échantillon contenant de l'ADN génomique provenant de l'individu, le nucléotide ou les nucléotides en la position de polymorphisme d'un site SNP (polymorphisme à nucléotide unique), lequel site SNP est la Séquence N° 10 et lequel nucléotide est le nucléotide souligné dans le tableau 2A ou 2B.</claim-text></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Polynucléotide isolé comportant de 8 à 100 nucléotides, lequel polynucléotide fait la distinction, dans une réaction d'hybridation, entre un allèle d'un site SNP ou son complémentaire et l'autre allèle du site SNP ou son complémentaire, ledit site SNP étant la Séquence N° 10.<!-- EPO <DP n="85"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Polynucléotide conforme à la revendication 5, duquel polynucléotide c'est le dernier ou l'avant-dernier nucléotide en 3' qui s'hybride au nucléotide de polymorphisme du site SNP.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Polynucléotide isolé comportant de 8 à 100 nucléotides, lequel polynucléotide joue le rôle d'amorce pour l'ADNc du facteur IGF-2 (facteur de croissance apparenté à l'insuline de type 2), de telle sorte que le polynucléotide s'hybride à cet ADNc et le nucléotide en 3' du polynucléotide est complémentaire du nucléotide situé immédiatement en amont du nucléotide de polymorphisme d'un site SNP, ce site SNP étant la Séquence N° 10.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Polynucléotide conforme à la revendication 7, duquel polynucléotide au moins les dix nucléotides contigus en 3' sont complémentaires dudit ADNc.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Polynucléotide isolé comportant la séquence de site SNP qu'est la Séquence N° 10, ou la séquence complémentaire de celle-ci, dans lequel le nucléotide en la position de polymorphisme du site SNP est un nucléotide T.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Trousse comprenant un polynucléotide conforme à la revendication 5 ou 7.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Trousse conforme à la revendication 10, comprenant un polynucléotide conforme à la revendication 5 en tant que premier polynucléotide.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Trousse conforme à la revendication 11, laquelle trousse comprend en outre un deuxième polynucléotide isolé comportant de 8 à 100 nucléotides, lequel deuxième nucléotide fait la distinction entre le premier allèle du site SNP ou son complémentaire et le deuxième allèle du site SNP ou son complémentaire, et dans laquelle le premier polynucléotide contient le complémentaire du nucléotide de polymorphisme du premier allèle et le deuxième polynucléotide contient le complémentaire du nucléotide de polymorphisme du deuxième allèle.<!-- EPO <DP n="86"> --></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Trousse conforme à la revendication 10, laquelle trousse comprend en outre une ou plusieurs amorces servant à amplifier une région du locus IGF-2 qui englobe le site de polymorphisme, laquelle ou lesquelles amorces est ou sont différentes du polynucléotide isolé.</claim-text></claim></claims><drawings mxw-id="PDW16671939" load-source="patent-office"><!-- EPO <DP n="87"> --><figure id="f0001" num="1A,1B,1C"><img id="if0001" file="imgf0001.tif" wi="146" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="88"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="163" he="170" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="89"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="165" he="213" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="90"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="165" he="228" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="91"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="152" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="92"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="148" he="227" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="93"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="165" he="213" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="94"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="165" he="217" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="95"> --><figure id="f0009" num="9"><img id="if0009" file="imgf0009.tif" wi="165" he="218" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="96"> --><figure id="f0010" num="10"><img id="if0010" file="imgf0010.tif" wi="165" he="213" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
